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Abstract 
Parkinson’s Disease (PD) is a neurodegenerative disease, with severely reduced 
movement in patients. The main effect is the loss of dopaminergic neurons in the 
central nervous system (CNS). Null mutations of the parkin gene are known to cause 
PD. I found that Drosophila melanogaster (D. melanogaster) parkin null (dparkin) 
mutant larvae show neurophysiological abnormalities, a bradykinesia-like locomotory 
defect and synaptic overgrowth at the neuromuscular junction (NMJ). Neuronal 
overgrowth is rescued with either muscle or neuronal expression of wild-type dparkin 
in dparkin mutant larvae. The ubiquitous expression of antioxidant enzymes have 
varying degrees of rescue dependent on their properties and site of action in dparkin 
mutant larvae. Manipulating c-jun-N-terminal kinase (JNK) signaling components or 
JNK interacting detoxification enzymes (Glutathione-s-transferase (GST) or 
Thioredoxin reductase 2 (TRX-R2) ameliorated all the types of dparkin mutant larval 
phenotypes. Superoxide Dismutase 1 (Sod1) expression rescued overgrowth but failed 
to rescue the neurophysiological defect or the locomotion in dparkin mutant larvae. 
Additionally, genetically manipulating AMP-activated protein Kinase (AMPK), which 
is involved in the energy homeostasis, rescued overgrowth and neurophysiological 
dysfunction but not the locomotory defects. The pharmacological manipulation with 
dopaminergic drugs, and classical AMPK activators (metformin and 5-
Aminoimidazole-4-carboxamide ribonucleotide (AICAR)) or resveratrol failed to 
rescue dparkin larval phenotypes. I conclude that neuronal, rather than muscle, failure 
is key to the bradykinesia observed in dparkin mutant larvae. The main defect is 
suggested to be the depletion of neuronal energy reserve leading to synaptic 
dysfunction, rather than oxidative stress. Together these observations suggest 
oxidative stress could be a downstream consequence of a metabolic dysfunction. 
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Chapter 1 : Introduction 
1.1 Overview of Parkinson’s Disease  
Parkinson’s Disease (PD), was first described by James Parkinson in 1817, and is the 
most common movement disorder and the second most common neurodegenerative 
disease after Alzheimer’s Disease (AD). PD affects 1% of the population over 65 years 
of age increasing to 4-5 % after 85 years of age for males and females (Farrer, 2006). 
The mean onset of autosomal recessive juvenile parkinsonism (AR-JP), which gives rise 
to an early onset form of PD that is characterized by levodopa-responsive Parkinsonism, 
is 23.2 years for males and females (Saito et al., 1998). PD is a degenerative condition 
affecting the central nervous system (CNS). Clinically, PD is characterized by resting 
tremor, bradykinesia, rigidity and postural instability these can be accompanied by non-
motor symptoms such as autonomic dysfunction, olfactory deficits, sleep impairment, 
musculoskeletal abnormalities, skin lesions, dementia and neuropsychiatric disorders 
(Simuni and Sethi, 2008, Meissner et al., 2011). The profound dopamine deficiency is 
the cardinal biochemical abnormality in PD. This is primarily (but not exclusively) due 
to the loss of neurons from the substantia nigra pars compacta. These are dopaminergic 
neurons with very long axons that project to the striatum (Dauer and Przedborski, 
2003). Preceding the neuropathology associated with the death of neurons in the 
nigrostriatal pathway, are histological abnormalities often characterized by 
proteinaceous inclusions called Lewy body (LB) and also gliosis (Przedborski and 
Goldman, 2004). Since the introduction of L-3,4-dihydroxyphenylalanine (Levodopa or 
L-DOPA) in 1968 it has remained the most efficacious treatment in PD, despite a 
significant number of dopaminergic reagents becoming available (including dopamine 
agonists, dopamine reuptake inhibitors, and Monoamine oxidase B (MAO-B) inhibitors, 
and  surgical alternatives. Together, this provides clinicians with a range of viable 
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treatment options (Cotzias et al., 1969). Although dopamine replacement therapy 
alleviates some of the motor symptoms, it has its drawbacks as it becomes less effective 
over the course of the treatment accompanied by intolerable side effects. Motor 
complications (termed dyskinesias) are observed in patients who have been taking L-
DOPA for a long time. By 5 years, dyskinesias are seen in 50% of patients taking L-
DOPA, and by 8 years 80% (Golbe, 1991, Forno, 1996, Fahn, 2000),. The risk of 
developing of young onset PD is associated with a higher incidence of L-DOPA 
induced dyskinesias (LID) (Kumar, 2005). The risk of developing LID for patients on 
treatment for at least 5 years who are aged between 40-59 years was 50%, whereas it is 
16% for those with an onset of 70 years and over. This suggests that there are age-
related dynamics with L-DOPA treatment in PD patients. The nigral degeneration or 
disease severity is suggested also to be a key risk factor. It is reported, that with the 
administration of clinical dose of L-DOPA idiopathic PD patients develop LID almost 
exclusively whereas normal and others with different neurological disorders do not 
develop LID (Markham, 1971, Chase et al., 1973).   
Dopaminergic dysfunction contributes to few of the non-motor symptoms (NMS) 
(Chaudhuri and Schapira, 2009). Depression, anxiety and apathy are due to dopamine 
deficiency and are improved with L-DOPA treatment but these could lead to side effects 
including dopamine dysregulation syndrome, drug induced hallucinations, psychosis, 
hypomania, addiction to the and impulse control disorders (Voon et al., 2009). 
Additionally, this dopamine replacement treatment is not completely effective on all 
NMS. For example, depression occurs in approximately 28% of PD patients in the early 
stage of the disease (Ravina et al., 2007). Depression is thought to involve more than 
one pathway with damage to serotoninergic (raphe nuclei), dopaminergic (amygdala, 
cingular cortex, and mesolimbic and mesocortical mesothalamic pathways) and 
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noradrengeric (locus coeruleus) innervations (Tom and Cummings, 1998, Remy et al., 
2005). The majority of NMS are related to non-dopaminergic systems: serotonergic, 
cholinergic and noradrenergic neurotransmitter transmission (Wolters, 2009). Treatment 
for depression for PD patients include tricyclic antidepressants, selective serotonin 
uptake inhibitors and a combination therapy in which medication that acts on several 
neurotransmitter pathways is given, for example noradrenergic and serotoninergic 
medication (Devos et al., 2008). There is currently no cure or effective treatment to stop 
the progression or manage all debilitating symptoms of PD and the quest for novel 
treatments and to find a definitive cure remains a challenge for both basic science and 
clinical research.   
1.2 Classical hallmarks of PD 
1.2.1 PD pathology: Lewy bodies, ubiquitin and α-synuclein 
The post mortem brain samples from PD patients show Lewy body (LB) pathology, a 
classical hallmark of PD. These contain ubiquitin and α-synuclein. Ubiquitin is a 
cytosolic enzyme that plays a key role in protein degradation (Lecker et al., 2006). α-
synuclein is a small protein normally located presynaptically in vivo and suggested to 
play an important role in synaptic function (Chandra et al., 2004). The importance of α-
synuclein in PD is based on the observation that mutations in the α-synuclein gene lead 
to early onset PD (Polymeropoulos et al., 1997). α-synuclein induced dopaminergic 
neuronal loss has been successfully demonstrated in animal models including D. 
melanogaster (Feany and Bender, 2000, Auluck et al., 2002, Park and Lee, 2006) and in 
mouse (Oliveras-Salvá et al., 2013). The mechanism where by this selective loss of 
dopaminergic neurodegeneration occurs is unclear.  The cytotoxic effect of α-synuclein 
is likely to be due to a gain-of-function (GOF) rather than from a loss-of-function 
(LOF), consistent with the dominant inheritance pattern of mutations. This is supported 
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further by animal studies in mouse with the loss of α-synuclein that were observed to 
have minimal effects on their development and function (Abeliovich et al., 2000). D. 
melanogaster models have recapitulated other key anatomical and behavioral features 
as observed from PD patients including α-synuclein and ubiquitin positive LB-like 
pathology (Feany and Bender, 2000, Auluck et al., 2002) and locomotor dysfunction 
(Feany and Bender, 2000, Pendleton et al., 2002). 
Another cause of the disease is the genomic triplication of the wild-type allele SNCA, 
the gene that encodes the α-synuclein protein (Singleton et al., 2003). The measurement 
of wild-type protein levels indicates the predicted doubling of α-synuclein expression in 
the blood, while in the parts of the cerebral cortex region where LB are found, there is a 
rise in the levels and deposition of α-synuclein (Miller et al., 1999, Miller et al., 2004). 
Patients with SNCA duplication have a brainstem associated PD phenotype whereas the 
triplication of SNCA results in a widespread with LB associated PD pathology 
(Singleton et al., 2003, Fuchs et al., 2007).   
1.2.2 Anatomy of the basal ganglia and hypokinetic features of PD 
The classical view of PD is that it is the result of the damage in the basal ganglia. The 
basal ganglia consist of four nuclei (Fig 1.1) that include the following: the striatum 
(caudate nucleus, putamen and the ventral striatum that includes nucleus accumbens), 
the globus pallidus, the substantia nigra (pars compacta and pars reticulata) and the 
subthalamic nucleus. At the anterior part of the striatum it is divided into caudate 
nucleus and putamen by the internal capsule. The striatum is the main recipient of 
inputs to the basal ganglia from the cerebral cortex, thalamus, and the brain stem where 
its neurons project to globus pallidus and substantia nigra. Globus pallidus lies medial 
to the putamen and is divided into two parts, internal and external segments. The 
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neurons that project from the striatum to the internal globus pallidus segment and to the 
substantia nigra reticulata use gamma- aminobutyric acid (GABA) as their 
neurotransmitter. This inhibits neuronal activity. The Substantia nigra par compacta 
zone is a distinct nucleus that lies dorsal to the reticulata zone. The pars compacta zone 
contains dopaminergic neurons and neuromelanin, a black pigment derived from the 
oxidized dopamine. Dopaminergic neurons are also found in the ventral tegmental area. 
The subthalamic nucleus is connected both to the globus pallidal segments and the 
substantia nigra. The glutamatergic cells of the subthalamic nucleus are the only 
excitatory projection in the basal ganglia.  
The dopaminergic nigrostriatal projections from the Substantia nigra pars compacta to 
the striatum are important in the modulation of the direct and indirect pathway. The loss 
of dopaminergic neurons in the nigrostriatal pathway causes an imbalance in the 
activation and inhibition of the direct and indirect pathway respectively that leads to the 
PD associated motor dysfunction.  As the effects of the functioning nigrostriatal 
pathway excites the direct pathway and inhibits the indirect one, the loss of these 
dopaminergic neuronal input, tips the balance in favour of activity of the indirect 
pathway and the decreased activity on the direct pathway as dopamine has different 
actions on the two dopamine receptors (D1 and D2, respectively). These changes lead to 
increased activity of the internal pallidal segment that results in increased inhibition of 
the thalamocortical and midbrain tegmental neurons leads to the hypokinetic features of 
PD.   
 
 
!! 8!
! 
 
 
 
 
 
 
!! 9!
 
Figure 1.1 The basal ganglia. This region of the brain consists of: the striatum caudate 
nucleus, putamen and the ventral striatum that includes nucleus accumbens, the globus 
pallidus, the substantia nigra (pars compacta (SNc) and pars reticulata, (SNr)) and the 
subthalamic nucleus (STN). At the anterior part of the striatum (STR) it is divided into 
caudate nucleus and putamen by the internal capsule. The striatum is the main recipient 
of inputs to the basal ganglia from the cerebral cortex (C), thalamus (Th), and the brain 
stem where its neurons project to globus pallidus and substantia nigra. The Globus 
pallidus lies medial to the putamen and is divided into two parts, know as the internal 
and external segments (GPi and GPe). The GPi segment and SNr neurons release 
gamma-aminobutyric acid (GABA) as their inhibitory neurotransmitter. The SNc zone 
is a distinct nucleus that lies dorsal to the reticulata zone. The SNc zone contains 
dopaminergic neurons and neuromelanin, a black pigment derived from the oxidized 
dopamine. Dopaminergic neurons are also found in the ventral tegmental area. The STN 
is connected both to the globus pallidal segments and the substantia nigra.  
(No permission required to use this diagram (Obeso et al., 2002)).   
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1.3 Braak’s staging of PD pathogenesis  
Braak revolutionized our view of PD, suggesting it was a spreading pathology starting 
in the neurons of the olfactory and/or digestive system. This was based on observations 
that some non-motor symptoms preceded the motor symptoms for example, such as the 
loss of smell (Braak et al., 2003, Braak and Del Tredici, 2008) and frequently 
constipation (Jost and Schimrigk, 1991, Sakakibara et al., 2001). 
In Braak’s hypothesis, the earliest stage of PD is called Stage 1, and it is characterized 
by the abnormal α-synuclein immunostaining in only the medulla oblongata or the 
olfactory bulb. Later (Stage “2”), abnormal α-synuclein immunostaining is seen in the 
caudal raphe nuclei and the locus coeruleus (LC). In Stage 3 and 4 prominent α-
synuclein immunostaining is in the substantia nigra pars compacta. This is associated 
with clinical Parkinsonism and dopaminergic neuronal loss that spreads into the cortex. 
Thus Braak’s hypothesis proposes that synuclein pathology in the lower brainstem is 
required for the later appearance of PD. The idea that early stages of PD may start in 
non-dopaminergic structures of the brain stem or even the in the peripheral autonomic 
nervous system will continue to influence approaches to early diagnosis of PD, the 
development of biomarkers and how critically to think about animal models in the 
future (Burke et al., 2008) and thus reflects PD pathogenesis as a complex multifactorial 
disease.   
1.4 Models of PD 
1.4.1 Overview of PD models 
Studies on human materials are limited by ethical issues, slow reproductive turnover 
and by the limited genetic tools available, and thus require us to turn to model systems 
including the mouse, fly, worm and cell culture to understand etiology, the pathology 
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and molecular mechanisms of PD. 95% cases of PD are sporadic and are caused by a 
variety of risk factors including aging (Langston, 2002). However, age is not a risk 
factor for the early onset form of PD. Other risk factors are genetic susceptibility and 
environmental association. The association of environmental toxins, herbicides and 
pesticides with PD (Lees et al., 2009), has led to the development of several toxin-
induced models: 1-methyl-4-phenyl-1, 2, 3, 6-tetrahyropyridine (MPTP), 6-
hydroxydopamine (6-OHDA), paraquat and rotenone. These have provided insight into 
the molecular mechanisms underlying the pathogenesis of PD.  
1.4.2 Neurotoxin-induced models 
An accidental discovery in 1982 showed that the exposure of mitochondrial toxin 1-
methyl-4-phenyl-1, 2, 3, 6-tetrahyropyridine (MPTP) resulted in the death of 
dopaminergic neurons and induced PD-like motor symptoms in humans (Langston and 
Ballard, 1983, Bové et al., 2005). Rodent and primate models have used the following 
model to test compounds that induce both reversible (reserpine) and irreversible 
(MPTP, 6-hydroxydopamine (6-OHDA), paraquat and rotenone) effects that have been 
able to reproduce PD associated pathology and disease related symptoms. The two 
“classical” toxin models, 6-ODHA and MPTP that selectively and rapidly destroy 
catecholaminergic neurons (Bové et al., 2005), will be discussed further below. 
1.4.2.1 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine  (MPTP) 
As previously discussed above, abnormalities in indirect pathway activation have been 
studied using microelectrode technology to record activity from brains of monkeys 
treated with meperidine derivative 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine  
(MPTP) and symptoms have been ameliorated with lesions made to the overactive 
subthalamic nucleus which reduced the excessive excitatory drive onto the internal 
pallidal segment.  The cardinal motor symptoms (akinesia, tremor and rigidity) were 
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ameliorated with specific lesions to the sensorimotor portion of the subthalamic nucleus 
or the internal pallidal segment in MPTP-treated monkeys (Porras et al., 2012). 
1.4.2.2 6-hydroxydopamine (6-ODHA) 
Systemic administration of 6-ODHA fails to effectively cross the blood brain barrier 
(BBB) and thus poorly accumulates in the brain parenchyma and does not generate a 
nigrostriatal lesion, like other toxins (MPTP, rotenone or paraquat). To selectively 
damage the nigrostriatal dopaminergic pathways, stereotaxic methods have been 
employed to inject 6-ODHA into the substantia nigra, the medial forebrain bundle that 
is part of the nigrostriatal tract or the striatum. Injections into these three areas of 
lesions lead to dopaminergic cell death, reduced dopamine levels and gliosis. LB 
pathology has not been confidently shown in the brains of 6-ODHA infused rats, a 
major shortcoming of this model (Bové et al., 2005).  
6-OHDA shares some structural similarities to the neurotransmitters dopamine and 
noradrenaline (also known as norepinephrine). 6-OHDA has a high affinity for plasma 
membrane transporters including dopamine (DAT) and noradrenaline  (NET) 
transporters (Luthman et al., 1989). As a result of this, 6-OHDA enters both 
dopaminergic and noradrenergic neurons. Once the toxin enters the neurons via the 
transporters, it becomes a highly reactive molecule. 6-OHDA induces oxidative stress 
by generating reactive oxygen species (ROS) and quinones (Cohen, 1984) leading to 
cell death (Jeon et al., 1995). 
1.4.2.3 Common findings from toxin models of PD 
A common feature of all toxin models-induced models is their ability to recapitulate 
oxidative stress  (OS) and cell death in the dopaminergic neurons as observed in PD 
patient samples. Research from the neurotoxic models concluded that mitochondrial 
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dysfunction via complex I or III and OS are key players in the demise of dopaminergic 
neurons (Abou-Sleiman et al., 2006). Human samples obtained from PD patients have 
shown the presence of ROS along with compromised function of the mitochondrial 
respiratory chain component, complex 1 (Schapira et al., 1990, Mizuno et al., 1989). 
1.4.2.4 Evaluation of toxin models of PD 
Toxin-induced models fall short because of their acute nature: one or two injections, 
given over a short period of time, are enough to lead to rapid or immediate onset of 
symptoms. This limits their usefulness as a model of the slowly progressive PD 
observed in humans. The failures in clinical trials, after observing positive effects in 
these mouse models suggested the mechanisms underlying the pharmacological models 
of PD were different from those occurring in PD patients (Linazasoro, 2004, Meissner 
et al., 2011, Guo, 2012). There may be compensatory mechanisms that could occur 
during the course of PD in patients, whereas in these acute toxin models there is little 
chance of this taking place. Another difference is that, a large proportion of PD occurs 
in the elderly, whereas the majority of the pathology in these toxin models occurs in the 
early stages of rodent toxin models because of the cost and inconvenience of housing 
them for an extended period of time. Other factors which may explain the difference 
between PD drug trials and rodent experiments are differences in physiology, behaviour 
and gene expression.  
1.4.3 Genetic mutations of PD 
Although PD was initially believed to be idiopathic in nature (being of an unknown 
origin), the discovery of α-synuclein mutations as a cause of PD (Polymeropoulos et al., 
1997) led to a revolution in understanding (Hardy et al., 2009, Martin et al., 2011).  
However genetic mutations are rare and account for approximately 10-15% of all PD 
cases (Dauer and Przedborski, 2003, Houlden and Singleton, 2012). Nonetheless, the 
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development of genetic animal models of PD has revolutionized our understanding of 
the cellular mechanism underlying PD. 
Some PD-related mutations are associated with autosomal dominant forms of the 
disease. These include the amino acid substitutions in α-synuclein protein produced 
from the SNCA gene (PARK1). The A53T and A30P missense mutations in the α-
synuclein gene were discovered in a large Italian-American Greek and German kindred 
respectively (Polymeropoulos et al., 1997, Spillantini et al., 1997, Krüger et al., 1998). 
Triplication of SNCA is linked to a second form of inherited PD (called PARK4) where 
increased dosage of the wild-type α-synuclein gene results in autosomal dominant PD 
(Singleton et al., 2003). Other autosomal dominant forms include mutations in Leucine 
rich-repeat kinase 2 (LRRK2, PARK8) (Paisán-Ruíz et al., 2004, Zimprich et al., 2004), 
vacuolar protein sorting 35 (VPS35, PARK17) (Vilariño-Güell et al., 2011, Chartier-
Harlin et al., 2011, Zimprich et al., 2011) and eukaryotic translation initiation factor 4 
gamma-1 (EIF4G1, PARK18) (Chartier-Harlin et al., 2011).  
Other forms of PD are recessive: genes that are associated with these forms of PD 
include parkin (PARK2) (Kitada et al., 1998), DJ-1 (PARK7) (Bonifati et al., 2003), and 
phosphatase and tensin homolog (PTEN)-induced putative kinase-1 (PINK1, PARK6) 
(Valente et al., 2004b). Additionally, a mutation in ATP132A2 (PARK9) that encodes a 
lysosomal ATPase has also been linked to an atypical form of autosomal recessive PD 
(Ramirez et al., 2006). Other mutations have also been shown in FGF20, GIGYF2, 
ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1, PARK5) and High Temperature 
Requirement A2 (HtrA2/ Omi, PARK13) (Strauss et al., 2005) Heterozygous mutations 
in GBA gene encoding glucocerebrosidase is linked to Gaucher’s disease has also been 
linked to typical PD with LB pathology (Clark et al., 2007). Supporting this, genome-
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wide association studies have shown a handful of polymorphic variants, mostly genes 
already identified from familial PD (Peeraully and Tan, 2012).  
1.4.3.1 Genetic models shed light of idiopathic PD 
The epidemiological studies and the discovery of genes from the rare familial forms of 
PD have revealed cellular dysfunction implicated in the formation and/or progression of 
both familial and sporadic PD that include abnormal protein aggregation, oxidative 
stress and mitochondrial dysfunction. Inherited PD is often indistinguishable in terms of 
nature and severity from the sporadic form (Savitt et al., 2006, Hardy et al., 2009, 
Martin et al., 2011). This allows us to speculate that the basic molecular signals are also 
likely to be similar in both genetic and sporadic form. PD-related genes are used to 
study in vivo function of the disease causing mutations altered in patients to generate 
reliable animal model of PD. This has encouraged the engineering of genetic models. 
The thesis aims to look into the neuronal dysfunction caused by mutations in parkin 
gene in D. melanogaster and there will be more of a focus on the impact of the 
mutations in parkin which cause early onset PD.  
1.4.3.2 parkin gene  
The parkin gene accounts for the majority of the autosomal recessive juvenile 
Parkinsonism (ARJP) cases, with over 100 pathogenic mutations having been reported 
(Exner et al., 2012). In 1998, the parkin gene was identified as a cause of early onset 
ARJP (Kitada et al., 1998). The parkin gene in humans encodes a polypeptide chain 
with 465 length amino acid chain containing a ubiquitin-like (UBL) domain at the N-
terminus and an RBR (RING-between-RING) domain close to the C-terminus. The in-
between RING (IBR) domain sits in the middle of the two RING fingers that make up 
the RBR region that coordinates the six zinc ions. Additionally, another RING finger 
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domain has also been identified between the UBL and the RBR regions that are thought 
to assist in the binding of zinc ions (Hristova et al., 2009). Studies have shown that 
parkin functions as an E3 ubiquitin protein ligase (Shimura et al., 2000). A single 
Drosophila orthologue of mammalian parkin, CG10523, has been identified. It has a 
protein sequence of 482 amino acids (Greene et al., 2003, Pesah et al., 2004) and shows 
an overall similarity of 59% with its human homologue. The orthologue contains all of 
the characteristic canonical motifs of human Parkin, including a ubiquitin-like domain, 
two RING finger domains, and an in-between RING fingers domain (Fig 1.2). 
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Figure 1.2 Schematic diagram indicating functional domain organization and 
structural domain boundaries of parkin protein between human and D. 
melanogaster. Domain structure of parkin protein showing the C-terminal RING1, IBR 
and RING2 domains found in all RBR E3 ligase proteins. The ubiquitin-like (Ubl) and 
RING0 domains are specific to the parkin E3 ligase. Residue numbering is shown for 
both the human (top) and D. melanogaster (bottom) parkin sequences.  
(Modified from (Spratt et al., 2013) 
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1.5 Pathogenesis of PD  
Animal models have given great insight to the etiology, pathology and molecular 
mechanisms of PD (Dawson et al., 2010), but the complete disease process has yet to be 
determined. Over several decades, a variety of animal models have been developed 
based on toxins or genetic manipulations. Research from animal models has provided 
clues into the disease pathogenesis and cellular dysfunction: the role of oxidative stress, 
mitochondrial abnormalities, aggregation-induced toxicity and/ or impairment of the 
proteosomal/ lysosomal degradation pathways (Dawson et al., 2010, Corti et al., 2011, 
Martin et al., 2011, Shulman et al., 2011). These will be reviewed below.  
1.5.1 Oxidative stress and the generation of reactive oxygen species  
The mechanisms that result in the loss of dopaminergic cells have been debated for 
decades. The brain in particular, is susceptible to oxidative damage as a result of its high 
metabolic rate and its relatively reduced renewing capacity compared to other organs. 
Approximately 20% of the molecular oxygen and a quarter of the glucose consumed by 
the human body are used for cerebral functions, even though the brain only represents 
only 2% of the total body mass. The maintenance and restoration of ionic gradients 
altered by signaling processes results in high brain energy requirements (Attwell and 
Laughlin, 2001, Alle et al., 2009). Among the signaling processes, synaptic potentials, 
rather than action potentials, appear to represent by far the main energetic cost related to 
maintenance of excitability (Alle et al., 2009). 
Oxidative stress (OS) is defined as the imbalance between the production of reactive 
oxygen species (ROS) and the capacity of antioxidant defense mechanisms to scavenge 
these ROS, leading to an increase in free radicals. Severe OS can cause cell damage and 
death by several mechanisms (Halliwell, 1992). The balance of ROS production and 
antioxidant capacity has been shown to be compromised in many neurodegenerative 
!! 20!
conditions like PD, AD (Alzheimer’s Disease) and Amyotrophic lateral sclerosis (ALS).   
There are several markers of ROS damage reported within specific brain regions (Fig 
1.3), which eventually undergo neurodegeneration. These include 4-Hydroxynonenal 
(4-HNE) and malondialdehyde (MDA) that are markers of lipid peroxidation, and 
protein nitration that is a marker of protein oxidation, both of which have been reported 
to be present in all the above conditions. This however does not prove these are 
involved in the neurodegenerative process. Nigral dopaminergic neurons may be 
susceptible to OS as a result of dopamine metabolism which give rise to toxic species 
(Maker et al., 1981, Jenner, 2003).  
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Figure 1.3 Reactive oxygen species (ROS) and their interaction with reactive 
nitrogen species (RNS). ROS include the free radical group possessing highly reactive 
unpaired electrons such as superoxide (O2-.) and hydroxyl (OH.) radicals; and the 
second types of molecular species are hydrogen peroxide (H2O2) and peroxynitrite 
(ONOO-). O2-. is broken down to H2O2 by superoxide dismutases (SOD). H2O2 is 
broken down by catalase (CAT), glutathione peroxidase (GPX) and peroxiredoxins 
(PRX) to water (H2O). Additionally H2O2 can also be reduced to the OH. radical via the 
Fenton reaction in the presence of reduced transition metals such as iron (Fe2+) that can 
be further reduced to superoxide O2-.. O2-. is able to also react with a reactive nitrogen 
species (RNS) called nitric oxide (NO.) radicals to produce another RNS, ONOO-. NO. 
is formed from the conversion of conversion of arginine to citrulline by nitric oxide 
synthase (NOS). 
Diagram based on (Bogaerts et al., 2008)  
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1.5.2 Dopamine induced oxidative stress  
Dopamine is a neurotransmitter and itself has been widely held responsible for the 
induction of oxidative stress and impairment of mitochondrial function. This is due to 
the oxidization of cytosolic dopamine and its metabolites leading to the generation of 
highly ROS that oxidize lipids and other compounds (Berman and Hastings, 1999, 
Gluck et al., 2002, Greenamyre and Hastings, 2004, Sulzer, 2007, Naoi et al., 2009).  
Reduced sequestration of dopamine into synaptic vesicles has been proposed as a 
vulnerability factor of dopamine neurons. This is because at neutral or more alkaline pH 
dopamine undergoes auto-oxidation, but inside the synaptic vesicle the pH is lower and 
dopamine is unable to auto-oxidize (Obeso et al., 2010). Dopamine storage dysfunction 
can be caused by α-synuclein protofibrils, oxidative stress and neurotoxins such as 
methamphetamine (Caudle et al., 2008). A direct consequence of storage dysfunction is 
elevated dopamine in the cytosolic compartment resulting in the generation of reactive 
metabolites via two distinct pathways. Dopamine in the cytoplasmic compartment is 
metabolized by monoamine oxidase (MAO) located on the outer surface of the 
mitochondria or by auto-oxidation to generate harmful byproducts such as ROS, and 
subsequent neuromelanin formation. Oxidation of dopamine by MAO or aldehyde 
dehydrogenase results in the generation of hydrogen peroxide (H2O2) and 
dihydroxyphenylacetic acid (DOPAC). The generation of ROS from dopamine 
metabolism can inhibit complex I of the electron transport chain (Suzuki et al., 1992, 
Glinka and Youdim, 1995) and complex I activity has been found to be decreased in 
nigral tissues from PD patients’ brains (Reichmann and Janetzky, 2000). There is reason 
to question the “excess cytosolic dopamine leads to PD” hypothesis as L-DOPA 
administration ameliorates motor dysfunction by replacing lost dopamine and shows no 
accelerating effect on the disease progression of these patients (Fahn and Group, 2005). 
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This suggests that dopamine does not accelerate oxidative stress induced- PD 
pathogenesis.  
Additionally, there is regional variability in the loss of dopamine containing cells in PD 
where there are certain regions that show no sign of pathology (Damier et al., 1999). On 
the other hand a study has shown calcium entry through L-type channels stimulates 
dopamine metabolism in dopaminergic neurons thereby increasing the cytosolic 
concentrations to a toxic range with L-DOPA addition (Mosharov et al., 2009). Pro-
oxidants produced from dopamine metabolism such as H2O2, aldehydes and quinones 
could also react with other components that could result in cell loss. It should be noted 
non-dopaminergic cell death also occurs in PD, thereby arguing dopamine itself is 
unlikely to be the cause. 
1.5.3 The Reactive Oxygen Species (ROS) generated from mitochondria  
Oxidative damage has been shown to extend its effect to other cellular components such 
as lipid, proteins, RNA and DNA in the substantia nigra of patients with PD (Zhang et 
al., 1999), where the source of oxidative stress was shown to originate from the 
mitochondria. ROS are of two types: first the free radical group. These possess highly 
reactive unpaired electrons such as superoxide (O2-.), nitric oxide (NO.) and hydroxyl 
(OH.) radicals. The second type care composed of molecular species including 
hydrogen peroxide (H2O2) and peroxynitrite (ONOO-). O2-. is broken down to H2O2 by 
superoxide dismutase (SOD). H2O2 is broken down by catalase (CAT), glutathione 
peroxidase (GPX) and peroxiredoxins (PRX) to water (H2O). Additionally H2O2 can 
also be reduced to OH. radical via the Fenton reaction in the presence of reduced 
transition metals such as iron (Fe2+) that can be re-reduced to superoxide O2-.. O2-. is 
able to also react with NO. radicals to produce ONOO-. NO. is formed from the 
conversion of conversion of arginine to citrulline by nitric oxide synthase (NOS) 
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(Bogaerts et al., 2008). 
Mitochondria generate ATP coupled with the production of superoxide (O2.−) and ROS. 
1–2% of oxygen consumed during physiological respiration is converted into O2.− when 
electrons prematurely leak from the electron transport chain (ETC) and are aberrantly 
transferred to molecular oxygen (O2). The mitochondrial ETC, responsible for carrying 
out oxidative phosphorylation, is composed of five multi-subunit protein complexes, 
coenzyme Q (CoQ) and cytochrome c (Cyt c). Leakage of superoxides (O2.−) occurs at 
complex I, II or III. O2.− from complex I and II is released into the matrix, whereas O2.− 
from complex III can be produced on either side of the inner membrane. O2.− can then 
cross the outer mitochondria membrane (OMM) via a voltage-dependent anion-selective 
channel (VDAC). Additionally, O2.− can be converted into H2O2 in the matrix by 
superoxide dismutase 2 (Sod2) or in the intermembrane space by Sod1. In the cytosol, 
superoxide is converted by Sod1 into H2O2, which is further detoxified by the 
peroxisomal enzyme catalase. H2O2 can then freely cross mitochondrial membranes and 
can be further detoxified by additional antioxidant enzymes including peroxiredoxins 
(PRX) and glutathione peroxidase (GPX) (Veal et al., 2007) (Fig 1.4).  
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Figure 1.4 Reactive oxygen species (ROS) are produced during the oxidation of 
fuels in mitochondria. There are multiple sites of ROS production in the 
mitochondrion and ROS are kept within tolerable limits by a range of antioxidant 
systems, including glutathione and thioredoxin systems. The mitochondrial electron 
transport chain (ETC) is responsible for carrying out oxidative phosphorylation. 
Leakage of superoxides (O2.−) occurs at complex I, II or III. O2.− from complex I and II 
is released into the matrix, whereas O2.− from complex III can be produced on either 
side of the inner membrane. O2.− can then cross the outer mitochondria membrane 
(OMM) via a voltage-dependent anion-selective channel (VDAC). Additionally, O2.− 
can be converted into H2O2 in the matrix by superoxide dismutase 2 (Sod2) or in the 
intermembrane space by Sod1. In the cytosol, superoxide is converted by Sod1 into 
H2O2, which is further detoxified by the peroxisomal enzyme catalase. H2O2 can then 
freely cross mitochondrial membranes and can be further detoxified by additional 
antioxidant enzymes including peroxiredoxins (PRX) and glutathione peroxidase (GPX). 
Mitochondrial ROS emission levels are not simply scaled to fuel oxidation rate, but are 
affected by fuel type and by mitochondrial membrane potential. Glutathione (GSH) not 
only quenches ROS but also covalently modifies proteins to affect their function or 
protect proteins from oxidative damage. The fly does not have a glutathione reductase, 
and the reduction of glutathione disulphide (GSSG) is undertaken by the fly thioredoxin 
system (Kanzok et al., 2001).  
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During the cellular oxidation of fuels, electrons are used to power the proton pumps of 
the mitochondrial electron transport chain (ETC) and ultimately drive ATP synthesis 
and the reduction of molecular oxygen to water. During these oxidative processes, some 
electrons can ‘spin off’ during fuel oxidation and electron transport to univalently 
reduce O2, forming reactive oxygen species (ROS). In excess, ROS can be detrimental; 
however, at low concentrations oxyradicals are essential signaling molecules. 
Mitochondria thus use a battery of systems to finely control types and levels of ROS, 
including antioxidants. Several antioxidant systems depend on glutathione. 
1.5.3.1 Mitochondria and its associated functions 
Mitochondria are the “powerhouses of the cell” and they are responsible for the 
production of cellular energy, in the form of adenosine triphosphate (ATP), from the 
breakdown of carbohydrates and fatty acids, which are then converted to ATP by the 
process of oxidative phosphorylation in the inner mitochondrial membrane. The initial 
stages of glucose metabolism, glycolysis, occurs in the cytosol where glucose is 
converted into pyruvate. Pyruvate is transported into the mitochondria where pyruvate 
is converted in the process of being oxidized into Acetyl-Co enzyme A (Acetyl CoA) 
which is broken down to carbon dioxide in the citric acid cycle. The enzymes of the 
citric acid cycle is located in the matric of the mitochondria and play a central part in 
the breakdown of both carbohydrates and fatty acids.  
Mitochondria are also involved in other functions including biosynthesis of amino acids 
and steroids, beta-oxidation of fatty acids, homeostatic levels of cytosolic calcium 
concentration, buffering of calcium fluctuations and production and modulation of 
ROS. Mitochondria also play a central role in apoptosis. Taken together, the energy 
demands of neurons and their poor regenerative capacity, suggests mitochondrial 
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dysfunction could lead to poor neuronal survival.  
The importance of mitochondrial function has been highlighted throughout a variety of 
neurodegenerative diseases, including PD (Henchcliffe and Beal, 2008, Exner et al., 
2012).  Toxins that affect mitochondria cause PD phenotypes (Przedborski et al., 2004). 
One of the first links between PD and mitochondria came in the early 1980s, when it 
was discovered the neurotoxin MPTP that caused a form of Parkinsonian syndrome 
after being metabolized into MPP+ is taken up into dopaminergic neurons by dopamine 
transporter, vesicular monoamine transporter 2 (VMAT2), accumulates in the 
mitochondria and inhibits mitochondrial respiration (Langston and Ballard, 1983, 
Nicklas et al., 1985). Human post-mortem brain samples show substantial decrease in 
mitochondrial complex I (NADH ubiquinone oxidoreductase) activity in substantia 
nigra of PD patients (Mann et al., 1994), which appears to be a result of oxidative 
damage to complex I (Keeney et al., 2006). Mitochondrial DNA (mDNA) is vulnerable 
as they are close to the sites of superoxide generation and high levels of superoxide 
production are a possible cause of the increased number of somatic DNA mutations 
observed in dopaminergic neurons in the substantia nigra of PD patients (Soong et al., 
1992). Mutations in mDNA impact on electron chain function (Bender et al., 2006) and 
as a consequence cause disruption to the bioenergetics of substantia nigra neurons. 13 
proteins associated with the respiratory chain are encoded by the mitochondrial genome, 
7 of which are involved in complex I formation (Schapira, 2008). 
1.5.3.2 Mitochondrial abnormalities in PD 
Several of the genes found to be associated with PD are mitochondrially-linked proteins 
(Abou-Sleiman et al., 2006, Exner et al., 2012) (Fig 1.5). These include parkin, PTEN-
induced kinase 1 (PINK1), DJ1, and α-synuclein. 
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Figure 1.5 The association between familial PD and mitochondrial biology. The 
involvement of autosomal recessive PD proteins (pale blue) or autosomal dominant PD 
proteins (dark blue) in mitochondrial processes, have been represented in the diagram. 
This includes their life cycle, bioenergetic capacity, quality control, dynamics, and 
subcellular distribution.  
Adapted from (Exner et al., 2012) 
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The level of the characteristic muscle and germline defects seen in D. melanogaster 
parkin mutants are not observed to equally manifest in PD patients or mammalian 
mouse models. Mitochondrial abnormalities on the other hand are far more common in 
patients with early onset as well as sporadic PD. These organelle-associated defects are 
conserved in all model organisms and in humans with parkin mutations (Müftüoglu et 
al., 2004, Mortiboys et al., 2008, Palacino et al., 2004)  
Additionally, conditional knockout mice, disruptions to the gene for mitochondrial 
transcription factor A (Tfam) in dopaminergic neurons, lead to reduced copy number of 
mDNA and inefficient respiratory chain function leading the adult onset and progressive 
decline of motor dysfunction with LB pathology and nerve death (Ekstrand et al., 2007). 
Dawson and colleagues recently showed a parkin interacting substrate, PARIS, to 
suppress peroxisome proliferator-activated receptor γ co-activator (PGC)-1α expression 
induced mitochondrial biogenesis (Shin et al., 2011). When parkin is absent this 
elevates the activity of PARIS leading to suppression of PGC-α1 and causing 
dopaminergic cell loss (Shin et al., 2011). This implicates mitochondrial stress as an 
important factor in dopaminergic neuron survival, which could be due to the fact that 
dopaminergic neurons with their large arbors are metabolically very active than 
compared to other neurons. The increased metabolic demands may make dopaminergic 
neurons more vulnerable to mitochondrial dysfunction and cell death.  
 1.5.4 Aggregation induced proteolytic stress and the ubiquitin proteosomal system 
(UPS) 
In addition to impairments of the respiratory chain component, complex 1, and 
oxidative stress there is also evidence of aberrant activity of the ubiquitin proteosomal 
system (UPS) leading to proteolytic stress that may be involved in the demise of 
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dopaminergic neurons (Chung et al., 2001, McNaught et al., 2003). Two PD-related 
genes (parkin and UCH-L1) are involved in the UPS, supporting this notion. parkin is 
an E3 ubiquitin ligase that confers substrate specificity via the process of ubiquitination 
with the aid of E1 ubiquitin-activating enzyme and E2 ubiquitin-conjugating enzyme, 
thereby targeting damaged polyubiquitinated proteins to the UPS once recognized by 
the 26S proteosome (Fig 1.6) (Pickart, 2001). The over 30 or so putative parkin 
substrates have been identified including modified glycosylated form α-synuclein 
(Shimura et al., 2001), including PARIS (Shin et al., 2011). The overexpression some of 
these substrates has been shown to exert cytotoxicity and the overexpression of parkin 
protects against substrate toxicity (Dong et al., 2003, Ren et al., 2003, Staropoli et al., 
2003). parkin has been described as a multifaceted neuroprotective agent (Feany and 
Pallanck, 2003). 
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Figure 1.6 Parkin and ubiquitin proteasome system. A series of reactions are 
mediated by the enzymes of the UPS which ubiquitinate substrates and subsequently 
degrade them. Parkin binds to E2 enzymes and a number of substrates through its C-
terminal RING-box domain and promotes ubiquitination of the substrates. 
Polyubiquitinated substrates are transported to the 26S proteasome, which is thought to 
bind to the ubiquitin-like domain of Parkin, and are rapidly degraded. This an energy-
dependent protein degradation system in which proteins covalently modified with 
polyubiquitin chains are recognized and degraded by 26S proteasome. Ubiquitination is 
a sequential enzymatic reaction carried out by three enzymes, E1 (ubiquitin activating 
enzyme), E2 (ubiquitin conjugating enzyme) and E3 (ubiquitin ligase). E3 specifically 
recognizes the protein fated to be degraded and promotes its ubiquitination in concert 
with E2. Human Parkin has an E3 ubiquitin ligase activity (Shimura et al., 2001), a 
function that requires an intact RING finger and studies in D. melanogaster have shown 
similar mutations in this domain and others that compromise ubiquitin ligase activity 
(Cha et al., 2005). 
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1.6 Parkin models of PD 
1.6.1 D. melanogaster models of PD 
In D. melanogaster, dparkin is highly expressed in the central nervous system (CNS) 
and in the testis (Horowitz et al., 2001, Bae et al., 2003, Chintapalli et al., 2007). Adult 
flies with the loss of function of dparkin are semi-viable with reduced life span and 
locomotion (Greene et al., 2003, Pesah et al., 2004). Additionally, there are reports of 
dopamine-specific neuronal loss in dparkin mutant flies (Greene et al., 2003, Cha et al., 
2005, Whitworth et al., 2005, Sang et al., 2007, Wang et al., 2007), but one group failed 
to the show this age-dependent dopaminergic specific loss (Pesah et al., 2004). 
Irrespective of the loss of dopaminergic neurons, dparkin mutants have reduced staining 
in their CNS for tyrosine hydroxylase (TH), a key enzyme in the synthesis of dopamine 
(Greene et al., 2003, Cha et al., 2005, Whitworth et al., 2005, Wang et al., 2007). There 
is widespread apoptotic degeneration of adult fight muscles that correlates with the 
motor dysfunction as observed from geotaxis climbing assays of dparkin mutant flies 
(Greene et al., 2003). The locomotory defects observed in parkin mutant flies have been 
mainly shown to be due to muscle abnormalities rather than a neuronal failure (or more 
specifically to dopaminergic death) (Pesah et al., 2004). Additional defects include 
sterility in both male and female (Greene et al., 2003, Ottone et al., 2011). Male sterility 
is a result of late defects in spermatid formation in the germline (Greene et al., 2003).  
A key observation from dparkin mutant flies was the presence of droopy wings and 
associated loss of thoracic muscles (Greene et al., 2003). The thoracic muscles showed 
mitochondrial abnormalities (Greene et al., 2003) suggesting oxidative stress most 
likely occur in flies with dparkin mutations. Firstly, longevity was reduced when flies 
were fed with a free radical generator agent, paraquat (Pesah et al., 2004). Secondly, a 
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loss of function allele of Glutathione S-transferase (GST) was identified as an enhancer 
of dparkin25  (null) mutant phenotype from a genomic screen (Pesah et al., 2004). 
GSTS1 is an antioxidant and the flies without both the dparkin and GST genes show 
progressive loss of dopaminergic neurons and oxidative stress (Whitworth et al., 2005). 
Thirdly, D. melanogaster parkin is a negative regulator of the c-Jun N-terminal kinase 
(JNK) pathway suggesting its involvement in oxidative stress mediated signaling 
cascade (Cha et al., 2005). Finally, the lifespan of dparkin mutant flies was extended by 
enhancing antioxidant pathways (Saini et al., 2010). All of the above has shown that 
oxidative stress is as important in dparkin mutant fly models as in human PD. dparkin 
mutants are not only restricted to mitochondrial stress but also to proteosomal and 
endoplasmic reticulum stress. Mitochondrial dysfunction could explain the reduction in 
ATP in energetic tissues, like the muscle for instance, that results in the eventual 
degeneration (and also may affect some dopaminergic neurons) leading to motor 
dysfunction. The mitochondrial-associated defects in the form of their morphology, 
integrity and function observed in dparkin mutants has been shown to be ameliorated by 
up-regulating alternate modes of energy production via AMPK activity (Kim et al., 
2012).  
As noted above, most dparkin phenotypes in flies were not neuronal. Apart from one 
group that specifically stated that third instar dparkin mutant larvae have normal 
neuromuscular junction physiology, (Pesah et al., 2004) no other groups have reported 
whether or not they had investigated the any of the larval stages of dparkin mutant fly 
models. 
1.6.1.2 parkin/ PINK1 mitochondrial associated roles 
Both parkin and PINK1 have been shown to interact (Kim et al., 2008, Xiong et al., 
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2009), showing they are both involved in a common pathway to preserve mitochondrial 
integrity. Mutations in PINK1 gene, that encodes for serine threonine kinase, are also 
responsible for a proportion of early onset autosomal recessive PD (Valente et al., 
2004a). This enzyme possesses a kinase domain, with an additional mitochondrial-
targeting signal (Clark et al., 2006). PINK1 is rich in the heads as well as the testes of 
adult flies, similar to that of parkin expression (Park et al., 2006, Park and Lee, 2006). 
PINK1 mutants show very similar phenotypes to parkin mutants including reduced 
longevity, motor defects, mitochondrial abnormalities, male sterility and apoptotic 
muscle degeneration (Wang et al., 2006, Yang et al., 2006). PINK1 mutants show a 
decline in mitochondrial numbers from dopaminergic neurons with increasing age. 
PINK1-parkin double mutants show similar phenotypes as individual mutants. PINK1 
mutant phenotypes are rescued by wild-type expression of parkin, whereas PINK1 
expression failed to rescue parkin phenotypes, thereby implicating PINK1 action 
upstream of parkin in the PINK1-parkin pathway. This pathway is vital for the survival 
of the dopaminergic neuronal loss in PINK1 mutants, as this selective neuronal loss is 
rescued with wild-type parkin expression (Clark et al., 2006, Park et al., 2006, Vos et 
al., 2012). 
PINK1/parkin regulate mitochondrial integrity (Greene et al., 2003, Pesah et al., 2004, 
Guo, 2012, Vos et al., 2012). Cultured cells show that PINK1 and parkin regulate 
mitophagy in D. melanogaster. This is supported by mammalian work and suggests the 
exciting possibility that failure of mitophagy, a quality control process, underlies the 
pathogenesis of PINK1/ parkin pathway (Fig 1.7).  
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Figure 1.7 parkin-induced mitophagy. Under normal physiological conditions that 
maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where 
these two proteins interact to eliminate abnormal mitochondria through mitophagy. 
Alterations in mitochondrial membrane potential (ΔΨm; a key indicator of 
mitochondrial physiology and cell viability) initiates the PINK1-parkin cascade of 
events leading to mitophagy. High mitochondrial membrane potential causes PINK1 to 
be imported into mitochondria, then to be proteolytically processed and rapidly 
degraded (to have low endogenous levels of PINK1) under basal conditions. In the 
instance of low mitochondrial membrane potential, PINK1 accumulates on the 
mitochondrial surface that signals to parkin to translocate to the mitochondria. parkin 
ubiquitinates mitochondrial proteins at the outer membrane, causes the recruitment of 
adaptor proteins (e.g. p62), which link ubiquitinated cargo to the autophagic machinery. 
Dysfunctional mitochondria are engulfed by phagophores, which matures into 
autophagosomes and fuse with lysosomes to autolysosomes, which eventually degrade 
their content. 
Adapted from (Castillo-Quan, 2011). 
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dparkin (as well as PINK1) mutant phenotypes were rescued with the expression of pro-
fission genes and decreasing expression of genes that promote mitochondrial fusion  
(Deng et al., 2008, Park et al., 2009, Poole et al., 2008, Yang et al., 2008). Reduction in 
gene copy number of dynamin-related protein 1 (drp1), a pro-fission gene, in a PINK1 
mutant background caused lethality (Deng et al., 2008, Poole et al., 2008). Thus, 
suggesting mitochondrial fission is promoted by both PINK1 and parkin. The difference 
in the phenotypes of drp1 mutants compared to that of PINK1 or parkin mutant suggests 
that PINK1/ parkin pathway aid to regulate mitochondrial fission machinery. Parkin is 
recruited to dysfunctional (depolarized) mitochondria involved in the organelle specific 
turnover of mitochondria termed mitophagy (Narendra et al., 2009). 
1.7 D. melanogaster approaches to model neurodegenerative diseases 
1.7.1 Introduction to D. melanogaster genes and their conservation to human genes 
D. melanogaster, the common fruit-fly, has over 100 years’ worth of research and has 
been extensively used for investigating basic questions concerning biological processes 
(Bellen et al., 2010). The completion of the D. melanogaster and human genome 
sequences revealed D. melanogaster and humans have many genes they share in 
common. Although D. melanogaster possesses a compact genome, approximately 1/30 
of the human genome, approximately two thirds of the known human genes have a 
counterpart in D. melanogaster (666 of 911 genes in D. melanogaster) (Reiter et al., 
2001), while 77% of human disease related genes are conserved in the fly (Rubin, 2000, 
Bier, 2005). Additionally, there is a considerable degree of conservation of metabolic 
and signaling pathways at a cellular level, and more strikingly the molecular 
mechanisms for complex behaviors such as circadian rhythm, learning and memory, 
sleep and aggression (Hall, 2003, Mershin et al., 2004, Greenspan et al., 2001, Bellen et 
al., 2010). D. melanogaster has been widely used to research a variety of biological 
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processes including cell death, cell proliferation, growth and migration. This remarkable 
organism is useful in our understanding of disease mechanisms through the 
identification of novel targets for potential therapeutic approaches towards human 
diseases (Auluck et al., 2005, Tain et al., 2009).  
1.7.2 D. melanogaster models of neurodegeneration 
The studies on neurodegenerative diseases using D. melanogaster models have mostly 
focused on Huntington disease (HD) (Ravikumar et al., 2004), Parkinson’s disease (PD) 
(Pendleton et al., 2002) and Alzheimer’s disease (AD) (Torroja et al., 1999), involving 
the misexpression of the relevant mutant human genes for huntingtin, α-synuclein and 
Aβ1–42, respectively (Bilen and Bonini, 2005). Drosophila was shown to be an excellent 
model system for neurodegenerative disease (Hirth, 2010). D. melanogaster have short 
life cycles with 10 days generation time and 60-80 day life span allowing age related 
experiments to be completed within short periods of time. Therefore they are cheap to 
maintain compared to mammalian models (Guo, 2012). The fully sequenced and 
annotated D. melanogaster genome (Adams et al., 2000), along with the tools available 
for homology search algorithms, has aided the identification of several candidate D. 
melanogaster-disease homologues. Four of the five well-studied PD-related genes have 
fly homologues, these include single homologues for Dardarin/ LRRK2, parkin, PINK1 
and two closely related homologues for DJ-1. α-synuclein was the first gene associated 
with PD and the first PD-associated gene to be studied in D. melanogaster, although 
with no orthologue in the fly. 
1.7.3 Genetic approaches using D. melanogaster 
 
Reverse genetic approaches have been useful in the generation of loss-of-function 
(LOF) and gain-of-function (GOF) phenotypes that may successfully recapitulate 
symptoms of certain diseases. LOF phenotypes can be produced by inducing mutations 
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that lower or abolish the activity of gene of interest, e.g. by EMS mutation or by 
excision of P-elements. Alternatively, directed expression of an RNAi interfering 
transgene can be used to achieve subtle LOF phenotypes in, for example, specific types 
of neurons.  A GOF phenotype can be generated through the directed expression of a 
dominant gene of interest. This could be used to increase the expression of the gene to 
abnormally high level, in those tissues where it is normally expressed. Alternatively, it 
may be expressed in tissues where it is not normally expressed. These techniques are 
facilitated by the D. melanogaster stock centers (e.g. Bloomington, Kyoto), which make 
stocks readily available and the many worldwide research laboratories which 
generously share reagents (fly lines, antibodies etc.).  
 
1.7.4 D. melanogaster genetic toolbox used to model Parkinson’s Disease  
An array of sophisticated molecular genetic tools have been developed by the D. 
melanogaster community which has made the common fruit fly a remarkable organism 
to work with (Adams and Sekelsky, 2002; Johnston, 2002; Venken and Bellen, 2005).  
Genetic tools to achieve temporally controlled, tissue specific expression in vivo began 
with fusion of a promoter and a structural gene, for example, the ninaE promoter and 
the Rh2 opsin (Zuker et al., 1988). In this technique, the gene to be expressed was 
inserted next to the promoter, so that a new construct had to be generated for each gene 
to be expressed. This limited flexibility was overcome in the GAL4-UAS bipartite 
transcription activation system (Brand and Perrimon, 1993). In the GAL4-UAS system 
(Fig 1.8), two fly lines are deployed: in one stock, a promoter (or other genomic 
enhancer) is used to drive expression of GAL4 protein, which has no effect on the fly 
genome. The second transgenic fly line holds the gene of interest, under the control of 
Upstream Activating Sequence  (UAS) to which GAL4 binds. In this stock, since there 
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is no GAL4 protein, there is no binding to the UAS and hence no expression of the gene 
of interest. When these two fly lines are crossed, the progeny contain both GAL4-UAS 
components, the expressed GAL4 binds to the UAS site, and this activates transcription 
of the gene of interest in a controlled fashion. The construction of many UAS stocks 
allows the directed production of a wide range of proteins, all with the same pattern of 
tissue expression. Equally, the production of many GAL4 lines, each with a different 
tissue specific pattern, enables comparison of the effects of the protein in a known 
place. The types of neuron in which a particular promoter drives expression may be 
identified by expressing a reporter (e.g. lacZ or GFP) which can be easily visualised 
To generate GAL4 lines in D. melanogaster, enhancer trapping is often used. The 
principle of the GAL4 enhancer trap technique is the insertion of the GAL4 gene into a 
P-element. The P-element contains a weak promoter, which will respond to enhancers 
from the surrounding region of the genome. When these bind to the weak promoter in 
the genome, they activate GAL4 production (Bellen, 1999). The P-elements are 
transposable elements that insert randomly into the genome. Transposable elements are 
discrete pieces of DNA that are mobile, but the P-elements used in enhancer traps do 
not have transposase coding regions, which makes them stable insertions into the 
genome. P-elements used in enhancer trapping commonly also include a marker (e.g. 
mini-white+ eye colour gene) and sometimes lacZ or GFP as a reporter. The inclusion of 
the eye colour gene allows the investigator to trace the presence of the P-element during 
genetic crosses. By mobilising the P-elements and tracking lethality and expression 
patterns, new GAL4 lines are readily established (Duffy, 2002). 
 
The immense flexibility of the enhancer trap and GAL4/UAS system has rapidly 
advanced the fly as a model of disease as it allows the expression of human disease-
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related genes during the course of development and/or adulthood. The GAL4-UAS 
system has been very useful in the generation of models of PD, where pathological 
wild-type and mutant proteins (for example α-synuclein) have been specifically 
expressed in the fly brain in order to investigate effects on dopaminergic neurons 
(Feany and Bender, 2000).  
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Figure 1.8 The GAL4-UAS system. The bipartite expression system that is composed 
of two separate parental fly lines, the responder (UAS) and the driver (GAL4).  
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1.7.5 Advantages and disadvantages of D. melanogaster PD models  
Although many experimental advantages accrue from the lifespan and genetics of flies, 
the mouse does have some advantages. For disease-related gene homologs, the mouse 
has a higher degree of conservation to humans than the fly (Waterston et al., 2002). 
Additionally, having inbred mouse strains with the same genetic background and 
rapidly developing genetic tools may be able to induce a broad spectrum of phenotypic 
manifestations associated with PD. A few mouse models have shown mild perturbation 
of dopamine transmission in nigrostriatal circuits with behavioral defects (Fernagut and 
Chesselet, 2004) and some α-synuclein transgenic mice models show α-synuclein-
induced aggregation accompanied with neuronal degeneration (Anwar et al., 2011).  
Disappointingly, the majority of the genetic mice models fail to show all features of PD 
and many show no dopaminergic degeneration from substantia nigra (Fernagut and 
Chesselet, 2004, Von Coelln et al., 2004, Kitada et al., 2009, Gispert et al., 2009), 
whereas very few only show mild dopaminergic degeneration (Ramonet et al., 2011, 
Shin et al., 2011). The lack of dopaminergic cell death in mice, have been attributed to 
adaptive changes during the course of development over the life span of the mice. 
However there has been recent success in the development of mouse models 
recapitulating key aspects of PD, for example Dawson and co-workers used a 
conditional knockout mouse, to model the loss of parkin function. This model showed a 
progressive degeneration of dopaminergic neurons (Shin et al., 2011).   
 
1.7.6 Observations made from D. melanogaster PD models  
Flies have shown to be better at replicating the disease phenotypes as seen in humans, 
with specific dopaminergic degeneration and also presence of LB-like aggregates in fly 
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neurons. Manipulating the expression of PD-associated genes in the dopaminergic 
neurons in flies has been shown to lead to dopaminergic degeneration. For example 
Feany and Bender (2000) used transgenic flies to aberrantly express high levels of wild-
type human α-synuclein in dopaminergic cells and this caused the death of some 
dopaminergic neurons of the adult fly. Similar results were also obtained from the 
expression of A53T or A30P (which are PD-related mutations) forms of the α-synuclein 
gene, in the fly nervous system (Feany and Bender, 2000). More importantly, the 
serotonergic neuronal population and the gross brain morphology in the α-synuclein-
expressing flies were not altered, suggesting that toxicity caused by α-synuclein is 
specific to dopamine containing neurons in the CNS. Although, there is evidence to 
suggest α-synuclein toxicity is not restricted to the dopamine neurons as the expression 
of α-synuclein in the fly eye induced retinal degeneration (Feany and Bender, 2000). 
The adult fly brain contains clusters of dopaminergic neurons (Nässel and Elekes, 
1992). These dopaminergic neurons have been shown to degenerate when flies are fed 
with a complex 1 inhibitor, rotenone (Coulom and Birman, 2004). Rotenone has also 
shown to cause the degeneration of dopaminergic neurons in mammals (Sherer et al., 
2003, Bové et al., 2005). Together these provide evidence that the toxin rotenone 
induces similar effects on the dopaminergic neurons in two different animal models, 
suggesting the existence of a common conserved mechanism of rotenone between 
mammals and flies.  
Although some D. melanogaster PD models show dopaminergic cell death (Feany and 
Bender, 2000, Whitworth et al., 2005, Trinh et al., 2008), it is not common to all. PD 
models show much more than just dopaminergic cell death including non-dopaminergic 
neuronal dysfunction, locomotory deficits, reduced life span, abnormal wing posture, 
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aggregate formation, abnormal mitochondrial morphology and organization and 
energetic tissue degeneration.  
1.7.7 The D. melanogaster life cycle 
 
Through a series of larval moults, the larva grows approximately 100-fold in size until it 
crawls out of the food as a third instar larva and selects a site for pupation. When the fly 
undergoes metamorphosis, the majority of the larval tissues including muscles 
degenerate and adult tissues develop from imaginal discs and histoblasts. The larval 
nervous system is not lysed, although further development occurs. Other tissue 
including the Malpighian tubules (excretory structures), fat bodies and gonads remain.  
 
During pupal development, which lasts 3-4 days, the axons of the motoneurons 
innervating the degenerating muscles of the larva retract and renew their connections 
with newly regenerated adult muscles. At the end of the metamorphosis phase, an adult 
fly ecloses from the pupal case (Fig 1.9).  
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Figure 1.9 The D. melanogaster life cycle. The embryo develops and gives rise to a 
first instar larva, subsequent growth leads to the second and third instar larvae. The 
transitions between larval instars are moults. The process that converts a third instar 
larva to a pupa is termed pupariation. Emergence of the adult from the pupal case is 
termed eclosion. 
 
Derived from Hartwell, Genetics: From genes to genomes, McGraw-Hill (Hartwell et 
al., 2010). 
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1.7.8 The D. melanogaster nervous system 
The developmental period from the time of the unfertilized egg to reach a fully 
functional larval nervous system (or to the first instar larval stage crawling around the 
food) takes less than 24 hours. The larval CNS comprises the two lobes and the ventral 
nerve cord (VNC) where the motor neurons descend their neuronal axons to innervate 
muscle cells forming synapses at the level of neuromuscular junction (NMJ).  The larval 
CNS contains approximately 125,000 neurons (whereas the fully developed more 
complex fly brain has 250,000 neurons). This is a million fold less than an average 
human brain, but with a similar complexity of neuronal variety (Venken et al., 2011). 
Flies use the same neurotransmitters (glutamate, GABA and acetylcholine), as 
mammals, share biogenic amines (e.g. dopamine and serotonin) and also possess a 
variety of neuro-modulatory peptides. However, flies, unlike vertebrates, use glutamate 
as an excitatory neurotransmitter at the neuromuscular junction (NMJ) and 
acetylcholine in most sensory and central synapses. Another difference between the fly 
and vertebrate nervous system is the ratio of neurons to glia, in flies this is 1:10 whereas 
in vertebrates it is 10:1 (Venken et al., 2011). This may be because glia surround the 
bundles or fascicles of neurons, rather than individual neurons in flies. However, a 
number of glial types exist in flies (Venken et al., 2011).  
 
D. melanogaster neuronal cell bodies are located in a cortical rind encapsulating the 
brain neuropile and made up of axons, dendrites and synapses. The majority of synapses 
make contacts with multiple postsynaptic targets often forming diads, triads or tetrads. 
On average, there are far fewer fly synapses per neuron compared to vertebrate synapse 
(Venken et al., 2011). A variety of sensory nerves are embedded in the body wall 
muscles and feedback to the ventral nerve cord occurs through these nerves.  
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The larval CNS gives rise to segmental nerves (SN), which innervate the body wall 
sense organs and muscles, with each muscle being consistently innervated in the same 
way from larva to another, with a recognizable pattern of synaptic boutons (Budnik et 
al., 1990, Cattaert and Birman, 2001, Barclay et al., 2002). 
 
1.7.8.1 The D. melanogaster dopaminergic system  
The biosynthesis of the neurotransmitter, dopamine, is conserved between D. 
melanogaster and humans. Dopamine is synthesized in the cytoplasm from its 
precursor, tyrosine, with two enzymatic steps.  Firstly, tyrosine is broken down by 
tyrosine hydroxylase (TH) to produce L-3,4-Dihydroxyphenylalanine (LEVODOPA or 
L-DOPA), and then subsequent decarboxylation occurs by the aromatic L-amino acid 
decarboxylase (AAAD) to produce dopamine. Dopamine does not cross the blood brain 
barrier (BBB) whereas L-DOPA and AAAD can. Gene products involved in dopamine 
homeostasis have the potential to hold neuroprotective properties, as dopamine itself is 
suggested to possess neurotoxic effects (Miller et al., 1999).  
The excess dopamine from extracellular spaces is taken up via the plasma membrane 
dopamine transporters (DAT) (Nass and Blakely, 2003, Ritz et al., 2009). Additionally, 
dopamine packaging into synaptic vesicles via the vesicular monoamine transporter 
(VMAT) removes excess dopamine. VMATs are required by all aminergic cells to 
transport the dopamine synthesized in the cytoplasm to be taken up into the lumen of 
the synaptic vesicles (Chaudhry et al., 1998). Dopamine is stored in high millimolar 
concentration in synaptic vesicles (SV) by the vesicular monoamine transporter, where 
it is kept in a stable form (Staal et al., 2004). Mammals possess two VMAT genes 
(VMAT1 and VMAT2). In mammals, the neural isoform VMAT2, is responsible for the 
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storage of dopamine, serotonin, and noradrenaline in all central aminergic neurons 
whereas the VMAT1 gene is expressed at the periphery and in neuroendocrine cells (Liu 
and Edwards, 1997, Erickson and Varoqui, 2000, Eiden et al., 2004). D. melanogaster  
contains a single VMAT ortholog (dVMAT) that is expressed in all dopaminergic, 
serotonergic, and octopaminergic cells in both larvae and adults (Greer et al., 2005, 
Chang et al., 2006). 
Dopamine is an essential neuromodulator in the mammalian CNS that is involved in 
attention, movement control, motivation and cognition (Riemensperger et al., 2011). 
The dopaminergic system is involved in locomotor control in humans as well as in D. 
melanogaster (Yellman et al., 1997, Lima and Miesenböck, 2005), although complete 
understanding of the underlying circuits that govern locomotion are still unknown. 
Approximately 70 dopaminergic neurons have been described in the CNS of the fly 
third instar larva (Budnik et al., 1986). Dense dopaminergic projections almost 
completely cover the entire neuropil of the D. melanogaster larval CNS. The adult fly 
brain contains additional dopaminergic neurons, in 15 clusters (Budnik and White, 
1988, Nässel and Elekes, 1992, Mao and Davis, 2009), some projecting to higher brain 
centres including the central complex and the mushroom bodies (Tanaka et al., 2008, 
Mao and Davis, 2009).  
 
1.7.9 Larval locomotion for motor function assays 
 
Although the D. melanogaster brain has a far smaller population of neurons compared 
to a mammal, the fly still exhibits a large number of behaviors. A promising start has 
been made on understanding the motor circuits involved in escape behavior, larval 
crawling and flight, but much of the detail remain to be fully defined (Crisp et al., 2008, 
Fotowat et al., 2009). The simpler larval nervous system controls a number of 
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stereotyped behaviors including locomotion, and so provides a platform to make an 
excellent model system to study nervous system related disorders.  
 
The D melanogaster larva posses a range of motions including peristalsis, bending, 
turning and feeding: peristaltic movement has been extensively studied (Heckscher et 
al., 2012). The larva has 10 segments: three thoracic segments (T1-T3) and seven 
abdominal segments (A1-A7) with specialized structures at the anterior and posterior 
ends (Keshishian et al., 1996). There are approximately 60 muscles in a segment under 
the epithelium.  
 
The larva propels forward via contraction from the posterior segments to anterior 
segments leading to forward peristaltic locomotion. During peristalsis, the muscle 
contraction travels in approximately 1 second from the posterior to anterior. When the 
peristaltic wave reaches the anterior segment, the head is moved forward and then 
attached on the crawling surface with mouth hooks. The next cycle resumes when the 
peristaltic wave is initiates in the posterior end: cycles may be separated by  brief 
pauses, during which head swinging and turning occurs. For the consecutive waves of 
peristalsis to follow, motor neurons in each segment have to be sequentially activated 
throughout the body axis in a highly regulated fashion.  
 
1.7.9.1 Neuronal network contribution to larval locomotion 
 
Electrophysiological manipulations allow the recordings of regular rhythmic bursts of 
motor neuronal activity that concurrently occur with locomotive waves to be monitored 
(Fox et al., 2006). Rhythmic motor behaviors like crawling involve specialized circuits, 
central pattern generators (CPGs), to contribute to the patterned discharges in motor 
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neurons via their peripheral axons to muscles (Johnston and Levine, 1996, Marder and 
Bucher, 2001). The activities of motor neurons that innervate the body wall muscles 
have been used as a measure of output from the CPG (Fox et al., 2006). Both the CPG, 
the neural network involved in the timing of the motor discharge, and the sensory 
feedback control the rhythmic movements. This concept has been applied to the 
neuronal networks involved in larval locomotion although the identity of CPGs 
responsible is presently unknown. However, there is some evidence that patterned 
motor outputs can be generated in the absence of sensory outputs by central circuits 
alone (Fox et al., 2006, Hughes and Thomas, 2007). When sensory feedback is 
compromised, change in peristalsis pattern is observed. This shows that neural circuits 
including the motor neurons, sensory feedback and interneurons in the CPG, participate 
in the regulation of coordinated pattern of peristaltic locomotion.  
 
1.7.10 Motoneuron development and connectivity to muscle  
 
D. melanogaster neurons and glia in the embryonic CNS are derived from progenitor 
cells called neuroblasts, which undergo asymmetric cell divisions to generate a diversity 
of cell types (Goodman and Doe, 1993). A population of approximately 400 neurons, 
including an estimated 38 motor neurons, are generated from 30 distinct neuroblasts 
within each half-segment (also known as hemisegment) of the embryonic ventral nerve 
cord (VNC) (Schmid et al., 1999). Abdominal hemisegments in the embryo have 30 
highly stereotyped body wall muscles, each of which is innervated by one or more of 
the 38 different motor neurons (Landgraf et al., 1997). 
Several transcription factors have been identified as crucial in regulating the process by 
which motor neurons choose their peripheral branch to later form contact with the 
muscle, and form the neuromuscular junction (NMJ) (Landgraf and Thor, 2006b, 
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Landgraf and Thor, 2006a). These include Even-skipped (Eve), Nkx6, Hb9, LIM, Lim3 
and POU (Landgraf et al., 1999, Thor et al., 1999, Broihier and Skeath, 2002, Certel and 
Thor, 2004). The vertebrate orthologues of these transcription factors have similar 
functions and molecular mechanisms in motor neuron specification. This shows that 
there is conservation between fly and  higher organisms in synapse formation (Thor and 
Thomas, 2002). Molecules that participate in axon guidance and regulate branch 
selection have also been discovered these include Toll which inhibits motor innervation 
when expressed in muscles; and Netrin B, which is a secreted protein from the netrin 
family, that is expressed in certain muscles including muscle 6 and 7 (Ruiz-Cañada and 
Budnik, 2006).  
 
The connectivity of motor neurons to muscles determines the intricate pattern of motor 
output. Approximately 38 motor neurons in the ventral nerve cord descend their axons 
via one of the six branches of the peripheral nerves that include the intersegmental 
nerves (ISN, ISNb and ISNd), segmental nerves (SNa and SNc), and a transverse nerve 
(TN) (Keshishian et al., 1996, Landgraf and Thor, 2006a). Internal muscles in the 
dorsal, ventro-lateral and ventral domains are innervated by ISN, ISNb and ISNd 
respectively. Both SNa and SNc motor neurons innervate external muscles in the lateral 
and ventral domains respectively.  
 
1.7.10.1 The Neuromuscular junction  (NMJ)  
The synaptic connection between the postsynaptic muscle and the presynaptic motor 
neuron is often interchangeably termed a synapse or a NMJ (Fig 1.10). Both embryonic 
and larval nervous systems, with particular emphasis on NMJ, have allowed us to 
understand the basic mechanisms of nervous system development and function.  
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Figure 1.10 The organisation of the neuromuscular junctions (NMJ) of D. 
melanogaster larvae. Movement of the larva is produced by peristaltic waves of 
contraction of the body wall musculature. The rhythmic contractions of the body wall 
segments are coordinated by the central pattern generator (CPG). The motor neurons 
that drive locomotion are located in the dorsal region of the ventral ganglion. (A) The 
brain and ventral nerve cord (VNC) of the larval CNS. (B) The stereotyped organization 
of the peripheral body wall muscles. In each abdominal hemisegment, motor axons 
from the six main nerve branches (ISN, ISNb, ISNd, SNa, SNc, and TN) innervate the 
30 muscles.  
Reproduced from (Kim et al., 2009) with permission.  
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Mammals and arthropods have shown that during the course of their NMJ development, 
dramatic changes in morphology take place both pre and post-synaptically (Gorczyca et 
al., 1993). An increase in D. melanogaster larval muscle size occurs during the course 
of development to late larval stage, to accommodate this change, to retain synaptic 
efficacy, the NMJ expands, making forming new branches and synaptic boutons 
(Schuster et al., 1996, Zito et al., 1999, Ruiz-Cañada and Budnik, 2006). Thus, this 
makes the NMJ an excellent model synapse to study synaptic growth and plasticity 
(Ruiz-Cañada and Budnik, 2006, Collins and DiAntonio, 2007). Another important 
characteristic of these synapses is their ability to homeostatically regulate synaptic 
activity for example, by increasing neurotransmitter release or altering their receptivity 
to pre-synaptic signals in order to retain the consistent physiological levels of 
postsynaptic potentials, in the instance of muscle expansion (Davis, 2006).  
 
The patterned neuromuscular connection is developed by the end of embryogenesis and 
this pattern remains throughout larval life with small changes in soma position, axon 
projection and dendrite morphology (Hoang and Chiba, 2001). The molecular 
mechanisms that regulate synapse formation and function are inherently similar 
between vertebrates and D. melanogaster (Keshishian et al., 1996, Featherstone and 
Broadie, 2000). Key molecules and processes that are regulate NMJ development, for 
example TGFβ/BMP and Wnt/Wg pathways, endocytic machinery, autophagy, and 
electrical excitability, have been uncovered (Budnik et al., 1990, Keshishian et al., 
1996, Featherstone and Broadie, 2000, Marqués, 2005, Dickman et al., 2006, Collins 
and DiAntonio, 2007, Shen and Ganetzky, 2009). The synaptic growth is achieved 
typically by a synaptic bouton budding from a parent bouton at the end of the nerve 
branch, where it extends from the parent bouton and becomes an individual mature 
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bouton itself thereafter (Zito et al., 1999). The NMJ typically consists of branched 
chains of varicosities called synaptic boutons (often described as ‘pearls on a string’) 
that arise (or ‘sprout’) from the motor neurons and are embedded by an elaborate 
membranous compartment formed by the muscle. The larval NMJ terminals, synaptic 
boutons, are classified into larger type I endings, smaller type II endings and minor type 
III endings. Type I are subdivided into type-I small (Is) and type-I big (Ib) (Atwood et 
al., 1993) (please refer to methods). Motor neurons with terminals type-Ib have bigger 
boutons with low threshold firing project onto single muscles, whereas type-Is motor 
neurons have smaller boutons with a high threshold innervate groups of muscles (Choi 
et al., 2004, Schaefer et al., 2010) 
Individual boutons posses multiple release sites, termed active zones, where synaptic 
vesicles dock and later fuse. In front of each active zone there are postsynaptic 
glutamate receptors clustered ready to sense the release of glutamate, the transmitter 
(Marrus et al., 2004). Each bouton contains roughly ten active zones and each motor 
neuron can form around 500 such synapses onto an individual muscle cell.   
1.9 Neurotransmission 
1.9.1 Membrane potential and action potentials 
The precise electrophysiological understanding of nerve and muscle emerged from the 
discovery of electricity itself. Techniques were devised by a number of European 
scientists including Luigi Galvani, Emil Du Boi-Reymond, Carlo Matteucci and 
Hermann von Helmholtz (Brazier, 1979). These electrophysiologists showed through 
the application of electrical stimulus to the nerve and the muscles, that the flow of the 
electricity along the nerve fibres was the cause of movements generated from such 
commands from the brain to the muscle.  
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Electrophysiological studies of electrical activity of nerves revealed that the conduction 
of information along the length of the axon was mediated via the active generation of 
electrical potential known as the action potential (AP). The squid giant axon is an 
excellent preparation to study the AP as its diameter (0.5 mm) made it amenable to 
intracellular recording. Alan Hodgkin and Andrew Huxley demonstrated that axons at 
rest are electrically polarized thus having a resting membrane potential (RMP) that was 
negative, ~ –60 mV inside compared to the outside (Hodgkin, 1939, Hodgkin and 
Huxley, 1945). The RMP is maintained by the sodium-potassium pumps, which extrude 
3 sodium ions outwards and 2 potassium inwards, at the cost of ATP hydrolysis. When 
an AP is generated, the polarization seen at rest is abolished (consequently the cells 
became depolarized) and shifted toward and beyond 0 mV.  At rest all of the sodium 
permeable voltage gated ion channels are closed.  When a stimulus reaches the 
threshold (~ -55 mV) this causes the initiation of an AP, where the voltage gated 
sodium channels open allowing the sodium ions to enter the cells. All voltage gated 
sodium channels open to allow more sodium into the cell until it reaches its equilibrium 
potential. Thereafter, repolarization occurs and as it becomes slightly more negative in 
comparison to the RMP. This period of increased polarization is known as the after-
hyperpolarization (also known as the undershoot). The AP generation in all types of 
neurons and muscle cells follows the same principles of those described in the giant 
squid by Hodgkin and Huxley (HODGKIN and HUXLEY, 1952, Squire et al., 2003). 
Flies and mammals have sodium channels that propagate action potentials, additionally 
the potassium and calcium channels that regulate the membrane potential are from the 
same families (Venken et al., 2011).  
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1.9.2 Advantages of D. melanogaster NMJ for assessing synaptic function 
The release of neurotransmitters at the fly NMJ is similar to the chemical transmission 
at the vertebrate synapses. However the neurotransmitter released at the fly NMJ is 
glutamate whereas acetylcholine is released from vertebrate motor neurons. The fly 
NMJ mimics a central synapse. The neurotransmitter is packaged into synaptic vesicles 
and then releases glutamate into the synaptic cleft upon exocytosis. Miniature excitatory 
junctional postsynaptic potentials (mEJPs) also known as “minis” occur when single 
vesicles fuse spontaneously giving rise to individual ‘quantal’ events.  
The D. melanogaster NMJ is an accessible model synapse for the studying all aspects of 
synaptic development, function and plasticity. The NMJ has played a significant role in 
understanding neurotransmitter release. The molecules involved in synaptic 
transmission are also conserved between D. melanogaster and vertebrates. For example, 
acetylcholine and glutamate are neurotransmitters in both groups, and calcium, syntaxin 
and synaptobrevin are always involved in vesicle release (Richmond and Broadie, 2002, 
Broadie and Richmond, 2002). The function of proteins involved in synaptic 
transmission has been explored using biochemistry and genetics in flies (Broadie, 1995, 
Broadie et al., 1995, Schulze et al., 1995). Studies now shed light on the nature of 
exocytotic event, distinctions between exocytotic pathways in neurons and the 
mechanisms regulating synaptic strength. The mechanism of neurotransmitter release is 
important in the context of the development of synaptic function and how synaptic 
activity can shape development.  
 
The third instar larval preparations are well suited for electrophysiological 
manipulations as they possess large muscle fibers that are relatively easy to access and 
impale. Additionally, it is possible to draw the segmental nerves from the ventral nerve 
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cord into a stimulating pipette, so that the neuromuscular junction activity can be 
controlled precisely.  In comparison, the first instar larvae are a little more challenging 
to work with, but this earlier stage allows recordings of strains with lethal mutations. 
From embryonic to third instar, quantal events along with evoked (stimulated) 
postsynaptic responses can be observed and resolved from noise signals (Ruiz-Cañada 
and Budnik, 2006). Jan and Jan’s (1976) electrophysiological studies demonstrated the 
multiple motorneurons innervate individual body wall hemi-segment (Jan and Jan, 
1976). The stereotypical arrangement of fly NMJ synapses shows comparability and 
little variation from animal to animal (Keshishian et al., 1996). A physiological saline 
based on the composition of larval hemolymph, HL3 (Stewart et al., 1994), preserves 
synaptic transmission as well as muscular function, synaptic integrity and offers 
extended period in which recordings can be undertaken. The majority of the recordings 
are undertaken in the third instar larva or an earlier stage, once an incision is made 
along the dorsal midline, commonly on muscle 6 and 7 due to their accessibility and the 
large size (Li et al., 2002). These muscles are innervated by two different types (Ib and 
Is terminals) of motor neuron contributing to the generation of the postsynaptic 
response, Excitatory Junctional Potentials (EJPs) (Atwood et al., 1993, Hoang and 
Chiba, 2001, Lnenicka and Keshishian, 2000). 
1.10. Rationale for the thesis project 
PD is characterized by motor dysfunction accompanied with selective loss of dopamine 
producing cells. The parkin gene, as previously mentioned, encodes a highly conserved 
E3 ubiquitin ligase involved in the UPS degradation pathway. LOF mutations in parkin 
gene are a common cause early onset autosomal recessive juvenile Parkinsonism 
(ARJP), with an average age of onset of 32 years old. Previous D. melanogaster parkin 
(dparkin) models confidently describe non-neuronal phenotypes, for example, apoptotic 
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muscle degeneration, defects in spermatogenesis and droopy wings. Adult fly models of 
dparkin knockouts have shown promising phenotypes (including mitochondrial 
abnormalities, locomotory defects and dopaminergic loss) that have been related to 
human forms of PD. Some studies (not all) have shown dopaminergic degeneration in 
specific clusters. At the start of the investigation, there were no known reports of 
investigations into the dparkin larva except for one group that found normal NMJ 
morphology and physiology (Pesah et al., 2004). The characteristic neuronal death 
associated with PD suggested that it was important to examine neuronal (rather than 
muscle) phenotypes. Finally, working with the larva, a juvenile stage in the fly, offered 
the opportunity to test for early phenotypes at the start of the (neuro) degenerative 
process. 
1.10.1 Aim and objectives of the thesis 
The aim of the project was uncover neuronal dysfunction in parkin larvae. 
Objectives: 
1. What are the neurophysiological or anatomical dysfunctions observed in the 
juvenile parkin larvae? 
a. Is their synaptic function altered? 
b. Do they show a motor dysfunction at the level of behavior? 
c. Do they show abnormal synapse morphology? 
d. Is there a metabolic dysfunction? 
 
2. What role does oxidative stress play in parkin larval dysfunction? 
a. What is the impact of ubiquitous expression of ‘pure’ antioxidant 
transgenes? 
b. What is the impact of ubiquitous expression of multi-action 
antioxidant transgenes? 
c. Are oxidative stress-induced signals up-regulated? 
!! 67!
d. What effect does manipulating energy homeostatic mechanism have? 
 
3. What are the benefits of pharmacological manipulation of AMPK or 
dopamine synthesis?  
a. What does activation of AMPK have on larval phenotypes? 
b. parkin larvae show reduced crawling, is this a indicator of a loss of 
dopamine signaling? 
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Chapter 2: Methods and Materials 
 
2.1 Overview 
D. melanogaster is one of the most genetically tractable model organisms. This chapter 
describes the genetic techniques employed in this project. It also describes the ways in 
which the behavioural, electrophysiological and anatomical changes in dparkin mutant 
larvae were measured.  
2.1 Fly husbandry and protocols  
2.1.1 D. melanogaster stocks 
dparkin (parkin25/ TM6B and parkinZ3678/ TM6B) mutant D. melanogaster lines were 
kind gifts from Dr Alex Whitworth (University of Sheffield). D. melanogaster stocks 
for this project were originally purchased from Bloomington Stock Centre (Indiana; 
http://flystocks.bio.indiana.edu/), already present in the lab or created by Dr Sean 
Sweeney. All the stocks used for this research are outlined in table below.  
Stocks obtained from external sources were quarantined for at least two generations. 
These stocks were transferred twice a week to fresh food to be confident they were free 
of mites. Mites feed on the eggs and prevent breeding. Thereafter, the flies were 
maintained either at 25oC or 18oC. Stocks were transferred into fresh food as required, 
as the D. melanogaster life cycle takes 10-11 days at 25oC and twice as long at 18oC. 
2.1 Table of Stocks 
STOCKS STOCK SPECIFIC 
INFROMATION 
SOURCE REFERENCE 
Control Stocks 
w1118  White-eyed mutant  
Loss of function 
(referred to as w- in the 
Gift of John Sparrow, 
(University of York, 
(UoY)) 
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text and w- in legends) 
Canton S Wild-type 
Red eyes 
Gift of John Sparrow, 
UoY 
 
CS/w- Cross between our 
Canton S and w1118 
stocks 
  
 
Balancer Stocks 
 
CyO-GFP/If; 
TM6b/MKRS 
Second and Third 
chromosome balancers 
 
Gift of Sean Sweeney, 
UoY 
 
TM3/TM6b 
 
Third balancer 
chromosome 
Gift of Sean Sweeney, 
UoY 
 
 
GAL4 Stocks 
 
elav3E1-GAL4/ 
TM6b 
 
 
Embryonic lethal 
abnormal vision; Third 
chromosome; 
Pan-neuronal driver 
Bloomington Stock 
Centre 
 
G14-GAL4/ 
CyO-GFP 
 
Second chromosome; 
Muscle driver 
Akinao Nose (Tokyo) 
 
(Shishido et al., 
1998) 
TH-GAL4 Tyrosine hydroxylase 
driver; Third 
chromosome; 
Dopaminergic neuron 
driver 
Friggi-Grelin (Friggi-Grelin 
et al., 2003) 
Act5c-GAL4/ 
CyO-GFP 
Second chromosome; 
Ubiquitous driver 
 
Bloomington Stock 
Centre 
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STOCKS STOCK SPECIFIC 
INFROMATION 
SOURCE REFERENCE 
UAS Stocks    
UAS-fosDN Second chromosome;  
Reduces expression of 
FOS 
Bloomington 
Stock Centre 
(Sanyal et al., 
2002) 
UAS-junDN Second chromosome;  
Reduces expression of 
JUN 
Sean Sweeney, 
UoY 
(Eresh et al., 
1997) 
UAS-
BSK(K53R)DN 
Third chromosome; Lack 
of kinase activity 
Sean 
Sweeney,UoY 
(Weber et al., 
2000) 
UAS- AMPK- 
αT184D 
Third chromosome; 
Phosphomimetic, 
activated version of 
AMPK  
Jay Brennan (Swick et al., 
2013) 
UAS-Sod1 Second chromosome; 
Wild-type Superoxide 
dismutase 1 
(Cytoplasmic) 
Sean Sweeney, 
UoY 
(Milton et al., 
2011) 
UAS-Sod2 Second chromosome; 
Wild-type Superoxide 
dismutase 2 
(Mitochondrial) 
Sean Sweeney, 
UoY 
(Milton et al., 
2011) 
UAS-Cat Second chromosome; 
Wild-type catalase 
Fanis Missirlis, 
Queen Mary’s 
London (QML) 
(Missirlis et al., 
2001) 
UAS-TRX-R2 
 
Third chromosome; Wild-
type (mitochondrial) 
Thioredoxin reductase 
Fanis Missirlis,  
QML  
(Tsuda et al., 
2010) 
UAS-gst-S1 
 
Third chromosome; Wild-
type glutathione-s-
transferase Sigma-1 
Alex Whitworth, 
University of 
Sheffield (UoS) 
(Whitworth et al., 
2005) 
UAS-parkinC2 
 
Second chromosome; 
Wild-type Drosophila 
parkin 
Alex Whitworth,  
UoS 
(Whitworth et al., 
2005) 
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STOCKS STOCK SPECIFIC 
INFROMATION 
SOURCE REFERENCE 
Mutant Stocks  
 
parkin25 
/TM6b 
Third chromosome; 
parkin (null) mutant 
induced by p-element 
excision of the full 
first three exons and 
half of exon 4. 
Complete loss of 
protein. 
 
Alex 
Whitworth, 
UoS 
(Greene et al., 2003) 
parkinZ3678 
/TM6b 
 
 
Third chromosome; 
parkin (hypomorph) 
mutant; an ethyl 
methanesulfonate 
(EMS)- induced 
missense point 
mutation (stop 
codon). Some protein 
produced. 
 
Alex 
Whitworth, 
UoS  
(Whitworth et al., 2005) 
 
 
nubian/  
CyO 
Second chromosome; 
Phosphoglycerate 
kinase mutant 
 
Troy Littlejohn (Wang et al., 2004) 
 
RNAi Stocks   
  
dparkin 
RNAi 
Third chromosome; 
RNAi knockdown of 
parkin transcript 
 
Bingwei Lu, 
(Stanford 
University, 
USA) 
(Yang et al., 2003) 
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2.1.2 D. melanogaster diet 
Experimental crosses were reared at 25oC and parental flies were transferred into fresh 
fly media every 3-4 days to prevent overcrowding of larvae, mixing of generations or 
death of parental flies by sticking onto the surface of churned media. All stocks and few 
experiments, detailed later, were raised on standard yeast-sugar-agar media. The 
Technology Facility (TF) at the University of York produced autoclaved standard media 
based on Carpenter’s recipe (Carpenter, 1950). All the following components were 
mixed in a large conical flask: yeast, 25 g/l sucrose, 3.75 g/l agar, 0.125 g/l calcium 
chloride, 0.125 g/l ferrous sulphate, 0.125 g/l manganese chloride and 0.125 g/l sodium 
chloride, and 2g/l potassium-sodium tartrate. After autoclaving and cooling anti-fungal 
agents were added to the medium: 0.0015 g/l Bavistine and 0.2 g/l p-hydroxybenzoic 
acid methyl ester (Nipagin). ~8 ml of medium was pipetted into each 25 cm3 vial which 
was topped with a cotton wool bung (ensuring air circulation but no escape of flies). 
‘Instant media’ Formula 4-24 (Carolina Biological Supplies) was prepared for drug 
experiments. This proprietary mixture is a trade secret formula. The media was prepared 
by using equal volume of water (in which drugs or vehicle had been dissolved) and 
instant media flakes along with a pinch of yeast granules for each vial. This instant 
media was also used to overcome problems of reliability and viability of dparkin mutant 
lines, because (when they were grown on yeast-sugar-agar media) mould and/or slime 
sometimes developed.  
Fly food was prepared freshly every week as required and extra trays were stored at 
18oC before use.  
2.1.3 Fly Pushing 
A dissection microscope (Zeiss Stemi 2000 Dissection Microscope) was used to 
distinguish between the sexes, to look for virgin traits and to identify phenotypic 
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markers. Flies from vials were transferred onto a porous pad connected via tubing 
leading to an outlet valve on the CO2 gas cylinder (Dutscher Scientific, UK) allowing 
gas to seep through and anaesthetize the flies.  
The primary method of collection of virgin females involves tipping out all flies from 
the vial in the morning and collecting females within 8 h after the time of emptying the 
vial, as flies do not mate for up to 8 hours after eclosion.  Secondly, flies that had 
eclosed during the night and early morning can be identified on this basis. Freshly 
eclosed female flies (less than 2 h old) were identified by their light body color and dark 
meconium in the gut, or by their unexpanded wings. Females that could be potential 
virgins were collected separately, dated and left for a week to check their virginity 
status by ensuing any eggs laid by them remained unhatched.  
2.1.4 Recombination crossing scheme 
Recombination was employed when a mutation of the recessive third chromosome gene 
parkin was required along with a third chromosome UAS transgene, for example 
parkin25 and UAS-AMPK. The scheme for this is shown in (Fig 2.1).  First, w-
;parkin25/TM6b flies were crossed with UAS-AMPK flies and virgin females were  
selected from the progeny. The virgin females were chosen because recombination only 
occurs in female in D. melanogaster. These females were individually crossed with a w-
;TM3/TM6b male. As the parkin25 and UAS-genes are both marked with w+, potential 
recombinants have darker orange eyes.  
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Figure 2.1 Recombination Crossing Scheme 
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The progeny of this cross was scanned for males or virgin females with dark eyes. 30-
40 flies were individually mated with w-;TM3/TM6b flies. The offspring of each pair 
carrying a TM6b chromosome 3 (identified by the tubby (Tb) marker) were used to 
generate stocks of potential recombinants. To confirm recombination, a single fly from 
each stock was later screened via polymerase chain reaction (PCR) for the parkin null 
mutation (see section 2.3). Other third chromosome UAS stocks included: UAS- 
AMPK, UAS-BSK-DN, UAS-TRX-R2 and UAS-GST. 
2.2 Molecular Biology 
Screening for dparkin null mutation was performed via polymerase chain reaction 
(PCR) to identify potential recombined mutant stocks (Fig 2.2). 
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Figure 2.2 PCR of dparkin mutant recombinants. Wild-type (CS/w-) larvae and 
dparkin (p25/p25) larvae were used as controls against the possible dparkin mutant 
recombinants. The PCR products were run in parallel with a 1kb ladder. The sample in 
Lane 1 was not successfully extracted. Lane 2 shows a successful extraction from a 
CS/w- larva. Lanes 3 and 4 show successful extraction of two dparkin larvae. Lanes 5-8 
are from larvae that were possible recombinations of dparkin with UAS-GST; 
recombination was not successful in samples 5, 7 and 8. However, Lane 6 shows a 
dparkin (p25/p25) larvae recombinant with UAS-GST transgene. 
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2.2.1 Genomic DNA extraction  
A single fly together with 50 µl of DNA extraction buffer (10 mM Tris pH 8.2, 1mM 
EDTA, 25 mM NaCl) and with fresh 200 µg/ml proteinase K, was used to rupture and 
release the DNA by repeated squishing motion using the end of a pipette tip. Then, the 
homogenized mixture was incubated at 37oC for 30 minutes and then at 85oC for 10 
minutes where the proteinase K is deactivated. The mixture was centrifuged at 13,000 
for one minute to form a pellet, where 2-3 µl of the supernatant was used as a template 
PCR reaction thereafter.   
2.2.2 Polymerase chain reaction (PCR) 
2X PCR mastermix (Promega, UK) was used to make up a 20 µl reaction volume 
containing 0.5 µM of each primer and 2-3 µl of homogenized fly DNA template to 
amplify the genomic DNA. Primers were designed using Primer3 software and 
synthesized by Eurogentec (UK). The melting temperature (Tm) was calculated using 
Net Primer. The annealing temperature was set 5oC lower than the lowest melting point 
temperature of all primer pairs used. The elongation time for a fragment was determined 
based on the fact that 1kb of DNA is produced per minute by Taq polymerase. 
Standard PCR cycling were as follows: initial denaturation was at 94oC for 10 minutes, 
followed by another denaturation step of 94oC for 30 seconds, then annealing step at Tm 
(explained above) for 60 seconds, followed by 72oC for initial elongations step (1kb for 
1 minute), followed by final elongation cycles at 72oC for 5 minutes. Reaction mixtures 
were set to cool to 4oC. 
2.2.3 DNA agarose gel electrophoresis 
DNA products from the PCR were analysed by agarose gel electrophoresis made from 
agarose and 1x TAE buffer (Tris-Acetate and 0.05M EDTA). 0.7 % or 1.4 % agarose 
gels were made depending on the product size being large (>1kb) or small (<1kb) 
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respectively. 0.1% SYBR Safe (Invitrogen, UK) was added to the heated and dissolved 
agarose, to visualize the PCR products later. 10 µl of PCR product was mixed with 
loading dye (Bromophenol Blue, 10% glycerol) at a time and loaded into individual 
wells of the solidified agarose gel placed in a tank filled with 1x TAE buffer. A 1 kb or 
100kb DNA ladder (NEB, Ipswich or Promega depending on the % agarose gel), was 
also loaded to determine the size of the PCR products.  The gel was run for 
approximately 45 minutes at 90 volts. The gel was placed on a safe imager 2.0 Blue 
Light Transilluminator (Life technologies), to visualize the PCR products and the 
ladder, and an image taken (Fig 2.2).  
2.3 Techniques to assess D. melanogaster larval physiology 
2.3.1 Experimental Solutions  
Phosphate Buffer Solution 1x (PBS) was composed of 10 mM PBS: 137 mM NaCl; 
2.7 mM KCl; 10 mM Na2HPO4 and 2 mM KH2PO4. Modified ‘haemolymph-like buffer 
‘HL3’ solution was made with sodium chloride, 70 mM; potassium chloride, 5 mM; 
calcium chloride, 1mM; sodium hydrogen carbonate, 10 mM; BES (N, N-bis(2-
hydroxyethyl)-2-aminoethanesulphonic acid), 5 mM; trehalose, 5mM; sucrose, 115 
mM; pH 7.5. This solution was used previously at York (Hill & Elliott, unpubl.) in 
assays of octopaminergic modulation, and was found to give stable resting membrane 
potentials. It is based on the original composition detailed by Stewart et al. (1994), but 
omits magnesium chloride (Stewart et al., 1994). This modified HL3 solution was used 
to dissect the wandering third instar larvae in all the electrophysiological experiments 
(see section 2.4.2). 
2.3.2 Larval Dissection 
Third instar wandering larvae, found on the sides of food vials that have crawled out of 
the food, were picked using sharp forceps and placed on a Sylgard petri plate (Silicone 
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elastomer kit, Dow Corning) immersed in either PBS or modified Haemolymph-like 
buffer ‘HL3 solution’. The larva was pinned down at both anterior and posterior ends 
using dissection minuten pins (Austerlitz Insect Pins 0.1mm diameter, Fine Science 
Tools, Heidelburg, Germany). An incision was made using sharp BowSpring scissors 
(Fine Science Tools, Heidelburg, Germany) at the two ends close to each pin.  From the 
posterior dorsal, the scissors were used to cut open the larva along the dorsal midline, 
up to the anterior end. All internal organs including trachea, gut, fat bodies and salivary 
glands were removed cautiously using a plastic Pasteur pipette. The body cavity was 
washed in fresh PBS or HL3. The larval body wall was fully exposed by pinning out the 
four corners. 
2.3.3 Electrophysiology: Intracellular muscle recordings 
All preparations used for recording resting membrane potential (RMP), basal level 
synaptic activity (excitatory junctional potentials, EJPs) (Fig 2.3) and spontaneous 
minis (mEJPs) were dissected in a 21-22oC room where the rig was set up for the 
intracellular recordings and the dissected preparations were used within 5-10 minutes 
from the start of pinning them down. As temperature affects glutamate receptor kinetics 
and EJP amplitudes, the room was checked for fluctuations of temperature from 21-
22oC and the HL3 solution was left in the room to acclimatize to room temperature 
before use.  
Sharp micropipettes were pulled using 1mm diameter borosilicate glass with a 
resistance of 10-20Mohms from a puller (Flaming Brown micropipette puller model P-
97, Stutter Instrument Co) and filled with 3 M potassium acetate. 
RMP recordings were taken from muscles 6, 7, 13, or 12 using a sharp electrode from 
abdominal A2-A6 segments. When recording basal synaptic transmission, the larval 
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brain was left in place, so that the motor neurons still synapsed onto the body wall 
muscles and frequent spontaneous EJPs could be recorded. Spontaneous EJPs were 
recorded from muscles 6 and 7 of the A3 segment (Fig 2.3). All EJPs from a range 
RMPs were recorded to disk and later replayed to determine the mean amplitude. The 
RMP was also noted from the overlaid EJP trace. 
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Figure 2.3 Recording at the NMJ. Spontaneous EJPs were recorded from muscles 6 
and 7 of the A3 segment from wild type (CS/w-) and dparkin (p25pz3678) larvae. At the 
larval NMJ, the Type I synaptic boutons are subdivided into type-I small (Is) and type-I 
big (Ib) (Atwood et al., 1993). Motor neurons with terminals type-Ib have bigger 
boutons with low threshold firing, project onto single muscles and produce small EJPs 
(arrows), whereas type-Is motor neurons have smaller boutons with a high threshold and 
innervate groups of muscles, producing large EJPs (arrows). 
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For mEJPs the brain was removed during dissection. All mEJPs were recorded from 
muscle 6 or 7 of the A3 segments only. Only mEJPs that had a RMP around -60mV 
were used for analysis. Recordings lasted up for 2 minutes and the first 50 mEJP 
amplitudes were calculated manually. mEJPs were represented on a cumulative 
frequency chart.  
All data files were recorded using DASYLab software (Dasylab v9, Measurement 
Computing).  The RMP, EJPs or mEJPs were measured using DASYView (Version 
2.1.1, customised software, C. Elliott, University of York). A scatter graph was 
constructed, plotting the EJP values against the RMP at which they had been recorded. 
The line of best fit (regression or trend line) was calculated for the dparkin mutants 
using their EJP/RMP points. The residual plot was constructed by calculating the mean 
distance of all individual points from the dparkin mutant line for all the different 
genotypes.   
2.3.4 Behavioral locomotion assay 
Larval crawling was determined as follows: larvae were dipped and washed in HL3 
solution in the 25oC room where the apparatus was set up. A camera and computer 
software VirtualDub (Hill, 2008) (Fig 2.4) was used to record larval tracks on a 1% agar 
plate (0.01 g/ml agar in water). The AVI video file containing the recording of larval 
crawling across an agar petri dish was opened using the ImageJ analysis program 
(Schneider et al., 2012). The average background image was calculated using the 
median z projection algorithm across the entire file (Image/ Stacks/ Z project). The 
image showing only the larvae against a dark grey frame was produced by subtracting 
the background image from their individual frame (Process/ Image calculator- subtract 
the original from median image). In the Mtrack2 plugin, a minimum object size of 5 
pixels was selected to eliminate speckles. The other default settings (maximum object 
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size (999999), maximum velocity (10) and minimum track length (2)) were used. All 
the option boxes (Save results file, Display path length, Show labels, Show positions & 
Show path) were ticked. This produced the larval tracks and the individual x-y 
coordinates throughout the 2 minutes recording.  The x-y coordinates were saved to disk 
in an Excel format file, and an Excel template used to calculate the distance travelled in 
2 minutes by each larva. The number of pixels occupied by a 20 mm bar on the ruler 
was used to determine the distance represented by each pixel. In daily use, this 
procedure was automated using the tools at 
(http://biolpc22.york.ac.uk/drosophila/larvae/) giving an output of the median speed of 
each larva (Fig 2.4). 
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Figure 2.4 Analysis of larval crawling by ImageJ and MTrack2. A An AVI file 
recording the motion of wild-type larvae across the agar plate is opened in the ImageJ 
analysis program. B ImageJ is used to calculate the median intensity across the entire 
file of 120 frames, giving a background image.  C The image sequence showing just the 
larvae that is produced by subtracting the background image from each of the individual 
frames. D MTrack2 is used to locate the center of each larva in each frame. It generates 
a sequence of frames showing the calculated x-y coordinates for each larva (for 
example, in the illustration shown, for position 1, x=304, y=170). These positions are 
then are saved in an Excel format file by the MTrack2 software.  
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2.4 Anatomy at the larval neuromuscular junction (NMJ) 
2.4.1 Fixing and immunohistochemistry  
PBS was completely removed from the freshly dissected larval preparation and replaced 
with a solution of 3.7% formaldehyde in PBS for 7mins at room temperature (RT). The 
pins were taken off the preparation and the preparation was transferred to an Eppendorf 
tube containing PBS-T (PBS with 0.1% (v/v) Triton X-100) at RT to rinse off any 
remaining fixative and placed on a rocker, followed by another 3 washes in PBS-T left 
on the rocker for 10 mins incubation each at RT. Primary antibodies (see Table 2.2) 
were added at their desired concentrations (1/200 or 1/1000) and left to incubate 
overnight at 4oC on a rocker. To remove excess primary antibody, 3x 10 mins washes 
with PBS-T at RT were carried out before adding the secondary antibody (see Table 
2.2) for 2 hrs on the rocker at RT. The final 3 washes with PBS-T for 10 mins at RT 
were undertaken to remove any excess secondary antibody.  To reduce air bubbles, the 
preparations were transferred into fresh Eppendorf tubes containing 70% (v/v) 
glycerol/PBS and left for 2 h standing upright at RT or 4oC overnight until they sank to 
the bottom of the tubes. Larval preparations were taken and mounted onto microscope 
slides with a drop of Vectashield (Vector Laboratories) and a 22mm x 22mm coverslip 
was placed directly on top. Nail varnish was used to seal the edges of the preparation 
with Vectashield and the slide was stored in the dark (slide box). 
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2.2 Table of antibodies used for NMJ bouton counts  
2.4.2 Confocal images of the NMJ  
NMJ images were taken using a laser scanning confocal microscope (Zeiss LSM 510 
meta Axiovert 200M). The following objectives were used: 10x, 20x and 63x oil 
immersion. The 63x objective was used to take a z-stack image of the NMJ.   
 
 
Antibody/!stains! Raised! host!species!! Dilution!factor! Source!! !
AntiBHorseradishB!!peroxidaseBCy3!!(HRPBCy3)!!!Neuronal!!Tissue!
Goat! 1:200! (Middleton!et!al.,!2006)!
AntiBsynaptotagmin!!(AntiBSYT)!!!Synaptic!!Boutons!
Rabbit! 1:1000! (Sweeney! and!Davis,!2002)!
FITC!secondary! Goat! 1:200! Jackson!Laboratories,!USA!!
!
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2.4.3 Measuring and quantifying at the NMJ 
 
Bouton count quantification was undertaken where individual spherical structures 
stained with anti-synaptotagmin at the NMJ at the A3 segment from NMJ 6/7 were 
counted using a Leica DMLA fluorescence microscope using a 40x objective and FITC 
filter (Fig 2.5). Muscle surface area (MSA) measurement was found by taking an image 
with a 10x objective using bright field of the A3 muscle (Fig 2.6) which had also been 
used to count the number of boutons. ImageJ was used to analyse the resulting images. 
The length and width of the muscle was measured in pixels and this was converted into 
µm. An image was taken of a 1mm graticule with 100 divisions using the 10x objective 
used to take the muscle images. The markings of the graticule permits the calculation of 
pixel to µm ratio.  
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Figure 2.5 Confocal image of the NMJ anatomy. D. melanogaster wild-type (CS/w-) 
third instar larval NMJ stained with horseradish peroxidase (HRP, purple) and 
synaptotagmin (SYT, green). HRP stains neuronal membrane and SYT is a synaptic 
bouton marker, both of which are used together to determine the raw bouton count. 
To provide a fair comparison of larvae of different sizes, a normalized bouton count was 
calculated as follows: for each neuromuscular junction, the actual “raw” bouton count 
(Fig 2.5) was divided by the corresponding individual MSA (Fig 2.6). To compare 
different genotypes, or the effects of drug treatment, the mean raw bouton count/MSA 
for each genotype or treatment was calculated. The mean was then expressed as a 
percentage of the normalized average of control (normally the wild-type or drug-free) 
larvae. 
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Figure 2.6 Light microscope image of the NMJ. D. melanogaster wild-type (CS/w-) 
third instar larval NMJ muscle 6/7 is indicated on the diagram by a cross. The surface 
area of this region was measured to normalize bouton count.  
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2.5 Statistics  
Here we report the results of Tukey post hoc tests. While these are not as conservative 
as the Bonferroni tests, the Tukey tests provide an accurate indication of the 
significance level. Kolmogorov–Smirnov test statistics was used to calculate the 
probability for the cumulative frequency histogram plot. In the figures, * →  P<0.05; ** 
→ P<0.01; *** → P<=0.001. 
 
2.6 Rationale for drug concentration  
Preliminary unpublished data from student projects suggested that L-DOPA at 3 µM 
concentration was successful in experiments recording behavioral phenotypes in D. 
melanogaster adults.  Metformin and AICAR started with 3 µM concentrations. 
Additionally, other higher concentrations (50 µM) were used for AICAR and these were 
starting points for Resveratrol experiments. A 200 µM concentration of Resveratrol 
used based on studies by Partridge’s group for adult flies (Slack et al., 2012). 
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Chapter 3: dparkin mutant larvae show reduced locomotion, synaptic dysfunction 
and overgrown synapses 
 
3.1 Introduction 
D. melanogaster is a good model system to model PD, which has been reviewed in 
Chapter 1. Since PD is characterized by motor dysfunction, it was logical to test 
whether the dparkin mutant larvae showed signs of a motor defect. Larval locomotion 
has been studied using a number of crawling assays (Fox et al., 2006, Steinert et al., 
2012), for example showing reduced velocity when octopamine or tyramine levels were 
manipulated (Hill, 2008, Selcho et al., 2012). The method developed in York by Hill 
(2008) will be used to measure the overall velocity. The velocity index used for the 
experiments in this thesis will be the overall distance covered by the larva in a period of 
2 minutes. Crawling assays were used to test for locomotory dysfunction in all dparkin 
mutant larvae, as this is characteristic of the human disease.  
Morphological and electrophysiological analysis from larval synapses will test for 
abnormal anatomy and physiology to complement the behavioral analysis. The 
electrophysiological (in vivo) recordings will be taken from larval longitudinal body 
wall muscles 6, 7, 12 and 13, as these have been well characterized and studied 
extensively (Atwood et al., 1993). This will allow the comparison of the resting 
(spontaneous not stimulated) synaptic function between mutants and control. 
A key experiment is to assess the extent of overgrown synapses in the dparkin larva, as 
overgrown synapses are indicative of oxidative stress in a range of neurodegenerative 
and chemically-induced D. melanogaster models (Milton et al., 2011). Therefore, we 
investigated whether there was neuronal overgrowth in dparkin mutant larvae that might 
be caused by oxidative stress.  Mitochondrial-associated defects are observed in humans 
with parkin mutations and this is conserved in all model organisms (Müftüoglu et al., 
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2004, Mortiboys et al., 2008, Palacino et al., 2004).  
To investigate the effect of loss of dparkin, we deployed 2 well-characterized 
mutations. Like other mutations in the PARKIN gene, these result in a loss of function, 
(rather than a gain of function as seen with other PD genes such as α-synuclein (Eriksen 
et al., 2003). parkin25 flies were generated by P-element induced excision, in which the 
first three exons of the dparkin gene have been deleted along with half of exon 4. 
parkin25 is a null with complete loss of parkin protein (Greene et al., 2003). parkinZ3678 
is EMS induced point (missense) mutation (stop codon, Whitworth, personal 
communication). It is a hypomorph with reduced protein production. A 
transheterozygote (parkin25/ parkinZ3678) mutant combination was normally used to 
avoid artifacts due to second site mutations, but additionally there will be comparisons 
of transheterozygote mutant data with the homozygous parkin25 null mutants in this 
chapter.  
The GAL4-UAS system was used to rescue the mutant phenotypes in a tissue specific 
manner, expressing wild-type dparkin in a mutant background. For ubiquitous 
expression of dparkin, the Actin5c-GAL4 driver was used, and the G14-GAL4 enhancer 
trap line was used to express dparkin in all somatic muscles and salivary glands (Aberle 
et al., 2002). Embryonic lethal abnormal vision (elav3E1-GAL4) enhancer trap (Davis et 
al., 1997) was used to express dparkin pan-neuronally.  This will test whether the 
presynaptic or postsynaptic loss of dparkin is responsible for the respective mutant 
phenotypes.  
A second approach to manipulate dparkin levels was used. In this RNAi targeted at 
dparkin was expressed to knock down parkin protein in all tissues, or in a tissue specific 
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Lu’s lab developed an in vivo D. melanogaster RNAi model with dparkin-mediated 
neurotoxicity and showed targeted expression of dparkin dsRNA in fly dopaminergic 
and serotonergic neurons in which the expression of GAL4 is under the control of the 
DOPA decarboxylase gene promoter (Ddc-GAL4) (Li et al., 2000) that did not result in 
neuronal loss.  However, targeted overexpression of human Pael-R protein, another 
parkin substrate, resulted in the reduction of TH-positive dopaminergic neurons. The 
co-expression of dparkin dsRNA and Pael-R protein exacerbated the Pael-R phenotype 
age dependent selective loss of D. melanogaster dopaminergic neurons whereas the co-
expression of Pael-R with human parkin resulted in the degradation of Pael-R and 
prevented the degeneration phenotype (Yang et al., 2003). The knock down of dparkin 
by RNAi under a heat shock (hs)-GAL4 was confirmed with RT-PCR analysis that 
showed the dparkin mRNA transcript levels was undetectable  (Yang et al., 2003).  
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3.2. Results 
dparkin larvae crawl more slowly 
Motor dysfunction is a classical feature in PD patients. The crawling assay for D. 
melanogaster larvae was used to assess motor dysfunction. This was done by placing 
larvae on the surface of an agar plate and tracking the full path travelled over the course 
of 2 minutes. The crawling assay showed that, with a global loss of dparkin, the tracks 
were, on average, 26% shorter. As velocity is distance/time, this corresponds to a 26% 
reduction in velocity (p < 0.007) in dparkin (p25/pZ3678) transheterozygote mutant larvae 
(0.57mm/s) compared to their wild-type (CS/w-) controls (0.73mm/s),  (Fig. 3.1).  
Dopaminergic neurons are metabolically active neurons having extensive arbors and 
many synapses, and so are prone to oxidative insults and energy depletion. To test the 
role of dparkin on dopaminergic integrity and function, the tyrosine hydroxylase (TH)-
GAL4 driver was chosen to induce knock down of dparkin specifically in dopaminergic 
cells by RNAi silencing using dparkin RNAi (Yang et al., 2003). TH-GAL4 expression 
studies are known to target most of the dopaminergic neurons in the central nervous 
system (CNS) with the exception of protocerebral anterior medial (PAM) cluster 
(Friggi-Grelin et al., 2003, Botella et al., 2008). Expressing dparkin RNAi with the TH-
GAL4 did not affect the speed of crawling (0.71mm/s, p = 0.975) compared to their 
wild-type (0.73mm/s, CS/w-) controls. The TH-GAL4 (TH/CS) control showed no 
significant difference to wild-type (CS/w-) controls (Fig.  3.2).  
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Figure 3.1 dparkin mutant larvae show reduced locomotion 
dparkin (p25/pZ3678) transheterozygote mutant larvae show reduced velocity compared to 
wild-type control (CS/w-) larvae (p = 0.007). 
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Figure 3.2 Dopaminergic expression of transgenic dparkin RNAi fails to show 
dysfunction in larval crawling 
The dparkin RNAi line was crossed with the tyrosine hydroxylase driver (TH-GAL4), 
to induce the loss of dparkin specifically in dopaminergic neurons. Such TH>dparkin 
RNAi larvae showed no difference in crawling speed compared to wild-type (CS/w-) 
larvae (p = 0.975). The GAL4 control larvae (TH/CS) showed no difference in crawling 
to wild-type larvae (p = 0.810) or the knockdown (p = 0.752). TH/CS was used as a 
control to see whether the insertion of the GAL4 had any effect in a wild-type (CS) 
background.  
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dparkin mutant larvae show neuronal overgrowth at the neuromuscular junction 
With the findings of motor impairment in our dparkin (p25/pZ3567) transheterozygote 
mutant line, we next checked for morphological abnormalities. The neuromuscular 
junction (NMJ) of dparkin (p25/ pZ3567) mutant larvae was shown to be 82% overgrown 
(p = 0.001, Fig. 3.3A) compared to their wild-type (CS/w-) controls. The overgrowth is 
a result of an increase in neuronal growth (24%, p = 0.001, Fig. 3.3B) and a reduction 
(29%, p = 0.001, Fig. 3.3C) in muscle surface area (MSA) compared to wild-type 
(CS/w-) synapses. The neuronal (elav3E1-GAL4) or muscle (G14-GAL4) expression of 
wild-type dparkin in the dparkin (p25/ pZ3567) mutant background rescued the normalized 
overgrowth to 5% and 10% below wild-type (CS/w-) levels respectively (Fig.  3.3). The 
neuronal or muscle expression of wild-type dparkin in a dparkin (p25/pZ3678) mutant 
background also decreased raw bouton number (B, p < 0.001 and p < 0.001 
respectively) and increased muscle surface area (C, p = 0.05 and p < 0.001 
respectively), when compared to dparkin (p25/pZ3678) mutant larvae. There is no 
difference in overgrowth (normalized bouton count, raw bouton count or muscle surface 
area) between the neuronal (elav3E1 > dparkin; p25/pZ3678) or muscle (G14 > dparkin; 
p25/pZ3678) rescue in a mutant background compared to wild-type control (CS/w-) larvae 
(A, p = 0.984 and p = 0.842; B, p = 0.326 and p = 0.914; C, p = 0.538 and p = 0.823 
neuronal or muscle respectively). 
To support this data, we used a second technique, expressing dparkin RNAi by the 
ubiquitous Act5c-GAL4 driver. This resulted in an increased overgrowth (49%, p = 
0.008, Fig. 3.4A) compared their wild-type (CS/w-) control. The dparkin 
transheterozygote mutants showed overgrowth at approximately twice the level of that 
of global knockdown of dparkin RNAi (Fig. 3.4A). The global knockdown of dparkin 
RNAi shows an increase in raw bouton number (p = 0.008, Fig. 3.4B) and a decrease in 
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muscle surface area (MSA) (p < 0.001, Fig. 3.4C), when compared to wild-type (CS/w-) 
larvae. There is no significant difference between the actin control (Act5c/CS) and the 
wild-type (CS/w-) control  (normalized, raw bouton count and MSA; p = 0.918, p = 
0.121 and p = 0.683 respectively; Fig. 3.4A-C).  
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Figure 3.3 Loss of dparkin-induced overgrowth rescued by neuronal or muscle 
expression of wild-type dparkin 
A-C dparkin (p25/pZ3678) mutant larval neuromuscular junctions show an increase in 
normalized bouton overgrowth (A, p < 0.001), an increase in raw bouton number (B, p 
< 0.001) and a decrease in muscle surface area (C, p < 0.001), when compared to wild-
type (CS/w-) larvae. The neuronal or muscle expression of wild-type dparkin in a 
dparkin (p25/pZ3678) mutant background also decreased raw bouton number (B, p < 0.001 
and p < 0.001 respectively) and increased muscle surface area (C, p = 0.05 and p < 
0.001 respectively), when compared to dparkin (p25/pZ3678) mutant larvae. There is no 
difference in overgrowth (normalized bouton count, raw bouton count or muscle surface 
area) between the neuronal (elav3E1 > dparkin; p25/pZ3678) or muscle (G14 > dparkin; 
p25/pZ3678) rescue in a mutant background compared to wild-type control (CS/w- larvae 
(A, p = 0.984 and p = 0.842; B, p = 0.326 and p = 0.914; C, p = 0.538 and p = 0.823 
neuronal or muscle respectively). 
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Figure 3.4 Global expression of transgenic dparkin RNAi shows an enhanced 
overgrowth phenotype. 
A-C The global expression of the dparkin transgenic RNAi shows an increase in 
normalized bouton overgrowth (A, p = 0.008), an increase in raw bouton number (B, p 
= 0.008) and a decrease in muscle surface area (C, p < 0.001), when compared to wild-
type (CS/w-) larvae.  
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dparkin mutant larvae have depolarized resting membrane potentials 
The larval neuromuscular junction (NMJ) is a glutamatergic synapse that models a 
central synapse of mammals as it uses glutamate as its transmitter in the NMJ synapse. 
The intracellular recordings from the longitudinal body wall muscles 6 and 7 of dparkin 
(p25/pZ3678) transheterozygote mutant larvae commonly show depolarized resting 
membrane potentials (RMPs, N= 34), (Fig. 3.5). This is confirmed by the mean data: 
dparkin (p25/pZ3678) mutant larvae show more positive (depolarized) RMPs compared to 
wild-type (CS/w-) larvae (mean difference 12 mV, p < 0.001, Fig. 3.5). Global (Act5c-
GAL4) or neuronal (elav31E) expression of wild-type dparkin in a dparkin (p25/pZ3678) 
transheterozygote mutant background failed to rescue the RMP defects (p = 0.734 and p 
= 0.504 respectively, Fig. 3.5). On the other hand, muscle (G14-GAL4) expression of 
wild-type dparkin rescued the mutant RMP phenotype (p = 0.017, Fig. 3.5). dparkin 
mutant larvae have smaller EJPs (Fig. 3.6). 
In preparations in which the brain and nerves are left intact, intracellular recordings 
from larval muscles frequently show spontaneous excitatory junctional potentials 
(EJPs). In recordings from dparkin transheterozygote larvae, the EJPs appear smaller 
(Fig. 3.6). To examine this in detail we focused on the Is EJPs, finding that the mean 
size of the dparkin (p25/pZ3678) mutant larvae was 14% of the wild-type (CS/w-) controls. 
The size of the EJPs is affected by transmitter binding to the postsynaptic glutamate 
receptors, but also by the muscle RMP. As the RMP becomes more depolarized, and 
moves towards the reversal potential (-1mV, (Jan and Jan, 1976)) Jan and Jan, 1976) the 
EJP will decrease; conversely as the RMP becomes more negative, the EJP will 
increase.  As the RMPs of dparkin (p25/pZ3678) transheterozygote mutant larvae were 
more depolarized compared to wild-type (CS/w-) controls, the synaptic potentials might 
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be smaller just because of this difference in membrane potential. To explore this, the 
size of the Is EJP was plotted against the RMP (Fig. 3.6). It appears that the data points 
from the dparkin (p25/pZ3678) mutant larvae tend to lie below those from the wild-type 
(CS/w-) controls. To confirm this, the best-fit regression lines were drawn for both 
genotypes, using data points in which the RMP was between -40 and -75 mV data to 
construct the line (Fig. 3.7). The lower regression line for dparkin (p25/ 
pZ3678) mutant larvae confirmed that their spontaneous EJPs appear smaller than those 
from wild-type (CS/w-) controls at the corresponding RMP (Fig. 3.7). To confirm this 
statistically, I measured the vertical distance between each data point and the dparkin 
(p25/pZ3678) mutant larvae regression line (the residual). For each genotype, I calculated 
the mean and standard error of the residual, and plotted this (Fig. 3.7). I tested the null 
hypothesis, that if each genotype had the same size EJP as the dparkin, the mean 
deviation from the dparkin regression line should be zero. For the wild-type (CS/w-) 
data, the t-test confirmed that the wild-type larvae have a larger EJP than the dparkin 
(p25/ pZ3678) mutant larvae  (p < 0.001, Fig. 3.7). On this analysis, which allows for the 
effect of RMP, the average synaptic potentials of dparkin larvae were estimated to be 
7mV smaller than the wild-type  (CS/w-) controls. In the same way, we examined the 
effect of expressing wild-type dparkin globally (Act5c-GAL4), neuronally (elav3E1-
GAL4) or in muscle (G14-GAL4) in a dparkin (p25/ pZ3678) transheterozygote 
background. In each case this rescued the synaptic transmission defect compared to 
dparkin (p25/ pZ3678) mutant larvae (p = 0.001, p < 0.001 and p = 0.033 respectively). 
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Figure 3.5 dparkin mutant larvae show more positive (depolarized) RMP that is 
rescued by global, neuronal or muscle expression of wild-type dparkin 
dparkin (p25/pZ3678) mutant larvae show more positive (depolarized) RMP (resting 
membrane potential) compared to wild-type (CS/w-) larvae (p < 0.001). Global (Act5c-
GAL4) or neuronal (elav3E–GAL4) expression of wild-type dparkin in a dparkin 
(p25/pZ3678) mutant transheterozygote background failed to rescue the RMP defects (p = 
0.734 and p = 0.504 respectively) compared to dparkin (p25/p25) mutant larvae, whereas 
the muscle (G14–GAL4) expression of wild-type dparkin rescued the mutant RMP 
phenotype (p = 0.017). These recordings were taken from muscle 6/7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
!! 116!
 
 
 
 
 
 
 
 
 
0"5"
10"15"
20"25"
30"35"
40"
(90" (80" (70" (60" (50" (40" (30" (20" (10" 0"
EJP"am
plitude
"(mV)"
Resting"membrane"potential"(mV)"
p25/pZ3678"CS/w("
Fig$$3.6$
!
CS/w%!
p25/pZ3678!!
!! 117!
Figure 3.6 Scatter regression plot show dparkin mutant larvae have depolarized 
RMPs and smaller EJPs across a range of RMPs.  
dparkin (p25/pZ3678) mutant larvae show more positive (depolarized) RMP compared to 
wild-type (CS/w-) larvae. The dparkin larval EJPs were on average smaller compared to 
their wild-type controls across a range of RMPs. The solid lines are the linear regression 
across dparkin and wild-type larvae. These recordings were taken from 6/7 muscles (n = 
12, CS/w- and n = 18, p25/pZ3678).  
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Figure 3.7 dparkin mutant larvae show reduced synaptic transmission is not 
rescued by either global, neuronal or muscle expression of wild-type dparkin 
For each observation, the difference between the recorded EJP and the value expected 
from the p25/ pZ3678 regression line was determined. This shows that the dparkin (p25/ 
pZ3678) larvae have reduced synaptic transmission compared to wild-type (CS/w-) control 
larvae (p < 0.001). Global (Act5c-GAL4), neuronal (elav3E–GAL4) or muscle (G14–
GAL4) expression of wild-type dparkin on a dparkin (p25/ pZ3678) mutant 
transheterozygote background failed to rescue the synaptic transmission defect (p = 
0.829, p < 0.093 and p = 0.283 respectively) compared to dparkin (p25/ 
pZ3678) mutant larvae. 
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dparkin mutant larvae have smaller mEJP amplitudes 
Synaptic EJPs are the result of release of many transmitter vesicles. In recordings from 
larval muscles, in which their innervation had been severed, miniature excitatory 
junctional potentials (mEJPs) were recorded (Fig. 3.8). The mEJPs correspond with 
spontaneous single vesicle release (Fatt and Katz, 1952, Dudel and Orkand, 1960, 
Usherwood, 1963). For these experiments mEJPs were recorded in a number of 
preparations. However, since the size of the mEJP is affected by membrane potential, 
we analyzed only a few preparations from dparkin (p25/ pZ3678) and wild-type (CS/w-) 
larvae in which the RMPs were similar in both genotypes (range -60 mV to -67 mV). 
The distribution of mEJP amplitudes in the dparkin (p25/ pZ3678) and wild-type (CS/w-) 
larvae were plotted (Fig. 3.9). The mean and mode of the dparkin (p25/ pZ3678) mEJPs 
mutant larvae were 0.7 mV and 0.5 mV, 40% and 16% smaller that of wild-type (CS/w-) 
control mEJPs (Fig 3.9). The cumulative frequency graph shows there are many smaller 
mEJPs in dparkin (p25/ pZ3678) mutant larvae than in wild-type (CS/w-) controls (Fig. 
3.9).  
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Figure 3.8 dparkin mutant larvae have smaller miniature excitatory junction 
potentials.  
Miniature excitatory junction potentials (mEJPs) are smaller in dparkin larvae 
(p25/pZ3678) compared to wild-type (CS/w-) controls, as shown in this sample recording.  
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Figure 3.9 The distribution of mEJP amplitudes show dparkin mutant larvae have 
smaller miniature excitatory junction potentials.  
Miniature excitatory junction potentials (mEJPs) are smaller in dparkin larvae 
(p25/pZ3678) compared to wild-type (CS/w-) controls. The distribution of mEJP 
amplitudes in the dparkin (p25/ pZ3678) and wild-type (CS/w-) larvae are plotted. The 
mean and mode of the dparkin (p25/ pZ3678) mEJPs mutant larvae were 0.7 mV and 0.5 
mV, 40% and 16% smaller that of wild-type (CS/w-) control mEJPs. 
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Figure 3.10 Cumulative frequency curve show dparkin mutant larvae have smaller 
miniature excitatory junction potentials.  
Cumulative frequency curves show the median mEJP amplitude from dparkin larvae 
(p25/pZ3678) is smaller than that from wild-type larvae (CS/w-), (Kolmogorov–Smirnov 
test statistic = 3.5, P < 0.001). Additionally, the lower and upper quartiles of the 
distribution of mEJPs of dparkin larvae are lower than those of wild-type controls.  
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dparkin null mutant larvae show electrophysiological deficits 
The last sections have shown that dparkin transheterozygote larvae have major 
electrophysiological deficits, in both RMP and synaptic transmission. In the next 
section we test if these defects are also seen in another dparkin mutant, the homozygote 
dparkin25 (p25/p25). In these larvae, no dparkin protein is synthesized (Greene et al., 
2003, Whitworth et al., 2005, Tain et al., 2009).  
Intracellular recordings from larval muscles 6 and 7 of dparkin (p25/p25) null mutant 
show the RMPs are 11 mV (p < 0.001) more positive compared to wild-type (CS/w-) 
controls (Fig. 3.11A). The global (Actin5-GAL4) driver or the pan-neuronal (elav3E1-
GAL4) driver or the G14-GAL4 driver (which expresses in all muscles), was used to 
express wild-type dparkin in the dparkin (p25/p25) mutant background. In each case, the 
RMP deficit was rescued (p =0.009, p < 0.001 and p < 0.001,respectively, Fig. 3.11A).   
These observations were extended by testing a second pair of muscles in the dparkin 
(p25/p25) null mutant, muscles 12/13, which run parallel to muscle 6 and 7 and are also 
innervated by type Is motoneuron terminals. These muscles were also 9 and 10 mV 
more depolarized compared to those of wild-type (CS/w-) controls (Fig. 3.11B). Global 
(Act5c-GAL4), neuronal (elav3E–GAL4) or muscle (G14–GAL4) expression of wild-
type dparkin on a dparkin (p25/p25) mutant background failed to rescued the RMP 
defects (p = 0.170, p = 0.329 and p = 0.906, respectively) compared to dparkin 
(p25/p25) null larvae. dparkin transheterozygote (p25/pZ3678) larvae show no difference in 
RMP compared to dparkin null (p25/p25)  larvae (p = 0.396). Wild-type control larvae 
(CS and CS/w-) show no differences in RMP (p = 0.590) (Fig. 3.11B). 
In a more extensive experiment, both the dparkin null (p25/p25) and transheterozygote  
(p25/pZ3678) larvae were also tested. As two mutant strains were used, two wild-types (CS 
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and CS/w-) were used. The dparkin null recordings of spontaneous EJPs in muscles 6 
and 7 showed reduced EJPs. As with the transheterozygote experiment, a scatter graph 
was plotted of the size of the EJP against RMP (Fig. 3.12). Using the data from dparkin 
(p25/p25) mutant and wild-type (CS and CS/w-) controls, lines of best fit were drawn to 
calculate the residual between EJP and regression line calculated (Fig. 3.12). dparkin 
(p25/p25) mutants showed reduced synaptic transmission compared to their wild-type 
controls (CS and CS/w-, p = 0.004 and p = 0.007 respectively, Fig. 3.13).  When wild-
type dparkin was expressed either in a global (Actin5-GAL4), pan-neuronal (elav3E1-
GAL4) or the G14-GAL4 tissue dependent manner in a dparkin (p25/p25) mutant 
background, the EJP was increased (p = 0.010, p = 0.024 and p = 0.001 respectively, 
Fig. 3.13A). Muscle 13 and 12 recordings also showed that dparkin 
(p25/p25) mutant larvae have a reduction in synaptic transmission compared to wild-type 
(CS, p = 0.007) control larvae, but not with the wild-type outcross (CS/w-, p = 0.703, 
Fig. 3.13B) larvae. Similar data was seen with muscle 6 and 7. The RMP of dparkin 
(p25/p25) mutant larvae are not significantly different from dparkin (p25/pZ3678) mutant 
larvae (p = 0.296). Global (Act5c-GAL4) or muscle (G14–GAL4) expression of wild-
type dparkin on a dparkin (p25/p25) homozygous mutant background showed an increase 
in synaptic transmission (p = 0.001 and p = 0.002, respectively) whereas neuronal 
(elav3E–GAL4) expression of wild-type dparkin showed no difference (p = 0.199) 
compared to dparkin (p25/p25) mutant larvae (Fig 3.13B). 
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Figure 3.11 dparkin mutant larvae show more positive (depolarized) RMP that is 
rescued by global, neuronal or muscle expression of wild-type  dparkin 
A Muscle 6 and 7 intracellular recordings revealed dparkin (p25/pZ3678 or 
p25/p25) mutant larvae show more positive (depolarized) RMP (resting membrane 
potential) compared to wild-type (CS or CS/w-) larvae (p < 0.001). Global (Act5c-
GAL4), neuronal (elav3E–GAL4) or muscle (G14–GAL4) expression of wild-type 
dparkin on a dparkin (p25/p25) mutant background rescued the RMP defects (p = 0.009, 
p < 0.001 and p < 0.001 respectively) compared to dparkin (p25/p25) mutant larvae. 
dparkin transheterozygote (p25/pZ3678) larvae show no difference in RMP compared to 
dparkin null (p25/p25)  larvae (p = 0.087). Wild-type control larvae (CS and CS/w-) show 
no differences in RMP (p = 1.0). B Recordings from muscle 12 and 13 show that 
dparkin (p25/pZ3678 or p25/p25) mutant larvae show more depolarized RMP compared to 
wild-type (CS or CS/w-) larvae (p < 0.001 and p = 0.001, respectively). Global (Act5c-
GAL4), neuronal (elav3E–GAL4) or muscle (G14–GAL4) expression of wild-type 
dparkin on a dparkin (p25/p25) mutant background failed to rescued the RMP defects (p 
= 0.170, p = 0.329 and p = 0.906, respectively) compared to dparkin 
(p25/p25) mutant larvae. dparkin transheterozygote (p25/pZ3678) larvae show no difference 
in RMP compared to dparkin null (p25/p25)  larvae (p = 0.396). Wild-type control larvae 
(CS and CS/w-) show no differences in RMP (p = 0.590). 
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Figure 3.12 Scatter regression plot show dparkin null mutant larvae have 
depolarized RMP and reduced synaptic transmission across a range RMP.  
dparkin (p25/pZ3678 or p25/p25, in red) mutant larvae show more positive (depolarized) 
RMP compared to wild-type (CS or CS/w-, in green) larvae. The dparkin larval EJPs 
were on average smaller compared to their wild-type controls across a range of RMPs 
recorded from either muscles 6 and 7, or 12 and 13 (Fig. 3.12 A and B respectively). 
The solid lines are the linear regressions across dparkin and wild-type larvae.   
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Figure 3.13 dparkin mutant larvae show a reduction in synaptic transmission and 
with either global, neuronal or muscle of wild-type dparkin expression shows 
partial rescue of synaptic  
A dparkin (p25/p25) mutant larvae show a reduction in synaptic transmission in muscle 6 
and 7 compared to wild-type (CS/w- or CS) control larvae (p = 0.007 and p = 0.004, 
respectively). dparkin (p25/p25) mutant larvae are not significantly different from 
dparkin (p25/pZ3678) mutant larvae (p = 0.964). Global (Act5c-GAL4), neuronal (elav3E–
GAL4) or muscle (G14–GAL4) expression of wild-type dparkin on a dparkin (p25/p25) 
homozygous mutant background showed an increase in synaptic transmission (p = 
0.010, p = 0.024 and p = 0.001, respectively) compared to dparkin 
(p25/p25) mutant larvae. B Recordings from muscle 12 and 13 show dparkin 
(p25/p25) mutant larvae show a reduction in synaptic transmission compared to wild-type 
(CS, p = 0.007) control larvae but not with the other wild-type (CS/w-, p = 0.703) larvae. 
dparkin (p25/p25) mutant larvae are not significantly different from dparkin 
(p25/pZ3678) mutant larvae (p = 0.296). Global (Act5c-GAL4) or muscle (G14–GAL4) 
expression of wild-type dparkin on a dparkin (p25/p25) homozygous mutant background 
showed an increase in synaptic transmission (p = 0.001 and p = 0.002, respectively) 
whereas neuronal (elav3E–GAL4) expression of wild-type dparkin showed no difference 
(p = 0.199) compared to dparkin (p25/p25) mutant larvae. Bold numbers indicate the 
number of larvae used in each genotype.  
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dparkin mutant larvae show pronounced difference in RMP at low external 
potassium concentrations 
Altering the external potassium concentration in the 1mM calcium-containing HL3 
solution that bathes the preparation caused a more positive shift in both wild-type 
(CS/w-) and dparkin (p25/pZ3678) mutant and RMP as the potassium concentration 
increased. When the Nernst equation line was plotted for potassium, the higher 
concentration points of both the wild-type and dparkin mutant larvae was consistent 
with the Nernst line whereas the lower concentration showed a deviation from the line. 
The deviation from the line suggests that different ions could result in the depolarization 
of RMP when there is lower a concentration of external potassium (Cl- and Na+ ions).  
The changing of extracellular potassium ion concentration caused changes in RMP in 
both wild-type controls and dparkin transheterozygote mutant larvae. dparkin mutants 
show a more depolarized RMP throughout the different concentration of potassium 
compared to their wild-type controls (Fig 3.14). 
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Figure 3.14 The difference in RMP between dparkin mutant and wild-type larvae 
is most pronounced at low external potassium concentrations. 
At higher potassium concentrations, above 4 mM, the RMP of both dparkin 
(p25/pZ3678) and wild-type (CS/w-) muscles were close together and followed the line 
calculated for the Nernst equation. At lower potassium concentrations the RMP of both 
genotypes is consistently above the line. At the lowest concentration, the difference 
between the dparkin and wild-type larvae is marked, with the dparkin larvae being more 
positive than the wild-type.  
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3.3 Discussion 
The key findings in this chapter are that dparkin mutant larvae show slower locomotion, 
overgrown synapses, a reduction in synaptic transmission (both spontaneous EJPs and 
mEJPs) and a more positive (depolarized) resting membrane potential (RMP), 
especially at lower extracellular potassium concentrations. These phenotypes are 
principally due to the neural impact of dparkin. Trans-synaptic signalling plays a key 
role in the phenotype. 
Crawling speed is reduced in dparkin transheterozygote mutant larvae 
dparkin transheterozygote mutant larvae show reduced velocity in the crawling assay 
used to measure motor performance. The homozygotes (p25/p25 null) also crawl more 
slowly (Vincent et al., 2012). Adult dparkin mutants also demonstrate reduced 
locomotion in adult negative geotaxic assays (Greene et al., 2003, Whitworth et al., 
2005). In these assays, locomotion could have been reduced by changes in sensitivity to 
mechanical stimuli or to changes in locomotory ability. Our assays, monitoring 
spontaneous crawling, provide a more specific demonstration of the loss of dparkin-
induced locomotory failure. 
Crawling speed rescued with the neuronal wild-type dparkin expression in dparkin 
transheterozygote mutant larvae  
Since the crawling phenotype was observed in the dparkin transheterozygote mutant 
larvae, it is likely that the phenotype was due to dparkin loss rather than a second site 
mutation. The reduced crawling phenotype was rescued by global expression of wild-
type dparkin in a dparkin mutant background (Vincent et al., 2012). More importantly, 
the neuronal expression of wild-type dparkin also rescued, unlike muscle expression of 
wild-type dparkin in a mutant background  (Vincent et al., 2012). This shows the 
reduced crawling speed was a result of dparkin loss in neurons rather than from the 
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muscles. Additionally, dparkin null mutant larvae show reduced number of contractions 
as observed from the larval extensometer or ‘bendy-beam’ assay  (Vincent et al., 2012), 
along with a bradykinesia-like phenotype (reminiscent of PD patients). Both phenotypes 
may lead to an overall reduction in crawling speeds in dparkin transheterozygote mutant 
larvae. Neuronal expression of wild-type dparkin in nerve rescues this defect whereas 
muscle expression does not  (Vincent et al., 2012). From this it was concluded that the 
behavioral (crawling) defect arises from the loss of dparkin in neurons and not the 
muscles. 
Are dopaminergic neurons key to the crawling defect? 
Our paper hypothesized that reduced dopaminergic function is key to the reduced 
crawling seen in dparkin mutants  (Vincent et al., 2012). To test this hypothesis of 
dopaminergic dysfunction, dparkin was knocked down by using the tyrosine 
hydroxylase (TH-GAL4) driver with the dparkin dsRNAi generated by Yang et al. 
(2003). There was no difference in crawling speed compared to wild-type controls. This 
result suggests dopaminergic dparkin is not absolutely essential for locomotory 
dysfunction. On the other hand, disruption to aminergic neurotransmission has been 
reported to have an impact on crawling behavior as seen by D. melanogaster vesicular 
aminergic transporter (DVMAT) mutants that exhibit a distinct slow crawling 
phenotype, thereby suggesting disruption to the aminergic system may be the reason 
behind the larval bradykinesia phenotype seen in our dparkin mutant larvae. 
However, we do not know how effective the TH > RNAi transgenes were at reducing 
the level of PARKIN protein, as this was not measured in these experiments. 
Expression of dparkin dsRNAi with our Act5c-GAL4 provided a marked overgrowth 
phenotype at the neuromuscular junction. Further, expression of this dsRNAi using a 
ubiquitous heat-shock-GAL4 driver showed both a reduction in mRNA levels (by PCR) 
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and an interaction with the Pael-R transgene. However, there was no net loss of 
dopaminergic neurons. My experiments indicate a synaptic role for dparkin in the 
overgrowth phenotype and so the wild-type dparkin from the surrounding cells could 
have provided a neuroprotective effect and thus not induce the dparkin 
transheterozygote mutant larvae crawling phenotype. I conclude that further 
experiments are needed to confirm if dparkin knockdown is effectively achieved in the 
dopaminergic neurons by the TH-GAL4. 
Synaptic overgrowth phenotype in dparkin mutants  
As neuronal loss of dparkin was shown to cause locomotory dysfunction I assessed the 
integrity of both the neuronal architecture involved in carrying signals required for 
movement by the postsynaptic cell (the muscle). dparkin transheterozygote mutants 
show overgrown synapses brought about with increased raw bouton count and 
decreased muscle surface area. Additionally, I assessed whether the neuronal or muscle 
loss was important for the overgrowth phenotype. Morphological analysis of dparkin 
mutant larval neuromuscular junction (NMJ) showed that either muscle or neuronal 
expression of wild-type dparkin is sufficient to reduce the overgrowth phenotype back 
down to wild-type control levels. This was achieved by either a decrease in raw bouton 
number alone or with an additional increase in muscle surface area with either (neuronal 
or muscle respectively) GAL4 driver induced expression of wild-type dparkin in a 
dparkin transheterozygote background. This suggests that unlike the crawling where 
only the neuronal expression of wild-type dparkin rescued the speed of dparkin 
mutants, the overgrowth phenotype is rescued by either the muscle or neuronal 
expression of wild-type dparkin and suggests it is sufficient to cause an overgrowth 
with either muscle or neuronal loss of dparkin. This is a non-cell autonomous effect 
where the tissue specific expression of wild-type dparkin (for instance in muscles) is 
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able to affect other tissues with the mutation (and reduce neuronal growth), as opposed 
to the tissue in which the wild-type dparkin is only being expressed. Global knockdown 
of dparkin showed approximately 50% of the overgrowth observed in that of dparkin 
transheterozygote mutant larval NMJs affecting both the raw bouton number and 
muscle surface area. This shows wild-type dparkin expression regulates overgrowth 
through a cell-cell signalling mechanism between neurons and muscle cells.  
Studies in D. melanogaster studies have identified a number of signalling pathways 
between postsynaptic targets and presynaptic terminals. These are important in synapse 
formation, growth and plasticity and survival of the presynaptic neuron. Retrograde 
signals include Transforming growth factor beta (TGF-β) and reactive oxygen species 
(ROS). TGF-beta signalling is necessary for normal NMJ associated synaptic growth 
(Aberle et al., 2002, Marqués, 2005) while enhanced TGF-beta signalling is linked to 
presynaptic overgrowth the spinster (spin) mutant, (Sweeney and Davis, 2002). 
Induction of autophagy has been shown to cause overgrowth (Shen and Ganetzky, 
2009). spin and other anti-oxidant compromised mutants are also shown to induce 
growth in response to the generation of ROS (Milton et al., 2011). Another mutant with 
an overgrowth phenotype is highwire (hiw), where the hiw mutation leads to 200% 
expansion of NMJ (DiAntonio et al., 2001). The highwire gene encodes an E3 ubiquitin 
ligase which that is expressed at the periactive zone (Wan et al., 2000). Hiw induced 
overgrowth is suppressed via mutations in wallenda a MAP kinase kinase kinase or by 
mutations that reduce c-jun N-terminal kinase (JNK) and fos activity. JNK or fos are 
required for the hiw mutant-induced overgrowth. Signalling by these molecules may 
account for the non- autonomous rescue that is seen when parkin is expressed in the 
muscle. 
There are other mutants in the literature that have altered bouton number but with no 
!! 142!
effect on neurotransmission. One of these is another PD-related gene, hLRRK2, where 
the pathogenic mutation G2019S has NMJ overgrowth (Lee et al., 2010).  
Other signalling pathways act in the opposite, anterograde manner. Davis demonstrated 
in his model that amount of growth factor regulated synaptic growth. It was also 
postulated in the paper, inhibitory growth and growth promoting signals exist, that 
balance the growth of synaptic terminals. The main conclusion from Davis paper was 
alteration to endosomal/lysosomal function, whether it may be pre- or post-synaptic, can 
cause misregulation of intercellular signalling systems.  
This may be the case with dparkin mutant larvae as either neuronal or muscle 
expression of wild-type dparkin in a mutant background was sufficient to completely 
rescue the overgrowth.  
Synaptic transmission is reduced in dparkin transheterozygote mutants  
dparkin transheterozygote larvae show reduced synaptic transmission, even after 
allowing for the change in RMP. Additionally, dparkin transheterozygote mutants show 
reduced spontaneous single vesicular release. The mEJPs are smaller in dparkin 
transheterozygote mutants than in wild-type controls. The EJPs and mEJPs are mediated 
by glutamate receptors with reversal potentials estimated between 0 and 1.7 mV (Jan 
and Jan, 1976, Macleod and Zinsmaier, 2006, Macleod et al., 2006). The reduced size of 
EJP observed in dparkin mutants is likely to be due to reduced size of mEJPs. This 
leads us to conclude that there is reduced neurotransmitter that is actively recycled into 
the synaptic vesicles in an ATP-dependent manner. Alternatively, it may also be as a 
result of the release mechanism failing, as the pre-synaptic motor terminals may be (like 
the muscles) more depolarized.  
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dparkin expression partially rescues the synaptic signalling defect  
At muscle 6/7, the global, neuronal or muscle expression of wild-type dparkin failed to 
rescue synaptic defects with wild-type dparkin expression using any of the above 
drivers in the dparkin transheterozygote mutants. However, at muscle 12/13, global or 
muscle expression of wild-type dparkin partially restored the synaptic transmission 
defect in dparkin null mutants. The global, neuronal or muscle expression of wild-type 
dparkin rescued synaptic defects with wild-type dparkin expression using any of the 
above drivers in the dparkin null mutants. Difficulties in collecting enough data due to 
the variability in food quality from tray to tray limited the sample size. The results may 
also be more difficult to interpret due to possible differences in genetic background. 
Nonetheless, overall, I cautiously conclude that dparkin global, neuronal and muscle 
rescue of EJP is likely to be effective with a larger population.  
Sang and colleagues showed a decrease in neuronal activity observed from parkin 
mutant adult fly brains (as a result of expression of human mutant parkin using Ddc-
GAL4) compared to their controls, as monitored by the measure of florescence intensity 
from genetically encoded calcium indicators (G-CaMP) (Sang et al., 2007, Wang et al., 
2003). The expression of wild-type human parkin (hparkin) using the Ddc-GAL4 driver 
showed no difference in the signal intensity compared to their wild-type controls, 
suggesting neuronal activity is not compromised with the overexpression of hparkin in 
aminergic cells in the fly (Sang et al., 2007). As with dparkin mutant larvae, another 
PD–related gene, LRRK2, has shown perturbed synaptic transmission in a dLRRK in 
vivo model where there is reduced neurotransmitter release in the dLRRK knockout (Lee 
et al., 2010).   
dparkin mutant show depolarized RMP  
RMP were more depolarized from the muscles 6/7 of both transheterozygote and the 
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null larvae and also this trend were as shown in another set of adjacent muscles/ 12/13. 
This suggests that all muscles are affected, rather than just the most frequently selected 
muscles. The resting membrane potential of D. melanogaster larval muscles changes 
with varied extracellular calcium concentrations in physiological studies (Jan and Jan, 
1976, Jan et al., 1977, Mackler et al., 2002). These effects are similar between HL-3 and 
standard saline A (SSA) saline although there are fundamental differences between the 
two salines’ compositions (Krans et al., 2010). RMP in wild-type larvae in other studies 
have shown voltage data of < -55 mV (Macleod et al., 2006). Calcium-dependent 
depolarization was noted in D. melanogaster by Jan and Jan (1976) in their early 
studies. Elevated potassium in HL3 was shown to have similar effect as the hemolymph 
concentration of Mg2+ that is the same concentration as the HL3 formulae. We had 
omitted Mg2+ from HL3 throughout the course of all electrophysiological experiments 
as it has deleterious effect on stable membrane potential (Hoyle, 1953, Stewart et al., 
1994). Additionally, HL3 contains 20 mM concentration of Mg2+, and it has been 
suggested that high Mg2+ would abolish neural activity in many crustaceans (Takeuchi 
and Takeuchi, 1963). Feng et al. (2004) recently adapted the HL3 with a reduced-Mg2+ 
version called HL3.1 (with a concentration of 4 mM Mg2+), which restores some 
attenuated electrophysiological phenomena in the larva (Feng et al., 2004). Here we 
note that the difference in RMP was largest at low external potassium concentrations. 
This suggests other ions (most likely Na+, Ca2+, Cl-) also make a contribution to the 
RMP.  
It must also be noted the rare depolarized RMP phenotype accompanied by synaptic 
dysfunction reported in this parkin model may have been detected here and not in other 
parkin models as a result of differences in the electrophysiological approach. Firstly, it 
was important to report on spontaneous recording rather than stimulated EJPs.  It must 
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be noted with electrophysiological recordings such as postsynaptic responses there is a 
chance there may be damage to the preparation, improper adjustment of the stimulating 
voltage, a result of high-frequency stimulating voltage or a mutant phenotype. All of 
which may cause one of the two axons being stimulated and thus cause a decrease in 
EJP amplitude. Secondly, the modified HL3 omitted magnesium chloride from the 
original recipe of HL3 solution (Stewart et al., 1994). This could have possibly affected 
the production of ATP (Ko et al., 1999) and so disrupted the RMP. Thirdly, a voltage 
clamp was not used to clamp the resting membrane potential to a set voltage. This 
means the residual plot had to be used. Working in high calcium saline with large EJP 
amplitudes helps to observe a clear distinction in amplitude reduction and failure of one 
of the axons to contribute to the EJP. In the case when one of the two is intermittently 
activated, the EJP amplitudes will fluctuate dependent on axons that have signaled. The 
failure of an action potential to spread throughout all the terminal branches of the axons 
onto the postsynaptic muscle also affects EJP amplitude. Since M6/7 and M12/13 are 
each innervated by two motoneurons this provides extra ambiguity. This could have 
been avoided by working with a muscle receiving input from only one motoneuron, for 
example muscle 5 (Hoang and Chiba, 2001). Such recordings would be more 
straightforward to interpret.  
dparkin rescues the RMP phenotype  
Electrophysiological data from muscle recordings showed the muscle expression of 
wild-type dparkin rescued the RMP in the transheterozygote background from muscle 6 
and 7 recordings, whereas the global, neuronal or muscle expression only partially 
rescue the RMP defect in dparkin null mutants. In muscles 12 and 13 of dparkin null 
larvae the RMP was also more depolarized compared to wild-type controls. In these 
muscles, the wild-type expression of dparkin globally, neuronally or in muscles failed 
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to show any rescue. This could be a result of the reduced count of muscle recordings for 
the muscle 12 and 13 data set compared to the muscle 6 and 7 for the dparkin null 
mutant larvae. The muscle recordings presented here from muscle 6 / 7 or 12 / 13 were 
from two complete data sets, each from one food batch to limit variability. The dparkin 
transheterozygote mutant data from muscle 6 / 7 had overall fewer data points compared 
to dparkin null mutant larvae but these were all undertaken in one day.  
Metabolic Dysfunction in parkin larvae is key to RMP depolarization and synaptic 
dysfunction  
Few D. melanogaster mutants show a depolarized RMP, but one which does is nubian 
(Wang et al., 2004). This is a mutation in phosphoglycerate kinase (PGK). This enzyme 
is key in the terminal stage of glycolysis that leads to the production of ATP, one of the 
two ATP steps before oxidative phosphorylation. This glycolytic mutant shows severe 
depletion of ATP, leading to the failure to maintain a more negative RMP.  dparkin null 
mutant larvae have 30% less oxygen consumption compared to wild-type larvae with 
ATP levels that were 14% of controls (Vincent et al., 2012). These both suggest aerobic 
respiration and mitochondrial production of ATP have been compromised. Recently, 
adult dparkin null mutant flies were reported to recover from their motor deficits after 
being fed with Vitamin K2. This compound targeted the respiratory chain and increased 
ATP generation (Vos et al., 2012). The depolarized RMP in dparkin mutant larvae is 
also suggested to be a result of metabolic dysfunction (a depletion of ATP stores to 
facilitate the ATP dependent pumps). RMP are maintained by the selective permeability 
of ions (potassium, sodium and chloride) and by the sodium-potassium (Na+/ K+- 
ATPase) electrogenic pump that is ATP dependent.  
The D. melanogaster sodium pump only becomes functional as an α–β heterodimer 
(Lingrel and Kuntzweiler, 1994, Lingrel et al., 1994a, Lingrel et al., 1994b). The fly, 
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Na+/ K+-ATPase α subunit is encoded by a single gene (Lebovitz et al., 1989), and but 
two β subunit genes (Nervana 1 and 2) code for three different β isoforms, which are 
expressed in a tissue specific manner (Sun and Salvaterra, 1995). During fictive 
crawling (when the peristaltic rhythm is recorded from the isolated CNS) each burst of 
action potentials are followed a brief period of hyperpolarisation. This is essential for 
restoration of neural activity (Pulver and Griffith, 2010). During the hyperpolarisation, 
ions are transported via ATP-dependent pumps to restore ionic balance. If the RMP is 
compromised, pumping deficits arising from ATP depletion could result in a much 
slower restoration of ionic balance, and thus causing a reduction in CPG activity. This 
would slow the initiation of subsequent contraction.  
 Metabolic dysfunction has been observed in PD patients. Neuronal samples cannot be 
readily obtained from human patients. Therefore skin biopsies were used to obtain 
fibroblasts to determine the metabolic status of tissue with a loss of parkin. Fibroblasts, 
which are known to make skin, were obtained from patients with mutations in parkin. 
These show metabolic failure with reduced complex I mediated ATP production 
(Mortiboys et al., 2008), similar to the ATP depletion observed in parkin larvae 
(Vincent et al., 2012).       
Locomotory deficits accompanied by synaptic dysfunction  
dparkin mutant flies have previously focused on describing adult phenotypes, with a 
single study reporting no larval phenotypes observed in dparkin null mutant (Pesah et 
al., 2004). My thesis is the first to report larval phenotypes at the level of behavior, 
physiology and anatomy caused by mutations in this early-onset gene.  The 
homozygous dparkin null mutants and the transheterozygote hypomorph mutants we 
raise on our standard food in our laboratory conditions often fail to survive beyond 
!! 148!
pupal stage. However, in other laboratories they seem to emerge into adults and have an 
average life span of 28 - 50 days (Greene et al., 2003, Whitworth et al., 2005, Tain et 
al., 2009). This difference could arise from their diet, as our food contains 0.125 g/l 
manganese chloride: manganese is known to reduce the viability of parkin- mammalian 
cell lines (Roth et al., 2012, Higashi et al., 2004) and is associated with the risk of 
developing Parkinson’s disease (Roth, 2014). Furthermore, low levels of other minerals 
may impact the survival of dparkin mutants since PARKIN interacts with Metal-
Responsive Transcription Factor (MTF-1) (Saini et al., 2011).  
Summary of key findings:  
* dparkin mutant larvae have synaptic dysfunction, locomotory defect and overgrown 
synapses at the NMJ 
*Expression of wild-type dparkin rescues synaptic potentials  
* Expression of dparkin rescue muscle RMP 
* dparkin mutant larvae have depolarized muscle RMP, as a global mutant thus 
suggesting the neurons too could be depolarized 
* Synaptic overgrowth is rescued with either muscle or neuronal dparkin expression 
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Chapter 4: Investigating the role of oxidative stress and metabolic dysfunction in 
dparkin mutant larvae 
4.1 Introduction 
Chapter 3 established that dparkin mutant larvae show reduced locomotion, overgrown 
synapses, a reduction in synaptic transmission and depolarized resting membrane 
potentials. This was also reported by Vincent et al., (2012). Global overexpression of 
scavengers of reactive oxygen species (ROS), acting in either cytoplasmic or 
mitochondrial compartments, reverted the synaptic overgrowth normally seen in the 
dparkin null background (Vincent et al., 2012). Further, the transcriptional profile 
clearly shows the up-regulation of oxidative stress response elements, while mutations 
in these oxidative response elements enhance dparkin mutant phenotypes (Greene et al., 
2005). All this supports the oxidative stress hypothesis of the dparkin phenotype. 
Oxidative stress is also a key driver of synaptic overgrowth in other fly systems (Milton 
et al., 2011).  This suggested that oxidative stress was a key component of the dparkin 
synaptic overgrowth phenotype.  
However, ROS scavengers did not revert the reduced locomotion, synaptic or resting 
membrane potential (RMP) physiology in the dparkin null larvae. This is contradictory 
to other studies, in the case of adult flies, where eliminating oxidative stress rescued all 
dparkin mutant phenotypes (Umeda-Kameyama et al., 2007, Underwood et al., 2010, 
Whitworth et al., 2005).  
These observations suggest we should explore the impact of oxidative stress in more 
detail. I therefore used the same (or related) transgenes as previously used in adults. 
These transgenes were for glutathione-S-transferase S1 (GST or GST-S1) and a 
mitochondrial enzyme thioredoxin reductase (Umeda-Kameyama et al., 2007, 
Whitworth et al., 2005). These systems are important in the brain where catalase 
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activity is very low. Both the thiol-reducing systems via thioredoxin or glutathione with 
glutathione peroxidase activity break down hydrogen peroxide to water and oxygen thus 
reducing oxidative damage.  
Studies have shown Complex I activity is redox-dependent and thiol-regulated (Sriram 
et al., 1998, Annepu and Ravindranath, 2000). PD pathogenesis has shown to 
consistently be associated to reactive oxygen and nitrogen species generation (Bové et 
al., 2005, Li and Holbrook, 2003, Przedborski and Ischiropoulos, 2005) and this may be 
the reason, at least in part, why complex I is inhibited. Thus, depletion of glutathione 
(GSH), an antioxidant and redox modulator, may be one of the early events leading to 
the inhibition of complex I activity and loss of mitochondrial function (Chinta et al., 
2006, Jha et al., 2000). This is relevant as dparkin larvae show reduced oxygen 
consumption suggesting mitochondrial abnormalities (Vincent et al., 2012). 
Thioredoxin has been found in the submicromolar range to protect neuronal cell lines 
from toxin-induced oxidative stress, which normally would lead to apoptosis (Andoh et 
al., 2002). The reduced forms of thioredoxin suppressed hydroxyl radicals, and the 
inhibition of thioredoxin reductase abolished the protective effects (Andoh et al., 2002).  
Reduced thioredoxin not only binds to and inhibits ASK-1 (Saitoh et al., 1998), it also 
enhances DNA binding to transcription factors including nuclear factor-kB and AP1. 
Thioredoxin system has a variety of actions that are neuroprotective due to suppression 
of hydroxyl radical damage, lipid peroxidation, caspase activation, cytochrome c release 
and apoptosis (Andoh et al., 2002, Andoh et al., 2003, Svensson and Larsson, 2007). D. 
melanogaster do not have glutathione reductase, but have thioredoxin reductase in 
which is part of the thioredoxin system, and which causes the glutathione disulphide 
(GSSG) reduction  reaction (Kanzok et al., 2001).  
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Glutathione-S-transferases are a set of enzymes that aid in the detoxification process as 
they promote the conjugation of glutathione to a variety of electrophilic substrates. 
Findings from Whitworth’s group suggested altered GST-S1 activity influenced dparkin 
mutant phenotypes: for example, increased GST-S1 activity rescued the dopaminergic 
neuronal loss seen in dparkin mutant adult brains. Additionally, a member of the GST 
family, Glutathione-S-transferase Omega 1 (GST-O1), rescues both degeneration of 
neuronal and muscle phenotypes of dparkin mutants including increased ATP 
production (Kim et al., 2012).  
dparkin has also been suggested to negatively regulate c-jun-N-terminal kinase (JNK) 
signaling (Cha et al., 2005) and oxidative stress activates JNK/AP-1 signaling pathway, 
thereby promoting overgrowth in D. melanogaster oxidative stress induced mutant 
larvae (Milton et al., 2011). Vincent et al. (2012) proposed that the oxidative stress-
induced overgrowth seen in dparkin mutants was a result of increased JNK/AP-1 
signaling (Milton et al., 2011, Vincent et al., 2012). Therefore the relationship of JNK 
activation and oxidative stress in dparkin mutant larvae was investigated.  
AMPK is activated in response to oxidative stress, hypoxia, high ATP consumption and 
low nutrient availability. This is regulated by elevated levels of adenosine 
monophosphate (AMP), adenosine diphosphate (ADP) or Ca2+ (Hardie, 2007, Hardie, 
2011, Hardie et al., 2011). AMPK activation is regulated by high concentrations of ATP, 
therefore the system is responsive to rises in AMP: ATP ratio rather than AMP alone.  
AMPK is a heterotrimeric complex that includes the following subunits: a catalytic 
alpha (α), regulatory gamma (δ) that bind AMP and a scaffolding beta (β) subunit. 
AMPK activity is increased upon phosphorylation of the Thr172 residue of the catalytic 
α-subunit by an upstream kinase, Ca2+ calmodulin kinase kinase (CaMKK) or liver 
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kinase B1 (LKB1) transforming growth factor beta activated kinase 1 (TGFβ1) (Shaw et 
al., 2004, Peng et al., 2010).  
AMPK activation has been shown to increase mitochondrial biogenesis via the 
expression of peroxisome proliferator-activated receptor-γ co-activator (PGC)-1α (Jäger 
et al., 2007).  AMPK has many other targets including autophagy initiator ATG1 and 
phosphofructosekinase-2 (PFK-2), and results in activation of autophagy and glycolysis 
respectively. These targets are relevant to dparkin mutant larvae as they show energy 
perturbation and oxidative stress. AMPK activation targets include autophagy gene, 
ATG1 (Egan et al., 2011, Kim et al., 2011). dparkin is also involved in mitophagy 
(Narendra et al., 2008, Narendra et al., 2009).  
As well as responding to oxidative stress, AMPK is a key sensor of cell autonomous 
energetic changes. This is important as there is an ATP deficit in dparkin mutants larvae 
(Vincent et al., 2012). I wish to investigate alternative modes of energy production via 
altering the expression of AMPK by expressing a constitutively active AMPKT184D-α 
form. This AMPKT184D-α construct is generated from a transgenic line, in which the 
Thr184 is replaced by an aspartate, which mimics the activating phosphorylation of this 
site by LKB1 (Lizcano et al., 2004). It has been shown to rescue LKB1 mutants from 
energetic stress (Mirouse et al., 2007).  
The use of PD-toxin induced mouse models have shown AMPK function is increased 
and additionally this activity is inhibited with, the AMPK inhibitor, compound C leading 
to cell death (Choi et al., 2010). More recently in dparkin and dLRRK2 have been 
shown to interact with AMPK in adults both genetically and pharmacologically (Ng et 
al., 2012).  
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4.2 Aims 
My aim in this chapter was to evaluate the role of oxidative stress on dparkin larvae. 
The experimental approach was to rescue dparkin larval phenotypes with transgenes 
known to play a role in oxidative stress in adult flies. The objectives were to test the 
effects of the transgenes on neuromuscular junction overgrowth, larval locomotion and 
resting membrane potential. 
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4.3 Results 
Cytosolic Sod1 ROS scavenger rescues overgrowth 
 To investigate the possible mechanisms underlying the neuronal overgrowth phenotype 
induced by the global loss of dparkin as shown in chapter 1, I determined whether the 
global expression of antioxidants Superoxide Dismutase 1 (Sod1), Sod2 or Catalase 
(Cat) would lead to the prevention of the overgrowth phenotypes in dparkin (p25/pZ3678) 
mutant larvae. Sod1 is an antioxidant enzyme present in the cytosol, nucleus, 
peroxisomes and mitochondrial intermembrane space of eukaryotic cells. Sod2 is 
expressed in the mitochondrial membrane whereas Cat is expressed in the cytosol. 
Global expression of Superoxide Dismutase 1 (Sod1) in a dparkin (p25/pZ3678) 
transheterozygote mutant background shows 22 % reduction in overgrowth from 
normalized bouton counts (p = 0.016), whereas Sod2 and Cat did not show an effect, 
when compared to dparkin (p25/pZ3678) mutant controls (Fig. 4.1A).  Global expression 
of Sod1, Sod2 or Cat all failed to affect raw bouton number (Fig. 4.1B), whereas the 
muscle surface area was only increased 31% by Sod1 (p = 0.001) but not by either the 
expression with Sod2 or Cat (Fig. 4.1C). As reported in chapter 3, there is overgrowth 
(60 %) in dparkin (p25/pZ3678) larval neuromuscular junctions (p < 0.001, p < 0.001 and 
p = 0.036, respectively) compared to wild-type (CS/w-) larvae (Fig. 4.1A). There are no 
differences between the GAL4/UAS control NMJ growth (normalized bouton count, 
raw bouton number or muscle surface area) compared to wild-type  (CS/w-) larvae (Fig. 
4.1).  
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Figure 4.1 Cytosolic ROS scavenger, Sod1, rescues overgrowth in dparkin larvae. 
A-C Global expression of Superoxide Dismutase 1 (Sod1) in a dparkin (p25/pZ3678) 
transheterozygote mutant background shows a 22% reduction in overgrowth from 
normalized bouton counts (A, p = 0.016), whereas Catalase (Cat) (A, p = 0.239) and 
Superoxide Dismutase 2 (Sod2) (A, p = 0.084) did not show an effect, when compared 
to mutant controls.  Global expression of Sod1, Sod2 or Cat all failed to affect raw 
bouton number (B, p = 0.742, p = 0.538 and p = 0.970 respectively), whereas the 
muscle surface area was only by 31% increased by Sod1 (C, p = 0.001) and not by 
either Sod2 or Cat (C, p = 0.998 and p = 0.853 respectively). As reported in chapter 3, 
there is an overgrowth of 60% in dparkin (p25/pZ3678) larval neuromuscular junctions (A, 
B and C, p = 0.001) compared to wild-type (CS/w-) larvae. There are no differences in 
NMJ growth (normalized bouton count, raw bouton number or muscle surface area) 
between the GAL4/UAS control (Act5c/CS, Act5c > Sod1, Act5c > Sod1 and Act5c > 
Cat) and wild-type  (CS/w-) larvae. 
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ROS scavengers fail to rescue RMP  
To further investigate the involvement of oxidative stress as a mechanism involved in 
other mutant phenotypes, we globally expressed Sod1, Sod2 or Cat in a dparkin 
(p25/pZ3678) transheterozygote mutant background and measured the RMP and found no 
differences in RMP compared to dparkin (p25/pZ3678) larvae. dparkin (p25/pZ3678) larvae 
show 13% more positive (depolarized) RMP compared to wild-type (CS/w-) larvae (p < 
0.001). There are no differences between the any of the controls (Act5c/CS, Act5c > 
Sod1, Act5c > Sod1 and Act5c > Cat) RMP compared to wild-type  (CS/w-) larvae (Fig. 
4.2).  
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Figure 4.2 ROS scavengers fail to rescue RMP defect in dparkin larvae. 
Global expression of ROS scavengers (Sod1, Sod2 or Cat) in a dparkin (p25/pZ3678) 
transheterozygote mutant background showed no difference in RMP (p = 0.923, p = 
0.123 and p = 0.752 respectively) compared to mutant (p25/pZ3678) larvae. As previously 
reported in chapter 3, dparkin (p25/pZ3678) larvae show 13% more positive (depolarized) 
RMP compared to wild-type (CS/w-) larvae (p < 0.001). There are no differences 
between the any of the GAL4/UAS control (Act5c/CS, Act5c > Sod1, Act5c > Sod1 and 
Act5c > Cat) RMP compared to wild-type  (CS/w-) larvae (p = 0.902, p = 0.913 p = 
0.319 and p = 0.482, respectively).  
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AMPK activation fail to rescue locomotory dysfunction  
When ATP is consumed there is a rise in AMP levels. This change requires activation 
of ATP synthesis, and a key mediator of the response is AMPK. dparkin (p25/pZ3678) 
larvae show reduced ATP levels (Vincent et al., 2012). To determine whether AMPK 
activation mechanism is sufficient to revert the locomotory phenotype, we globally 
expressed constitutively active AMPK-aT184D (AMPK) in a dparkin (p25/pZ3678) 
transheterozygote mutant background and found no differences in average velocity 
compared to dparkin (p25/pZ3678) larvae. As previously reported in chapter 3, dparkin 
(p25/pZ3678) larvae have reduced speed compared to wild-type control (CS/w-) larvae that 
was not rescued by global expression of AMPK in the mutant background (Fig. 4.3).  
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Figure 4.3 Global AMPK activation fail to rescue locomotory dysfunction in 
dparkin larvae. 
Global expression of constitutively active AMPK-αT184D (AMPK) in a dparkin 
(p25/pZ3678) transheterozygote mutant background shows no differences in average 
velocity compared to dparkin (p25/pZ3678) larvae (p = 0.512). dparkin (p25/pZ3678) larvae 
have 25% reduced speed compared to wild-type control (CS/w-) larvae (p < 0.001) that 
was not rescued by global expression of AMPK in the mutant background (p = 1.0). 
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AMPK activation rescues overgrowth 
To determine whether AMPK activation independent antioxidant mechanism is 
sufficient to revert the mutant overgrowth we used the global expression of 
constitutively active AMPK-aT184D (AMPK) in a dparkin (p25/pZ3678) transheterozygote 
mutant background shows a 32% reduction in overgrowth from normalized bouton 
counts compared to mutant controls (p < 0.001). As reported in chapter 3, there is an 
overgrowth at the dparkin (p25/pZ3678) larval NMJ (p > 0.001) compared to wild-type 
(CS/w-) larvae. There are no differences between the GAL4 control NMJ normalized 
growth, compared to wild-type  (CS/w-) larvae (Fig. 4.4). 
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Figure 4.4 Global expression of AMPK rescues neuronal overgrowth in dparkin 
larvae. 
 Global expression of constitutively active AMPK-αT184D (AMPK) in a dparkin 
(p25/pZ3678) transheterozygote mutant background shows a 32% reduction in overgrowth 
from normalized bouton counts compared to mutant controls (p < 0.001). There is a 
60% overgrowth in dparkin (p25/pZ3678) larval neuromuscular junctions (p > 0.001) 
compared to wild-type (CS/w-) larvae. There are no differences between the GAL4 
controls (Act5c > AMPK, Act5c/CS) and wild-type  (CS/w-) larvae (p = 1.0). 
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AMPK activation rescues RMP defect 
Global expression of constitutively active AMPK-aT184D (AMPK) in a dparkin 
(p25/pZ3678) transheterozygote mutant background shows a 7% more negative RMP (p = 
0.012) compared to the dparkin (p25/pZ3678) larvae. The mean difference is 4mV. As 
previously reported in chapter 3, dparkin (p25/pZ3678) larvae again show a more positive 
(depolarized) RMP compared to wild-type (CS/w-) larvae (p < 0.001). There are no 
differences between the GAL4 or UAS controls (Act5c/CS and AMPK/CS) RMP or the 
rescue compared to wild-type (CS/w-) larvae (p = 0.908 and p = 0.911 respectively). 
The GAL4 control also has a 30% more negative RMP compared to dparkin (p25/pZ3678) 
larvae (p < 0.001). There is no difference in RMP between the UAS control and wild-
type  (CS/w-) muscles (Fig. 4.5). 
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Figure 4.5 Global AMPK activation rescues RMP defect in dparkin larvae. 
Global expression of constitutively active AMPK-αT184D (AMPK) in a parkin (p25/pZ3678) 
transheterozygote mutant background shows a 7% more negative RMP (p = 0.012) 
compared to the dparkin (p25/pZ3678) larvae. dparkin (p25/pZ3678) larvae show more 
positive (depolarized) RMP compared to wild-type (CS/w-) larvae (p < 0.001). There are 
no differences between the UAS control (Act5c/CS and AMPK/CS) RMP or the rescue 
compared to wild-type (CS/w-) larvae (p = 0.908 and p = 0.911 respectively). The 
GAL4 control is different compared to dparkin (p25/pZ3678) larvae (p < 0.001). 
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GST, and not TRX-R2, expression rescues locomotory dysfunction 
Global expression of GST expression in a dparkin (p25/pZ3678) transheterozygote mutant 
background shows a 28% increase in the average velocity (p = 0.001), whereas global 
TRX-R2 expression in the mutant background did not show any differences in velocity 
compared to dparkin (p25/pZ3678) larvae. As previously reported in chapter 3, dparkin 
(p25/pZ3678) larvae have reduced speed compared to wild-type control (CS/w-) larvae (p < 
0.001). There are no differences between the GAL4/UAS control speeds compared to 
wild-type  (CS/w-) larvae for Act5c > GST or Act5c > TRX-R2 (Fig 4.6). 
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Figure 4.6 Global GST, and not TRX-R2, expression rescues locomotory 
dysfunction in dparkin larvae. 
Global expression of GST expression in a dparkin (p25/pZ3678) transheterozygote mutant 
background shows a 28% increase in the average velocity, whereas global TRX-R2 
expression in the mutant background did not show any differences in velocity compared 
to dparkin (p25/pZ3678) larvae (p = 0.001 and p = 0.329, respectively). dparkin (p25/pZ3678) 
larvae have a reduced speed compared to wild-type control (CS/w-) larvae (p < 0.001). 
There are no differences between the GAL4 UAS control (Act5c > GST or Act5c > 
TRX-R2) speeds compared to wild-type  (CS/w-) larvae (p = 0.995 and p = 0.469 
respectively). 
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GST or TRX-R2 expression rescues RMP defect in parkin larvae 
Global expression of either GST or TRX-R2 in a dparkin (p25/pZ3678) transheterozygote 
mutant background shows a 20 % and 29% more negative RMP (p = 0.001 and p < 
0.001 respectively) compared to mutant (p25/pZ3678) larvae. As previously reported in 
chapter 3, dparkin (p25/pZ3678) larvae show more positive (depolarized) RMP compared 
to wild-type (CS/w-) larvae (p < 0.001). There are no differences between the 
GAL4/UAS control RMP, Act5c > GST or Act5c > TRX-R2 compared to wild-type  
(CS/w-) larvae (Fig. 4.7). 
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Figure 4.7 Global GST or TRX-R2 expression rescues RMP defect in dparkin 
larvae. 
Global expression of either GST or TRX-R2 in a dparkin (p25/pZ3678) transheterozygote 
mutant background shows a 20% and 29% more negative RMP (p = 0.001 and p < 
0.001 respectively) compared to mutant (p25/pZ3678) larvae. As previously reported in 
chapter 3, dparkin (p25/pZ3678) larvae show more positive (depolarized) RMP compared 
to wild-type (CS/w-) larvae (p < 0.001). There are no differences between the GAL4 
UAS control (Act5c > GST or Act5c > TRX-R2) RMP compared to wild-type  (CS/w-) 
larvae (p = 0.191 and p = 0.396, respectively). 
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BSKDN, not JUNDN, expression rescues locomotory dysfunction in parkin larvae 
Global expression of BSKDN expression in a dparkin (p25/pZ3678) transheterozygote 
mutant background shows a 20 % increase in the average velocity (p = 0.018), whereas 
global JUNDN expression in the mutant background did not show any differences in 
velocity compared to dparkin (p25/pZ3678) larvae (Fig. 4.8). 
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Figure 4.8 Global BSKDN, not JUNDN, expression rescues locomotory dysfunction in 
dparkin larvae. 
Global expression of BSKDN expression in a dparkin (p25/pZ3678) transheterozygote 
mutant background shows a 20% increase in the average velocity (p = 0.018), whereas 
global JUNDN expression in the mutant background did not show any differences in 
velocity (p = 0.472) compared to dparkin (p25/pZ3678) larvae. As previously reported in 
chapter 3, parkin (p25/pZ3678) larvae have reduced speed compared to wild-type control 
(CS/w-) larvae (p < 0.001).  
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JUNDN expression rescues overgrowth  
Global expression of JUNDN in a dparkin (p25/pZ3678) transheterozygote mutant 
background shows a 54% reduction in overgrowth from normalized bouton counts 
compared to mutant controls (p < 0.001). As reported in chapter 3, there is an  
overgrowth in dparkin (p25/pZ3678) larval neuromuscular junctions (p > 0.001) compared 
to wild-type (CS/w-) larvae. There are no differences between the GAL4 control or the 
JUNDN rescue, NMJ normalized growth, compared to wild-type  (CS/w-) larvae (Fig. 
4.9). 
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Figure 4.9 Global JUNDN expression rescues overgrowth in dparkin larvae. 
Global expression of JUNDN in a dparkin (p25/pZ3678) transheterozygote mutant 
background shows a 54% reduction in overgrowth from normalized bouton counts 
compared to mutant controls (p < 0.001). As reported in chapter 3, there is an 
overgrowth in dparkin (p25/pZ3678) larval neuromuscular junctions (p > 0.001) compared 
to wild-type (CS/w-) larvae. There are no differences between the GAL4 control 
(Act5c/CS, p = 0.896) NMJ normalized growth, compared to wild-type  (CS/w-) larvae. 
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JUNDN and BSKDN expression rescues RMP defect  
Global expression of or either JUNDN or BSKDN in a dparkin (p25/pZ3678) 
transheterozygote mutant background shows a (%) more negative RMP (p < 0.001 and 
p < 0.001 respectively) compared to mutant (p25/pZ3678) larvae. As previously reported 
in chapter 3, dparkin (p25/pZ3678) larvae show more positive (depolarized) RMP 
compared to wild-type (CS/w-) larvae (p < 0.001). There are no differences between the 
GAL4 control RMP or either of the rescues (JUNDN or BSKDN) compared to wild-type  
(CS/w-) larvae (Fig. 4.10). 
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Figure 4.10 Global JUNDN and BSKDN expression rescues RMP defect in dparkin 
larvae. 
Global expression of or either JUNDN or BSKDN in a dparkin (p25/pZ3678) 
transheterozygote mutant background shows a more negative RMP (p < 0.001 and p < 
0.001 respectively) compared to mutant (p25/pZ3678) larvae. As previously reported in 
chapter 3, dparkin (p25/pZ3678) larvae show more positive (depolarized) RMP compared 
to wild-type (CS/w-) larvae (p < 0.001). There are no differences between the RMP of 
the wild-type  (CS/w-) larvae, the GAL4 control (Act5c/CS, p = 0.413) and the rescues 
(JUNDN or BSKDN, p = 0.701 and p = 0.629 respectively). 
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4.4 Discussion 
Globally expressing the ROS scavengers Sod1, Sod2 or Cat fails to rescue RMP. 
Ubiquitous expression of Sod1 partially rescues overgrowth, whereas expression of 
Sod2 or Cat fails to show a significant rescue. GST rescued both RMP and locomotion 
whereas TRX-R2 only rescued RMP. Inhibiting D. melanogaster JNK globally via 
BSKDN rescues RMP and locomotion. On the other hand, inhibiting JUN via JUNDN 
globally rescues only overgrowth and RMP but fails to rescue locomotion. Expressing 
the AMPK catalytically active subunit globally, rescues overgrowth and RMP but fails 
to rescue locomotion. 
Sod1 expression rescued overgrowth but failed to rescue RMP in dparkin larvae.  
Of the ROS scavengers tested, only the expression of Sod1 rescued the synaptic 
overgrowth seen in the dparkin knockout. The synaptic growth depends on both the 
number of boutons and the muscle surface area. The expression of Sod1 showed rescue 
of the overgrowth through the increase in muscle surface area, but not by changes in the 
raw bouton count. The differences in rescue between Sod1 and the other two ROS 
scavengers (Cat and Sod2) might be explained by differences in their location: SOD1 is 
predominantly cytoplasmic with some expression in the inner mitochondrial membrane 
while Sod2 is expressed in the mitochondrial matrix and Cat, located in the 
peroxysomes in the cytoplasm. Another, less likely explanation is the difference in 
function: both forms of Sod aid the break down of superoxide radicals to oxygen and 
hydrogen peroxide, while Cat accelerates the breakdown of hydrogen peroxide, into 
water and oxygen. 
An increase in Sod levels alone might increase the hydrogen peroxide levels in the cell. 
This might lead to a problem if the physiological levels of Cat are insufficient to keep 
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up with the levels of hydrogen peroxide. Mitochondrial hydrogen peroxide levels seem 
to exceed that of antioxidant defence. The right balance of antioxidants to break 
hydrogen peroxide down to maintain physiological levels of reactive oxygen species 
(ROS) are absent in dparkin larvae (Whitworth et al., 2005, Vincent et al., 2012). This 
suggests there is increase sensitivity to mitochondrial insult with hydrogen peroxide 
compared to the cytosolic insult in dparkin mutant. A dual expression of Sod and Cat 
together on the other hand could generate better rescues of other phenotypes. 
Expression of both Sod1 and Cat together has been shown to increase lifespan of D. 
melanogaster (Orr and Sohal, 1994). However, another study did not find a significant 
increase in lifespan in D. melanogaster (Sun et al., 2004). Globally expressing either 
Cat, Sod1 or Sod2 was shown to rescue the synaptic overgrowth in a dparkin null 
background (Vincent et al., 2012), but in my data from the transheterozygote 
background, there was no change with locomotion and RMP in dparkin larvae.  
Thioredoxin reductase, TRX-R2, expression rescues RMP but fails to rescue 
locomotion in dparkin larvae 
The electrophysiological readout, the RMP of muscle, was rescued in the dparkin larvae 
with the global expression of TRX-R2. The Act5c-GAL4 transgene in a wild-type (CS) 
background showed no significant difference in RMP compared to wild-type controls 
(CS/w-).  
Adult flies expressing wild-type thioredoxin in a dparkin toxicity-induced model had 
increased locomotor activity and no degeneration of dopaminergic neurons compared to 
aged matched controls. Additionally, it was found that neuronal function and anatomy 
were restored as a result of thioredoxin’s chaperone activity rather than its antioxidant 
function (Umeda-Kameyama et al., 2007). The global expression of thioredoxin 
reductase (TRX-R2) in dparkin larvae, failed to rescue the locomotion. This could be as 
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a result of different GAL4 transgenes used to drive expression (elav as opposed to the 
Act5c used here) and/or due to different mutant backgrounds. The tissues in which the 
transgene is expressed may have different degree of impact on larval locomotion (CNS 
v global).   
Glutathione-S-transferase, GST, expression rescues both RMP and locomotion 
Glutathione-S-transferases participate in the detoxification process and have been 
shown to prevent dopaminergic neuronal loss in dparkin mutants in a range of models 
of PD (Whitworth et al., 2005, Trinh et al., 2008, Kim et al., 2012). GST ameliorates 
viability, locomotory deficits and dopaminergic cell death in dparkin adults. The 
expression of GST in muscle partially rescues climbing defects, and the expression in 
dopaminergic neurons prevents the death of these neurons in dparkin adults (Whitworth 
et al., 2005). In dparkin larvae the global expression of GST rescues locomotion close to 
wild-type speed, whereas dparkin adults shows only partial rescue of the climbing 
defect. The differences in the level of behavioral rescue could arise from the different 
GAL4 drivers used. The adult study used a muscle specific driver: the reasoning being 
that the deficit seemed to be in the muscle, GST would be best expressed in adult flight 
muscle. However, some expression was seen in the adult head (Clayton et al., 1998). In 
our study, we used a global GAL4 driver that provided a complete rescue of the 
behavioral phenotype possibly due to both muscle and neuronal effects of GST 
expression. Future studies following this may test for neuronal expression of GST in 
dparkin larvae to dissect the importance for a more complete rescue of behavior.  
The same effective rescue is seen in the RMP data. The RMP was also rescued with 
global expression of GST suggesting the importance of GST expression in dparkin 
larvae to ameliorate muscle phenotype close to wild-type RMP voltage. These results 
show neuronal and muscle phenotypes of dparkin larvae are rescued with varying 
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degrees. It would be interesting to observe how neuronal verses muscle expression of 
GST impacts the rescue levels of dparkin larval phenotypes. The expression levels may 
be quantified by Western Blots of larval brain verses the muscle with the GST 
expression using the neuronal and global GAL4 drivers.  
JUN-DN expression rescued overgrowth and RMP but failed to rescue locomotion 
whereas BSK-DN expression rescued RMP and locomotion. 
Similar to the GST and TRX-R2, c-jun dominant negative (JUNDN) globally expressed 
rescued overgrowth and RMP, unlike Cat or either of the Sods. On the other hand, D. 
melanogaster JNK, basket dominant negative (BSKDN) rescues RMP and locomotion. 
JNK signaling has been shown to be up-regulated in dopaminergic neurons of dparkin 
mutants (Cha et al., 2005). dparkin has been shown to suppress JNK signaling by 
reducing BSK transcription (Hwang et al., 2010). Inhibiting BSKDN, globally rescues 
overgrowth, RMP and locomotion. On the other hand, inhibiting JUN-DN globally 
rescues only overgrowth and RMP but fails to rescue locomotion. dparkin has been 
shown to be a repressor of JNK signalling via BSK and our dparkin loss of function 
mutants show rescue of oxidative stress, neurophysiological and behavioural 
phenotypes with inhibition of basket function. This suggests JNK signalling is activated 
in dparkin larvae, like in adult dopaminergic neurons in dparkin flies (Cha et al., 2005). 
It is likely that dparkin has a role in inhibiting BSK and thus inhibiting downstream 
phosphorylation targets such as the transcription factor c-jun, GST and TRX-R2, are 
detoxification genes also shown to be involved in oxidative stress mediated signaling 
via inhibition of JNK or ASK-1 respectively. GST or BSKDN when globally expressed 
rescued both locomotion, unlike Cat or either of the Sods or AMPK. Data suggests that 
inhibiting JNK activity (BSKDN) may likely attenuate JNK-associated apoptosis-induced 
degeneration in dparkin mutants. 
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AMPK expression rescues overgrowth and RMP but fails to rescue locomotion in 
dparkin larvae 
Genetic activation of AMPK by expressing constitutively active AMPK in dopaminergic 
neurons and in muscles of dparkin flies rescued abnormal upright wing posture, 
climbing and mitochondrial pathology seen in adults (Ng et al., 2012). Unlike in the 
adults, global expression of AMPK in dparkin larvae fails to rescue the locomotion 
phenotype. Similar to the rescue of mitochondrial phenotype in adults, in dparkin larvae 
upregulating AMPK rescues the muscle RMP phenotype by restoring a more negative 
voltage (nearly to the wild-type RMP level). This suggests there is an increase in the 
availability of ATP and so a reduction in energetic stress. Additionally, synaptic 
overgrowth was also rescued in dparkin larvae by increased AMPK activity, possibly 
through its action on the suppression of oxidative stress or on autophagy. The 
overgrowth rescues could be explained as a result of mitophagy induction, as AMPK is 
known to phosphorylate ATG1 (Hardie, 2011), leading to activation of the processes 
that remove damaged mitochondria from the cell. This alleviates the oxidative stress 
burden caused from damaged mitochondria. 
Finally, it should be noted that AMPK has been found to interact with both dparkin- and 
dLRRK2-related models of Parkinsonism, thus implicating these three genes in a 
common pathway in PD pathogenesis (Ng et al., 2012).  
Summary of key findings: 
* The neurophysiological and locomotory defects results from the metabolic 
dysfunction rather than oxidative stress in dparkin larvae. 
* The AMPK-related regulatory effects of metabolic homeostasis are important for 
restoring muscle-associated deficits (opposed to neuronal) in dparkin larvae. 
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 * Oxidative stress is a downstream consequence of metabolic dysfunction.  
* Oxidative stress-induced signaling plays a role in dparkin larval phenotypes. 
Targeting JNK signaling components or JNK-interacting (detoxification) enzymes 
alleviate both neuronal and muscle-related dparkin larval phenotype. 
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Chapter 5: Pharmacological manipulation of dopaminergic signalling and AMPK 
activity 
5.1 Introduction 
In chapter 3, I demonstrated that the dparkin larvae showed reduced locomotion, defects 
in neural signalling and overgrowth. This raised the question of whether these 
phenotypes could be rescued pharmacologically. 
5.1.1 Role of dopamine 
Dopamine is a biogenic amine. In D. melanogaster, dopamine plays a role in insect 
neural networks controlling locomotor activity and stereotypical behaviors (Yellman et 
al., 1997, Friggi-Grelin et al., 2003, Lima and Miesenböck, 2005). As noted earlier in 
the Introduction (Chapter 1) the main therapy for PD patients is L-DOPA. 
Administering L-DOPA to adult dparkin flies resulted in partial restoration of impaired 
locomotion suggesting reduced dopamine levels in their brain is partially responsible 
for their locomotory dysfunction (Cha et al., 2005). To address whether the crawling 
defect is a result of reduced dopamine signaling, L-DOPA, and a control D-DOPA, was 
used to replace lost dopamine signaling in the brain to potentially rescue the crawling 
defects observed in our dparkin mutant larvae.  
5.2 Role of AMPK in the manipulation of ATP synthesis  
As described in chapter 3 parkin larvae show depolarized resting membrane potential 
(RMP), defects in synaptic transmission and reduced crawling. This suggested a 
metabolic deficit. Since the RMP is highly dependent on ATP production due to the 
requirements of the sodium potassium-ATPase (Na+/K+-ATPase) to maintain the 
electrochemical gradients of Na+ and K+ ions that are necessary for normal resting 
potentials and ion flow across the membrane (Attwell and Laughlin, 2001, Niven and 
Laughlin, 2008, Howarth et al., 2012), the metabolism of the p25/p25 larvae was 
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examined. These had reduced oxygen consumption, higher sensitivity to metabolic 
poisons, low ATP levels and increased lactate (Vincent et al., 2012).  This suggested a 
switch from aerobic respiration to glycolysis to keep up with the ATP demand (Vincent 
et al., 2012).  Additionally, dparkin larvae exhibit oxidative stress induced overgrowth 
possibly as a result of increased energy demands (as previously described in chapter 3 
and Vincent et al., (2012)).  
AMP-activated protein kinase (AMPK) is a metabolic sensor of intracellular energy 
metabolism, acting through a combination of homeostatic mechanisms including 
autophagy and protein degradation at the cellular, organ and whole body level 
(Steinberg and Kemp, 2009). The background to this enzyme has been introduced in 
Chapter 4. 
5-aminoimidazole-4carboxamide ribonucleoside (AICAR) is a pharmacological 
activator of 5'-AMP-activated protein kinase (AMPK). In the cell, AICAR is 
metabolized to AICAR monophosphate (ZMP) (Sabina et al., 1985), which mimics the 
effects of AMP on AMPK. This causes its activation while the cellular levels of AMP, 
ADP and ATP remain unaffected (Corton et al., 1995, Hardie et al., 2003).   
A characteristic feature in Type 2 diabetic patients is their diminished activity of 5'-
AMP-activated protein kinase (AMPK) compared to healthy individuals. Metformin 
(1,1-dimethylbiguanide), from the family of biguanides, is a potent antihyperglycemic 
agent commonly used to treat type-2 diabetes (T2D) to at least to 120 million people 
worldwide (Adler et al., 2009, Nathan et al., 2009). Despite the introduction of 
metformin clinically in the 1950s the exact mechanism of action has not been fully 
uncovered. Clinical trials undertaken in recent years have shown extensive benefits of 
metformin beyond the treatment of T2D, and have highlighted therapeutic value in other 
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conductions including diabetic nephropathy, cardiovascular diseases, polycystic ovarian 
syndrome and cancer. This drug acutely decreases hepatic glucose production via mild 
and transient inhibition of the respiratory chain component, complex 1. As a result of 
decrease in hepatic energy levels, this causes the activation of AMPK (Zhou et al., 
2001).  
Another way to affect AMPK is by using a polyphenol, e.g. resveratrol. Dietary intake 
of polyphenols is thought to be sufficient to achieve nutritional benefits. At this level, 
they may activate one or more pathways (Schroeter et al., 2007, Vauzour et al., 2007, 
Schroeter et al., 2001, Mandel et al., 2008). In neurons, activation of hormetic pathways 
leads to the synthesis of cytoprotective proteins including neurotrophic factors, protein 
chaperone, antioxidant and Phase II enzymes and apoptotic proteins (Mattson, 2006, 
Mattson and Magnus, 2006, Calabrese, 2008). Polyphenols are characterized by their 
multiple hydroxyl groups on aromatic rings. They are divided into two groups: 
flavonoid and non-flavonoid, which are determined by the number of phenol rings and 
the ways in which the rings interact. Resveratrol possesses a 1,2-diarylethenes structure 
based on the C6–C2–C6 backbone and classed as the main stilbene in the non-flavanoid 
group (Vauzour, 2012). This polyphenolic compound is a naturally occurring 
phytochemical present in over 70 plant species including grapes, berries and peanuts 
(Das and Maulik, 2006).  
Resveratrol (3, 4, 5-trihydroxystilbene), rich in red wine, has been suggested in a variety 
of studies to show positive effects on health including in cancer, aging stress, 
cardiovascular and in neurological diseases (Howitz et al., 2003, Baur and Sinclair, 
2006, Valenzano and Cellerino, 2006, Goswami and Das, 2009). 
!! 194!
Resveratrol affects multiple proteins and pathways (Baur et al., 2006, Baur and Sinclair, 
2006, Fröjdö et al., 2008, Pacholec et al., 2010, Park et al., 2012).  In the nervous 
system a protective pathway involving the transcription factor NF-E2-related factor-2 
(Nrf2) that has been known to be activated. During basal condicitons Nrf2 interacts with 
a cytosolic repressor protein Keap1 (Kelch ECH associating protein) and prevents Nrf2-
mediated gene expression. In oxidative stress conditions, Nrf2 is released from Keap1 
and then it translocates to the nucleus (Itoh et al., 1999a, Itoh et al., 1999b).  Nrf2 is 
involved in the upregulation of genes implicated in the regulation of the cellular redox 
status and the protection of the cell from oxidative insult, when it binds to the 
antioxidant-responsive element (ARE) and it activates ARE-dependent transcription of 
phase II and antioxidant defense enzymes, for example glutathione-S-transferase (GST), 
glutathione peroxidase (GPx), and heme oxygenase-1 (HO-1) (Nguyen et al., 2003). 
Resveratrol was observed to protect H2O2-mediated oxidative stress in vitro (Chen et 
al., 2005) and to attenuate cerebral ischemic injury in rat (Ren et al., 2011) via the 
activation of Nrf2 and the upregulation of HO-1.  
The mechanism by which resveratrol acts is still controversial: Park et al. (2012) have 
recently shown that SIRT1 is indeed activated indirectly by down stream signalling 
cascade involving cyclic AMP, Epac1 (a cAMP effector protein) and AMPK by 
resveratrol in a response to phosphodisesterase enzyme inhibition, its direct target (Park 
et al., 2012).  
SIRT1 has many cellular substrates such as the tumor suppressor p53, the transcription 
factor NF-κB, the forkhead box class O (FoxO) family of transcription factors, the 
peroxisome proliferator-activated receptor (PPAR)-γ, the PPAR-γ coactivator 1α (PGC-
1α), and endothelial nitric oxide synthase (eNOS) (Michan and Sinclair, 2007). 
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Using pharmacological activation of AMPK directly and indirectly by using AICAR, 
Metformin or Resveratrol was fed to dparkin mutants, as an aim to rescue their 
metabolic deficits (including ATP deficiency and increase in compensatory anaerobic 
metabolism, glycolysis) (Vincent et al., 2012) arising from mitochondrial abnormalities 
in dparkin mutant flies. The RMP defects in dparkin mutants are suggested to be 
associated with metabolic deficits in these mutants (Vincent et al., 2012), which are 
similar to the ATP deficient RMP defects described in an glycolytic mutant nubian 
(Wang et al., 2004). 
5.2 Aims 
The aim of this chapter is to address whether the crawling, RMP and synaptic 
overgrowth phenotypes observed in dparkin mutant larvae can be relieved 
pharmacologically. Dopaminergics (L-DOPA and D-DOPA) will be used to observe 
whether the effects the dopamine induced loss of signaling is the cause of dparkin larval 
bradykinesia-like phenotype.  
Secondly, to observe the impact on locomotion, RMP and neuronal overgrowth and 
other phenotypes in dparkin larvae with an increase in AMPK activity, I will use 
pharmacological agents that target AMPK directly  (AICAR) or indirectly (Resveratrol 
and Metformin). 
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5.3 Results 
Dopaminergics fail to rescue crawling defect 
To address whether the crawling defect described in chapter 3 in dparkin mutants were 
a result of reduced dopamine signaling, I fed the larvae with either L- or D-DOPA with 
a final concentration of 3 µM in food.  D-DOPA did not rescue crawling defect in 
dparkin mutant larvae (p25/pZ3678) larvae. D-DOPA increases by 32% the crawling speed 
of wild-type (CS/w-) larvae (A, p = 0.004). (As described before, chapter 3), dparkin 
(p25/pZ3678) larvae crawl with a reduced speed compared to wild-type (CS/w-) larvae (A, 
p = 0.009) (Fig 5.1A). 3 µM L-DOPA has no effect on the crawling velocity of either 
wild-type larvae (CS/w-) or the parkin larvae (p25/pZ3678) (Fig 5.1B). 
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Figure 5.1 Dopaminergics fail to rescue locomotory dysfunction in dparkin 
larvae.   
A D-DOPA (3 µM) does not affect the crawling speed of dparkin (p25/pZ3678) 
larvae (p = 0.564). D-DOPA increases the crawling speed of wild-type (CS/w-) 
larvae (p = 0.004). (As described before, chapter 3), dparkin (p25/pZ3678) larvae 
crawl with a reduced speed compared to wild-type (CS/w-) larvae (p = 0.009).  B 
L-DOPA has no effect on the crawling velocity of either wild-type larvae  
(CS/w-, p = 1) or the dparkin larvae (p25/pZ3678, p = 0.272). 
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Dopaminergics fail to rescue overgrowth  
To test whether dopamine causes further oxidative stress induced by dopamine neuronal 
overgrowth, dopaminergics were dissolved in the instant food (final concentration 3µM) 
throughout the larval stage. D-DOPA in instant food did not affect dparkin overgrowth 
compared to their mutant controls (p25/pZ3678). L-DOPA treatment did not affect dparkin 
overgrowth compared to mutant controls (p25/pZ3678) (Fig 5.2A-F). 
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Figure 5. 2 A-F Dopaminergics fail to rescue overgrowth in dparkin larvae. 
 A-C D-DOPA (3 µM) does not affect the normalized bouton counts of dparkin 
(p25/pZ3678) larvae raised on instant food (A, p = 0.107) or the raw bouton number or 
muscle surface area (µm2) compared to their mutant controls (B, p = 0.062 and C, p = 1) 
respectively). D-F L-DOPA (3 µM) also does not affect the normalized bouton counts 
of dparkin (p25/pZ3678) larvae raised on instant food (D, p = 0.676). There was also no 
difference in raw bouton number or muscle surface area compared to their mutant 
controls (E, p = 0.433 and F, p = 0.989, respectively).  
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AICAR, an AMPK activating drug, fails to rescue crawling 
dparkin (p25/pZ3678) larvae raised on instant food mixed with 2.5 µM to 50 µM AICAR 
at different concentrations have the similar average crawling speed as parkin (p25/pZ3678) 
larvae with no AICAR (with the vehicle, 50 µM PBS, added to the instant food). 
Furthermore, the AICAR concentration does not affect the velocity of wild-type (CS/w-) 
larvae. As shown in chapter 3, dparkin (p25/pZ3678) larvae crawl slowly on average 
compared to wild-type (CS/w-) larvae (p < 0.001). Wild-type (CS/w-) larvae crawl 35% 
faster than dparkin (p25/pZ3678) larvae at each AICAR concentration tested (P < 0.001) 
(Fig 5.3). 
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Figure 5.3 The AMPK activating drug AICAR fails to rescue locomotory 
dysfunction in dparkin larvae.  
dparkin (p25/pZ3678) larvae raised on instant food mixed with AICAR (2.5, 5, 10, 25 or 
50 µM dissolved in PBS ) have the same average crawling speed as dparkin (p25/pZ3678) 
larvae with no AICAR (with only 50 µM PBS), (p = 1). Again the AICAR 
concentration does not affect the velocity of wild-type (CS/w-) larvae, (p = 1). As shown 
in chapter 3, dparkin (p25/pZ3678) larvae crawl slowly on average compared to wild-type 
(CS/w-) larvae (p < 0.001). Wild-type (CS/w-) larvae crawl faster than parkin (p25/pZ3678) 
larvae at each AICAR concentration tested (p < 0.001). 
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AICAR, the AMPK-activating drug, fails to rescue synaptic overgrowth  
dparkin (p25/pZ3678) larvae raised on instant food with a range of concentrations of 
AICAR (2.5, 10 or 50 µM, dissolved in PBS) had the same synaptic overgrowth as the 
dparkin larvae raised on the vehicle control (Fig 5.4).  
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Figure 5.4 AMPK-activating AICAR, fails to rescue synaptic overgrowth in dparkin 
larvae.  
 A There is no difference in normalised bouton count in dparkin (p25/pZ3678) larvae 
raised on instant food with a range of concentrations of AICAR (2.5, 10 or 50 µM, 
dissolved in PBS) compared with dparkin controls without AICAR (with only 50 µM 
PBS), (p  = 0.669, p = 0.995 and p = 0.952 respectively). B-C dparkin (p25/pZ3678) larvae 
raised on AICAR showed no difference in raw bouton number (p = 0.995, p = 0.823 and 
p = 0.348 respectively) or muscle surface area  (p = 0.319, p = 0.968 and p = 0.996 
respectively), across a range of concentrations compared to dparkin controls without 
AICAR.   
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Metformin fails to rescue crawling 
Metformin used at a final concentration of 3 µM or 6 µM does not affect the speed at 
which dparkin (p25/pZ3678) larvae crawl, nor does it affect the speed of wild-type larvae 
(CS/w-). As previously reported in chapter 3, dparkin (p25/pZ3678) larvae crawl 20% more 
slowly than wild-type (CS/w-) larvae (p = 0.006) (Fig 5.5). 
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Figure 5.5 Metformin fails to rescue locomotory dysfunction in dparkin larvae.  
Metformin (6 µM or 3 µM) does not affect the speed at which parkin (p25/pZ3678) larvae 
crawl (p = 1.0 or p = 0.987, respectively), nor does it affect the speed of wild-type 
larvae (CS/w-, 6 µM, p = 0.798). As previously reported in chapter 3, dparkin 
(p25/pZ3678) larvae crawl more slowly than wild-type (CS/w-) larvae (p = 0.006). dparkin 
(p25/pZ3678) larvae raised on instant food mixed with metformin (3 µM or 6 µM) results 
in no overall change in velocity compared to mutant larvae without the drug (with only 
6 µM water), (p = 1.0).  The wild-type larvae raised on instant food mixed with 6 µM 
metformin (dissolved in water) has no effect on overall crawling speed compared with 
wild-type (CS/w-) controls without metformin (with only 6 µM water), (p = 1.0). 
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Metformin fails to rescue depolarized RMP defect  
Metformin does not affect the RMP of dparkin larvae raised on instant food mixed with 
3 µM of metformin (p = 0.969). dparkin (p25/pZ3678) larvae show more positive 
(depolarized) RMP compared to wild-type (CS/w-) larvae (p < 0.001), as previously 
described in chapter 3 (Fig 5.6). 
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Figure 5.6 Metformin fails to rescue depolarized RMP defect in dparkin larvae.  
Metformin does not affect the RMP of dparkin larvae raised on instant food mixed with 
3 µM of metformin (p = 0.969). dparkin (p25/pZ3678) larvae show 29% more positive 
(depolarized) RMP compared to wild-type (CS/w-) larvae (p < 0.001), as previously 
described in Chapter 3. 
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Resveratrol fails to rescue locomotory dysfunction 
Resveratrol does not affect the mean crawling speed of either wild-type (CS/w-) or 
dparkin (p25/pZ3678) larvae. As previously reported in chapter 3, dparkin 
(p25/pZ3678) larvae crawl with a reduced speed compared to wild-type (CS/w-) larvae (p < 
0.001) (Fig 5.7). 
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Figure 5.7 Resveratrol fails to rescue locomotory dysfunction in dparkin larvae.  
Resveratrol (200 µM) does not affect the mean crawling speed of either wild-type 
(CS/w-) or dparkin (p25/pZ3678) larvae (p = 0.923 and p = 0.819). As previously reported 
in chapter 3, dparkin (p25/pZ3678) larvae crawl with a reduced speed compared to wild-
type (CS/w-) larvae (p < 0.001). All data are from flies raised on instant food containing 
200 µM ethanol. 
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Resveratrol fails to rescue synaptic overgrowth in parkin larvae.  
dparkin (p25/pZ3678) larvae raised on instant food with Resveratrol (200 µM dissolved in 
ethanol) did not rescue dparkin (p25/pZ3678) overgrowth (Fig 5.8). There is no significant 
difference between the wild-type raised in 200 µM Resveratrol compared to their wild-
type control raised in vehicle. The vehicle controls, dparkin (p25/pZ3678) and wild-
type larvae, show a similar increase in synaptic growth (p = 0.023) as the larvae raised 
on solely instant food (Chapter 3).  
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Figure 5.8 Resveratrol fails to rescue synaptic overgrowth in dparkin larvae.  
A There is no difference in normalised bouton count in dparkin (p25/pZ3678) larvae raised 
on instant food with Resveratrol (200 µM dissolved in ethanol) compared with dparkin 
(p25/pZ3678) controls without Resveratrol (only with 200 µM ethanol), (p  = 0.061). There 
is no significant difference between the wild-type raised in 200µM Resveratrol 
compared to their wild-type control raised in only 200 µM ethanol (p  = 0.890). B-C 
dparkin (p25/pZ3678) larvae raised on Resveratrol showed no difference in raw bouton 
number (p = 0.710) or muscle surface area (p = 0.125), compared to dparkin 
(p25/pZ3678) controls without Resveratrol.  dparkin (p25/pZ3678) control larvae (with only 
ethanol) have overgrown synapses when normalised and compared to wild-type control 
(with only ethanol) larvae  (p = 0.023). 
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Resveratrol fails to rescue depolarized RMP defect  
Resveratrol does not affect the RMP of dparkin larvae. dparkin (p25/pZ3678) larvae show 
36% more positive (depolarized) RMP compared to wild-type (CS/w-) larvae (p < 
0.001), as previously described in chapter 3. The wild-type (CS/w-) larvae raised in 200 
µM Resveratrol (dissolved in ethanol) were 10 % depolarized compared to wild-type 
(CS/w-) control (ethanol vehicle only) larvae (p = 0.003) (Fig 5.9). 
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Figure 5.9 Resveratrol fails to rescue depolarized RMP defect in dparkin larvae.  
The RMP of dparkin larvae raised on instant food mixed with 200 µM of Resveratrol is 
the same as that of larvae raised on instant food alone (p = 0.338). dparkin 
(p25/pZ3678) larvae show more positive (depolarized) RMP compared to wild-type (CS/w-
) larvae (p < 0.001), as previously described in chapter 3. The wild-type (CS/w-) larvae 
raised in 200µM Resveratrol (dissolved in ethanol) were more depolarized compared to 
wild-type (CS/w-) control (in 200 µM ethanol only) larvae (p = 0.003). 
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5.4 Discussion 
The main findings of this chapter can be summarized as follows: both L-DOPA and the 
inactive stereoisomer control, D-DOPA, failed to rescue dparkin locomotory defect or 
the overgrowth. AICAR failed to rescue locomotory defects or the overgrowth in 
dparkin larvae. Metformin had no impact on crawling or RMP of dparkin larvae. 
Resveratrol failed to rescue locomotory or the overgrowth or the RMP defects in 
dparkin larvae.  
Dopaminergics failed to rescue crawling or the overgrowth 
Locomotor activity in both vertebrates and invertebrates relies on signaling from the 
brain dopaminergic system (Beninger, 1983, Giros et al., 1996, Yellman et al., 1997, 
Riemensperger et al., 2011). Studies have reported behavioral impairment that is 
accompanied by a gradual loss of dopaminergic neurons or tyrosine hydroxylase (TH) 
immunoreactivity in selective cell clusters of the brain (Feany and Bender, 2000, 
Auluck et al., 2005, Trinh et al., 2008). These studies highlight how brain dopamine 
plays an important role in the locomotor control in D. melanogaster. However, 
dopaminergics failed to rescue dparkin induced crawling or overgrowth defects in the 
larvae. L-DOPA is a substrate of the terminal step of dopamine synthesis. D-DOPA is 
an inactive stereoisomer (Cha et al., 2005). In adult flies, the dparkin induced locomotor 
defect was partially rescued by 1mM L-DOPA administration for a period of 10 days 
after emergence (Cha et al., 2005). This was a concentration approximately 300 times 
the one I used, and the duration of L-DOPA application was much longer. There are 
other reasons for the lack of effect seen by either L-DOPA or D-DOPA. The 3 µM final 
concentration of the drug made in instant food may have been reduced before reaching 
the larvae. There are two reasons for this: firstly, the breakdown of these drugs may 
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start in the food (e.g. by yeast or light).  Secondly, L-DOPA may be metabolized in the 
gut of the larvae and may not reach the neural tissue. Gut metabolism of L-DOPA is 
extensive in the human (Granerus et al., 1973) and so the inhibitor of peripheral 
metabolism, Carbidopa, is commonly administered along with L-DOPA (e.g. 1:10 
Carbidopa-Levodopa).  Additionally, the intake of food by larvae can also vary and may 
fail to reach the optimum concentration in the larval neuronal tissues. Experiments cited 
in the literature use adult flies, which feed less than larvae (Cha et al., 2005).  
My experiments are in contrast to those with the dominant mutations (parkinQ311X and 
parkinT240R). In these flies, knockdown of dVMAT increased cytosolic dopamine, along 
with the vulnerability of dopamine neurons (Sang et al., 2007). By contrast, increasing 
dVMAT expression in dparkin mutants partially rescues pupal lethality and 
dopaminergic degeneration most likely by reducing cytosolic dopamine. We commonly 
observe pupal lethality with only a few dparkin flies reaching eclosion where they die 
shortly.   
A weak base compound, methamphetamine, is known to cause damage to both 
dopaminergic and serotonergic nerve endings. The dopamine released from the synaptic 
vesicle resulted in the cytosolic oxidization induced dopaminergic injury as a result of 
methamphetamine exposure. Superoxides and hydroxyl radicals are generated by auto-
oxidation from cytosolic dopamine after methamphetamine exposure. The spontaneous 
oxidation of the catechol ring of dopamine, this generates reactive oxygen species 
(ROS) including superoxide and reactive electron-deficient quinones (Sulzer and Zecca, 
2000). Superoxide is converted by superoxide dismutase to hydrogen peroxide. 
Superoxide reacts with nitric oxide radicals to generate peroxynitrate of reactive 
nitrogen species (RNS) (Sulzer and Zecca, 2000, Sulzer, 2007).  Transition metals are 
abundant in dopaminergic neurons and hydrogen peroxide can react with these, in 
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particular with iron, to forms hydroxyl radicals (Hastings, 1995). The reactive quinones 
have the potential to react with cellular nucleophiles for example reduced sulfhydryl 
group on a small peptide and also protein cysteinyl residues. Protein thiols are targets 
and their structures are covalently modified by dopamine quinones. Protein 
modification and the resulting inactivation of their function may be detrimental to cell 
survival and may cause the degenerative process observed in PD patients (Stokes et al., 
1999).  
As noted in the Introduction (Chapter 1), Braak suggested PD did not start in the 
dopaminergic neurons, and that the early stages of the disease developed in the neurons 
of the olfactory and/or digestive system. Since our dparkin mutation is effective in all 
neurons, and L-DOPA administration does not seem to rescue the effects, it is possible 
that many of the effects of dparkin are mediated by non-dopaminergic neurons. Thus 
this larval model of an early stage form of PD, is (in this manner) reminiscent of the 
spreading pathology of the human disease.  
AICAR fails to rescue locomotion and the overgrowth defect 
AICAR failed to rescue crawling and the overgrowth. AMPK activation with the larval 
administration of AICAR treatment failed to rescue either the locomotion or the 
overgrowth defects. This may be due to the low concentrations of ZMP-induced 
activation of AMPK and the reduced level of effectiveness compared to the activation 
via phosphorylation of AMPK. In the literature ZMP has been reported not to be as a 
potent activator as AMP itself (Suter et al., 2006). 
Additionally, other D. melanogaster models of PD (including LRRK2 and PINK1) have 
shown metabolic dysfunction as key to tissue (dopaminergic) neurodegeneration, 
synaptic dysfunction and motor dysfunction (Morais et al., 2009, Vos et al., 2012, 
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Hindle et al., 2013). Recently in two fly models of PD, LRRK2 and parkin, mutant 
phenotypes were shown to be alleviated via increased AMPK activity using AMPK 
mimetics such as metformin and 5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside (AICAR). Additionally, Ng and colleagues recently showed LRRK2- and 
parkin-dysfunction  (including mitochondrial and dopaminergic defects) were rescued 
with a green tea-derived catechin, epigallocatechin gallate (EGCC) mediating its effects 
via AMPK (Ng et al., 2012). AICAR or its metabolites (ZMP or ZTP) can act on the 
ATP-sensitive potassium (KATP) channels. ZTP has shown to exert inhibitory action of 
KATP channel at particular concentrations (Malaisse et al., 1994). Another member of 
the KIR family (Kir2.1) has been recently shown to be inhibited by AMPK (Alesutan et 
al., 2011). AICAR toxicity is little to none and has shown promise as an in vivo exercise 
mimetic.  
Metformin failed to rescue crawling or RMP defect 
Metformin failed to rescue the crawling and RMP in dparkin mutant larvae. Metformin 
was confirmed to robustly activate AMPK in a dose dependent manner in D. 
melanogaster via mass spectrometry and western blot analysis (Slack et al., 2012). The 
efficacy of oral administration of metformin in the fly was measured by quantifying its 
accumulation in fly tissues. Adult flies were fed increasing concentrations of metformin 
for a period of 7 days. The fly extracts were prepared after the gut was cleared of 
ingested food by incubating them for period of 5 hours in the absence of metformin 
treatment. Western blot analysis of phospho-Thr172-AMPK expression was undertaken 
using the whole-fly protein extracts. After 7 days of metformin treatment at 
concentrations of 0, 5, 10, 25, 50 and 100 mM, the flies were sampled. A dose-
dependent increase in phospho-Thr172-AMPK levels was observed compared to actin 
as a loading control. A high concentration of Metformin (from 10 mM and 100 mM 
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dose in female or males respectively) was found to be toxic to flies. There was no 
increased survival observed in males or females with administration of Metformin at 
concentrations between 1 mM-100 mM (Slack et al., 2012). The concentrations of 
metformin used in this study were significantly lower than the levels found to be toxic 
to flies. The lowest level of metformin concentration (1 mM) was detected in the fly in 
the mass spectrometry experiment (Slack et al., 2012).  
The molecular targets of Metformin have not been well understood. In mammals 
Metformin is known to activate AMPK (Zhou et al., 2001), via phosphorylating LKB1 
(Fryer et al., 2002) to exert majority of it effects. Another hypothesis is that Metformin 
inhibits AMP deaminase, thereby reducing ATP concentration thus activating AMPK 
(Ouyang et al., 2011). The effects of metformin is preserved in liver-specific AMPK 
deficient mice, thus suggesting not AMPK but complex 1 of the respiratory chain as the 
primary target of metformin action (El-Mir et al., 2000, Owen et al., 2003). Metformin 
has been suggested to have lower maximal inhibitory action of complex 1 compared to 
rotenone (Batandier et al., 2006, Kane et al., 2010). It has also been proposed that in 
contrast to rotenone, metformin additionally exerts an inhibitory effect on mitochondrial 
ROS production by selectively blocking the reverse electron flow through the 
respiratory chain complex 1 (Batandier et al., 2006, Kane et al., 2010). 
Resveratrol failed to rescue crawling, overgrowth or RMP defect 
200 µM resveratrol final concentration in instant food administered larval treatment 
failed to rescue crawling, overgrowth or the RMP defect. Resveratrol treatment of adult 
flies exposed to manganese (Mn) results in an increase in life span and increase in 
motor activity.  However, when Resveratrol is given after Mn-exposure, resveratrol is 
unable to ameliorate the motor dysfunction caused by the metal (Bonilla et al., 2012). 
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0.43 mM concentration was used to feed the adult flies, a much higher dose than the one 
I used for my experiment (Bonilla et al., 2012).  A lower concentration of 200 µM was 
used in my experiments as larvae are in the food, whereas adults are on the food. 
The uptake of resveratrol into the larvae could be checked via mass spectrometry and 
SIRT1 fluorimetric analysis as described by Partridge group (Bass et al., 2007). The 
activity of resveratrol samples was measured using the SIRT1 Fluorimetric Drug 
Discovery Kit. Previous studies have reported that polyphenols may be neuroprotective 
in D. melanogaster acutely treated with oxidative stress inducing agents (Pallàs et al., 
2009, Chandrashekara and Shakarad, 2011).  Polyphenol exposure is suggested to 
increase life span and restore motoric defects of D. melanogaster chronically exposed to 
paraquat compared to their controls fed with only paraquat (Ortega-Arellano et al., 
2011). 
Howitz and colleagues and also other groups have shown resveratrol activated SIRT1 
NAD-dependent deacetylase in vitro and then in vivo and in some cases it did so 
directly (Baur and Sinclair, 2006, Knutson and Leeuwenburgh, 2008). On the other 
hand, there we reports suggesting resveratrol and sirtuins were not associated thereby 
claiming the activation of SIRT1 by resveratrol an artefact of the assay used (Baur, 
2010). Park and colleagues findings now show that SIRT1 is indeed activated indirectly 
by down stream signalling cascade involving cyclic AMP, Epac1 (a cAMP effector 
protein) and AMPK by resveratrol in a response to phosphodisesterase enzyme 
inhibition, its direct target (Park et al., 2012). The pathway to SIRT1 activation occurs 
via AMPK, an enzyme that is known to be essential for many of resveratrol’s beneficial 
metabolic effects (Park et al., 2012). These observations support previous reports that 
AMPK lies upstream of SIRT1 activity upon resveratrol exposure, as AMPK activation 
is still persistent in cells lacking SIRT1 (Dasgupta and Milbrandt, 2007). The 
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concentration used to achieve these beneficial effects in vitro exceed the those achieved 
in vivo, raising concerns about its specificity. Although, rolipram a phosphodiesterase 
enzyme inhibitor mimics the effects of resveratrol such as the prevention of diet induced 
obesity in mice (Park et al., 2012), all the beneficial effects are brought about via the 
downstream action of AMPK activity and thus could be mediated through alternative 
mechanisms of resveratrol treatment in vivo. Resveratrol treatment has been shown to 
enhance nitric oxide production (Wallerath et al., 2002) and in another study it was 
found to stimulate adenylate cyclase (El-Mowafy and Alkhalaf, 2003) either of these 
could result in phosphodiesterase inhibition. The impact of SIRT1 activation on AMPK 
has not been addressed in vivo. A range of more potent SIRT1 activators than resveratrol 
have now been developed that show promise with therapeutic potential (Milne et al., 
2007), some of which are being tested in phase 1 and phase 2 clinical trials for the 
treatment of cardiovascular, inflammatory and metabolic disease. The role SIRT1 plays 
is regulation of neurodegenerative disorders is an important one (Tang and Chua, 2008). 
SIRT1 inhibitors, sirtinol and nicotinamide, have shown to reverse the protective effects 
of resveratrol in a neuronal culture model of Huntington’s Disease (HD) (Tang and 
Chua, 2008).  SIRT1 cellular substrates include the tumor suppressor p53, transcription 
factor NF-kappaB, the forkhead box class O (FoxO) family of transcription factors, the 
peroxisome prolifreator-activated receptor (PPAR)-gamma, the PPAR)-gamma co-
activator 1-alpha and the endothelial nitric oxide synthase (Michan and Sinclair, 2007).  
As cytosolic dopamine and its metabolites are involved in the conjugation of cytosolic 
protein substrates such as parkin, it is likely this is the case in our dparkin 
transheterozygote mutants as they produce very little wild-type dparkin. This possibly 
results in the inactivation of the low levels of dparkin and consequently thereby leading 
to the increase in ROS levels (as parkin is involved in both degradation of misfolded 
!! 235!
proteins via proteosomal degradation pathway and also autophagy). This could lead to 
neuronal vulnerability as well as affecting other tissues such as muscles. This is further 
supported by the fact that dVMAT mutant flies show reduced numbers of dopaminergic 
neurons and the degeneration deteriorates further when these mutants are exposed to 
oxidative stress inducing agents such as paraquat or rotenone. Lawal and colleagues 
also show the effects of the dVMAT overexpression on dVAMT mutant flies, which 
inhibits the rotenone induced dopaminergic loss (Lawal et al., 2010). This is possibly 
closely linked to rotenone’s action, where it inhibits the mitochondrial respiratory chain 
component complex I and causes severe loss energy that leading to the failure of the 
monoamine transporters, such as dVMAT, which allow the ATP-dependent reuptake of 
extracellular amines (Lawal et al., 2010). The reuptake of rotenone into the synaptic 
vesicles prevents its interaction with mitochondria and further cause oxidative stress. 
The most plausible explanation is that cytosolic dopamine is limited as it is taken up 
into synaptic vesicles to prevent the interaction with the cytosolic rotenone to cause 
oxidative damage (Lawal et al., 2010). This model suggests the interaction of cytosolic 
dopamine with ROS or sites of ROS (mitochondria) could result in cell damage or 
death.   This also could implicate the dopaminergic cell loss seen in this mutant as a 
non-cell autonomous effect and caused by the defective signaling of other aminergic 
cells. 
Summary of key findings: 
* dparkin larvae support ‘Braak’s hypothesis’ and fail to exhibit dopaminergic 
dysfunction in this early model of PD.  
* Metformin and AICAR, the classical AMPK activators, fail to show an effect on 
parkin larval phenotypes at their respective concentrations.  
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* Resveratrol fails to rescue overgrowth, locomotory or neurophysiological defects. 
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Chapter 6: General Discussion 
 
6.1 Summary of main results of my thesis 
The aim of this thesis was to test for early neuronal dysfunction in dparkin mutant 
larvae. These mutant larvae show locomotory defects, neurophysiological dysfunction, 
and overgrowth at the neuromuscular junction (NMJ). Neuronal loss of dparkin is key 
to the synaptic failure observed in dparkin larvae. Oxidative stress induced signaling 
contributes to the dparkin mutant larval phenotypes, as increased expression of SOD1 or 
the detoxification enzymes Glutathione-s-transferase (GST) or Thioredoxin reductase 
(TRX-R2) rescues the phenotypes. Genetic manipulation of the c-jun-N-terminal kinase 
(JNK) signaling pathway also rescued the dparkin phenotype. Additionally, genetically 
manipulating AMP-activated protein Kinase (AMPK), which is involved in the energy 
homeostasis, rescued the overgrowth and neurophysiological dysfunction but failed to 
rescue the locomotory defects. Pharmacological manipulation with classical AMPK 
activators (metformin and 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR)) 
failed to show a rescue of dparkin mutant larval phenotypes. Resveratrol also failed to 
rescue either overgrowth, neurophysiological or locomotory defects. Dopaminergic 
manipulations, either pharmacological (L-DOPA) or genetic (TH> dparkin RNAi) 
failed to show an effect on overgrowth or locomotory defect. 
6.2 Main significance of this thesis 
The most significant finding is that it is the neuronal, rather than muscle, loss of dparkin 
that causes locomotory defect in the larva. As noted in chapter 3, previous work had 
focused on muscle phenotypes; my work is a direct demonstration of a neuronal 
phenotype at the centre of the dparkin defects, and these conclusions were supported by 
other assays in our lab (Vincent et al., 2012). This makes this larval model of dparkin, a 
particularly useful model of PD. In particular, the demonstration of defects in synaptic 
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signaling and synaptic overgrowth at a non-dopaminergic (glutamatergic) synapse is 
important for two reasons. First, it shows that dparkin affects not just the dopaminergic 
system, but other types of neurons, in accord with Braak’s hypothesis. Here I note that a 
larval phenotype was not induced by either TH > dparkin RNAi or L-DOPA 
application. Second, glutamatergic neurons are the most important excitatory neurons in 
the human brain and the fly neuromuscular junction (NMJ) is proving a significant 
model of their synapses. This means that the armory of the fly NMJ can, in the future, 
be deployed to examine the dparkin synapse in more detail.  
It was also demonstrated here (chapter 4) that oxidative stress was not the cause of 
neuronal dysfunction, but a secondary consequence. Again, this work was supported by 
other data presented in Vincent et al. (2012), showing metabolic deficits lead to a 
failure to maintain the normal RMP and synaptic failure, and subsequent oxidative 
stress. 
6.3 Further work investigating the neuronal dysfunction in dparkin larvae 
One of the key observations in chapter 3, was that dparkin expression in nerve or 
muscle provided rescue both pre- and post-synaptically (of at least some phenotypes). 
This implied trans-synaptic, non autonomous signaling. It was hypothesized that this 
trans-synaptic rescue could be mediated by D. melanogaster PARKIN itself, by ROS-
dependent signals or by a range of growth factors. The fly genetic toolbox provides 
ways to test these hypotheses. The first hypothesis could be tested by generating a 
tagged version of dparkin, e.g. with a GFP or his/or FLAG tag could be expressed, and 
immunocytochemistry used to test for its presence in/around the synapse. Secondly, 
reactive oxygen species (ROS)-signaling could be reduced either pre- or post –
synaptically by using elav- or G14-GAL4 expression of GST, in a manner similar to the 
ubiquitous expression in chapter 4. This would show if ROS signaling were key. 
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Equally, a range of growth factor transgenes could be deployed in the dparkin 
background, in a nerve/muscle specific manner.   
An exquisitely sensitive approach in this context would be to attempt rescue of dparkin 
in one muscle, while the adjacent muscle was still dparkin. The fly offers a suitable 
tool: the H94-GAL4 line that would drive wild-type UAS-dparkin in a mutant 
background in some of the muscles (not all). This would allow particular muscles to 
contain wild-type dparkin and others to possess a mutant background, all in a single 
larval (NMJ preparation). The H94 driver will drive specific expression of dparkin in 
few muscles including 6, 13 and moderately in 12 (and very low levels in some 
motoneurons) whilst others will contain the dparkin mutation (Davis et al., 1997). This 
will measure the RMP and synaptic activity within one preparation, thus limiting 
variability between preparations. Other drivers also exist such as 5053A-GAL4 line that 
drives highly in muscle 12 (Ritzenthaler et al., 2000). Similarly, ROS signaling or 
growth factors could be expressed in this way. Muscles 13 and 13 are innervated by two 
motoneurons, V and RP5, providing the opportunity for transgenic manipulation of a 
single motoneuron while using the muscle and other motoneuron as reporters.     
The depolarization of the muscle RMP in dparkin larvae suggested that the motoneuron 
may also be depolarized, as the same ATP-dependent system is required to maintain 
both nerve and muscle RMP.  The development of novel, genetically encoded voltage 
sensors offers the opportunity to record the motoneuron resting membrane potential 
directly (Jin et al., 2011). The change in mEJP suggested that calcium dynamics may be 
affected, and the latest genetically modified calcium indicators (G-CAMP) sensors 
provide tools to investigate this. Again the use of the specific GAL4 lines provides the 
opportunity to use in preparation controls.    
!! 240!
6.4 Larval and adult phenotypes 
A key reason for investigating the dparkin larva was to assess the early steps in the 
toxic cascade of PD. It is clear from Fig 6.1 that the physiological rescue by transgenes 
mostly results in behavioral rescue; whereas if the transgene only rescues the synaptic 
overgrowth, behavioral rescue is less likely. The larvae can, at this early stage, 
compensate for the neuronal overgrowth, but not for physiological failure. Third instar 
larvae are under a maximal metabolic load, as they prepare to pupate (Rechsteiner, 
1970a, Rechsteiner, 1970b). Those dparkin larvae that do eclose successfully as adults 
will have a lower metabolic stress, and so may be more responsive to genetic or 
pharmacological manipulations, for example, with the expression of GST or BSKDN as 
observed in chapter 4.  
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Figure 6.1 Summary of experiments with genetic expression of transgenes. dparkin 
mutant larvae show locomotory defects, neurophysiological dysfunction, and 
overgrowth at the neuromuscular junction (NMJ). Neuronal loss of dparkin is key to the 
synaptic failure observed in dparkin larvae. Oxidative stress induced signaling 
contributes to the dparkin mutant larval phenotypes, as increased expression of SOD1 or 
the detoxification enzymes Glutathione-s-transferase (GST) or Thioredoxin reductase 
(TRX-R2) rescues the phenotypes. Genetic manipulation of the c-jun-N-terminal kinase 
(JNK) signaling pathway also rescued the dparkin phenotypes. Additionally, genetically 
manipulating AMP-activated protein Kinase (AMPK), which is involved in the energy 
homeostasis, rescued the overgrowth and neurophysiological dysfunction but failed to 
rescue the locomotory defects.  
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6.5 Comparison of pharmacological and genetic approaches  
Whereas all the transgenes tested showed at least a partial rescue on either the dparkin 
transheterozygote (chapter 3) or on the dparkin homozygote (Vincent et al., 2012), none 
of the drugs tested showed significant rescue. Although feeding drugs to larvae in this 
way proved useful for the fly model of LRRK2-PD (Afsari et al., 2014), my work 
suggests that the genetic approach is more powerful than the pharmacologic. In this 
context, it should be noted that Vos et al. (2012) used bacterial culture of E. coli to 
provide vitamin K2 in their pharmacologic rescue of PINK1 or dparkin larvae (Vos et 
al., 2012).  
6.6 Implication for Parkinson’s Disease therapy 
Oxidative stress is commonly seen in a variety of neurodegenerative conditions, 
including PD. Oxidative stress has been an attractive target for the treatment of PD 
although it has been a challenge to place this pathogenic factor in the cascade of PD 
pathogenesis. A large clinical study, known as DATATOP, showed the lack of effect of 
α-tocopherol (Vitamin E) on the progression of PD (Shoulson, 1998). Coenzyme Q10 is 
responsible to shuttle electrons via the electron chain. Additionally, ubiquinol 
(Coenzyme Q10 reduced form) functions as an antioxidant (Ernster and Dallner, 1995). 
In one pilot study, positive effects were observed in PD patients, such as increased 
complex 1 activity, with administration of Coenzyme Q10 (Shults et al., 1998). Another 
later study showed negative effects in PD patients (Shults et al., 2002), thus showing 
mixed results from clinical trials. My data suggests that relieving oxidative stress does 
not affect the primary dparkin deficit, and (if this is a faithful model) that such clinical 
trials need further investigation and more care.  
The failure of the trials is not conclusive enough to state that oxidative stress is not 
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important in PD but may be attributable to the defects in the pharmacological agent 
used in patients. Small anti-oxidant molecules such as vitamin E seem to be far less 
effective. I speculate from the effective genetic rescue that a more promising approach 
could result from focusing our attention on the up-regulation of endogenous anti-
oxidant systems such as the thioredoxin and glutathione defence mechanisms. Thus, 
dysfunctional mitochondria, alterations in mitochondrial dynamics, increased ROS, 
mtDNA damage, and the loss of energy production are important contributors to the 
pathophysiology associated with several neurodegenerative diseases including 
Alzheimer’s (AD), PD, and Huntington Disease (HD), and also cancer. 
However, the treatment of one or few antioxidants is too simplistic, as reported by the 
several clinical studies that have shown modest success with antioxidants in the 
treatment of neurodegenerative diseases (Firuzi et al., 2011). This study showed the 
importance of energy maintenance to keep up with the demands of neuronal 
metabolism. A cocktail of drugs with a combination of antioxidant or combination of 
drugs targeted to other factors of PD such as the metabolic defects, may increase the 
likelihood of producing significant neuroprotective effect as PD is multi-factorial 
disease. Current drugs used to target other diseases, for instance metformin used to treat 
patients with type-2 diabetes could be trailed in PD to target metabolic dysfunction that 
could result in a neuroprotective effect in PD itself. More effort need to be put into 
solving energetic failure, as this is the root cause results in secondary effects (i.e. 
oxidative stress). Creatine/ phosphocreatine system provides an alternative pathway 
(from glycolysis and oxidative phosphorylation) to promote ATP synthesis. Supporting 
this, studies with creatine have shown to boost pathways that promote energy synthesis 
and additional antioxidant actions. Although efforts have begun on this potential 
neuroprotective agent in PD models (Matthews et al., 1999)
!! 245!
Creatine has been tested and shows signs as a promising agent, but large clinical trials 
need to be undertaken to validate it as a neuroprotective agent (Ravina et al., 2003). 
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Abbreviation List 
AD    Alzheimer’s Disease 
ADP    Adenosine Diphosphate 
AICAR   5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside 
AMP    Adenosine Monophosphate 
AMPK   AMP-activated Protein Kinase 
ANOVA   Analysis of Variance 
AP    Action Potential 
AP-1    Activator Protein-1 
ARJP    Autosomal Recessive Juvenile Parkinsonism 
ASK    Apoptosis Signal Regulating Kinase 
ATG    Autophagy Related Gene 
ATP    Adenosine Triphosphate 
Ca2+    Calcium ion 
CAT    Catalase 
CNS    Central Nervous System 
CPG    Central Pattern Generator 
CS    Canton-S 
Cy3    Cyanine-3 dye 
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CyO    Curly of Oyster 
D-DOPA   3-(3,4-Dihydroxyphenyl)-D-alanine 
DA    Dopaminergic Neurons 
DDC    DOPA decarboxylase 
DN    Dominant Negative 
DNA    Deoxyribose Nucleic Acid 
DOPAC   Dihydroxyphenyl Acetic Acid 
DVMAT   Drosophila Vesicular Aminergic Transporter 
EJP    Excitatory Junctional Potential 
ELAV    Embryonic Lethal Abnormal Vision 
EM    Electron Microscopy 
EMS    Ethyl Methane Sulfonate 
ER    Endoplasmic reticulum 
ETC    Electron Transport Chain 
EtOH    Ethanol 
FITC    Fluorescein Isothiocyanate 
GFP    Green Fluorescent Protein 
GST    Glutathione-s-Transferase 
H20    Water 
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H202    Hydrogen Peroxide 
HL3    Hemolymph-like Buffer solution 3 
HRP    Horseradish Peroxidase 
JNK    c-jun N-terminal kinase 
K+    Potassium ions 
L-DOPA   Levodopa 
MAO    Monoamine Oxidase 
MDA    Malondialdehyde 
mDNA   Mitochondrial Deoxyribose Nucleic Acid 
mEJP    Minature Excitaotry Junctional Potential 
minis    Minature Excitaotry Junctional Potential 
min    Minute 
MKKK   Mitogen-Activated Protein Kinase Kinase Kinase 
MKRS   Third Chromosome Stubble Marker 
mm    Millimeter 
mM    Millimolar 
MPP+    1-Methyl-4-Phenyl-Pyridinium 
MPTP    1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine 
mRNA   Messenger RNA 
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MSA    Muscle Surface Area 
mV    Millivolts 
Na+    Sodium ion 
Na+/K+ - ATPase Sodium/ Potassium-ATPase 
NMJ    Neuromuscular junction 
NO    Nitric Oxide 
NOS    Nitric Oxide Synthase 
Nrf2    Nuclear factor (erythroid-derived 2)-like 2 
O2    Oxygen 
O-.2   Superoxide Anions 
OH.    Hydroxyl Radical 
OH.-    Hydroxyl Anion 
PBS    Phosphate Buffered Saline 
PBS-T   Phosphate Buffered Saline-Triton 
PCR    Polymerase Chain Reaction 
PD    Parkinson’s Disease 
PDE    Phosphodiesterase enzyme 
PGK    Phosphoglycerate Kinase 
RMP    Resting Membrane Potential 
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RNAi    (Interfering) Ribonucleic Acid 
RNS    Reactive Nitrogen Species 
ROS    Reactive Oxygen Species 
Sec    Second 
SN    Segmental Nerve 
SOD    Superoxide Dismutase 
SPSS    Software for Statistical Analysis 
SYT    Synaptotagmin 
TH    Tyrosine Hydroxylase 
TM6B   Third Chromosome Tubby Marker 
TOR    Target of Rapamycin 
TORC   Target of Rapamycin complex 
Trx    Thioredoxin 
Trx-R    Thioredoxin Reductase 
UAS    Upstream Activating Sequence 
VMAT   Vesicular Aminergic Transporter 
ZMP    AICAR Monophosphate 
µm    Micrometer 
µM    Micromolar 
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